<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006055" GROUP_ID="STD" ID="353705091311322058" MERGED_FROM="" MODIFIED="2009-05-12 16:33:30 +0200" MODIFIED_BY="Fernanda Carvalho" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.20" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2009-05-12 16:33:30 +0200" MODIFIED_BY="Fernanda Carvalho">
<TITLE>The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women</TITLE>
<CONTACT MODIFIED="2009-05-12 16:33:30 +0200" MODIFIED_BY="Fernanda Carvalho"><PERSON ID="DC842ABF82E26AA201BA4B54681D7A9D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Oyinlola</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Oduyebo</LAST_NAME><POSITION>Lecturer</POSITION><EMAIL_1>oyinoduyebo@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medical Microbiology and Parasitology</DEPARTMENT><ORGANISATION>College of Medicine, University of Lagos</ORGANISATION><ADDRESS_1>F Block</ADDRESS_1><CITY>Lagos</CITY><ZIP>PMB 12003</ZIP><COUNTRY CODE="NG">Nigeria</COUNTRY><PHONE_1>+234 8023163319</PHONE_1><PHONE_2>+234 1 5453760 74 ext: 2230</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-05-12 16:33:30 +0200" MODIFIED_BY="Fernanda Carvalho"><PERSON ID="DC842ABF82E26AA201BA4B54681D7A9D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Oyinlola</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Oduyebo</LAST_NAME><POSITION>Lecturer</POSITION><EMAIL_1>oyinoduyebo@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medical Microbiology and Parasitology</DEPARTMENT><ORGANISATION>College of Medicine, University of Lagos</ORGANISATION><ADDRESS_1>F Block</ADDRESS_1><CITY>Lagos</CITY><ZIP>PMB 12003</ZIP><COUNTRY CODE="NG">Nigeria</COUNTRY><PHONE_1>+234 8023163319</PHONE_1><PHONE_2>+234 1 5453760 74 ext: 2230</PHONE_2></ADDRESS></PERSON><PERSON ID="17682" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rose</FIRST_NAME><MIDDLE_INITIALS>I</MIDDLE_INITIALS><LAST_NAME>Anorlu</LAST_NAME><POSITION>Senior Lecturer</POSITION><EMAIL_1>rianorlu2004@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Lagos</ORGANISATION><ADDRESS_1>College of Medicine</ADDRESS_1><ADDRESS_2>Surulere</ADDRESS_2><CITY>Lagos</CITY><ZIP>PMB 12003</ZIP><COUNTRY CODE="NG">Nigeria</COUNTRY><PHONE_1>+234 802 3016856</PHONE_1><FAX_1>+234 1 5851432</FAX_1></ADDRESS></PERSON><PERSON ID="DC84298682E26AA201BA4B549AA1105D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Folasade</FIRST_NAME><MIDDLE_INITIALS>T</MIDDLE_INITIALS><LAST_NAME>Ogunsola</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>ftogunsola@aol.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medical Microbiology and Parasitology</DEPARTMENT><ORGANISATION>College of Medicine, University of Lagos</ORGANISATION><CITY>Lagos</CITY><ZIP>PMB 12003</ZIP><COUNTRY CODE="NG">Nigeria</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-02-16 12:01:24 -0300" MODIFIED_BY="Rebecca Gray">
<UP_TO_DATE>
<DATE DAY="5" MONTH="12" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="12" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2009-02-16 12:05:52 -0300" MODIFIED_BY="Rebecca Gray"/>
<HISTORY MODIFIED="2009-02-16 12:06:30 -0300" MODIFIED_BY="Rebecca Gray">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-16 12:05:52 -0300" MODIFIED_BY="Rebecca Gray">
<DATE DAY="2" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>College of Medicine, University of Lagos</NAME>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Reviews for Africa Programme Fellowship</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-05-12 11:26:48 -0300" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-05-12 11:26:48 -0300" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-02-16 11:14:43 -0300" MODIFIED_BY="Rebecca Gray">The effects of antimicrobial treatment on bacterial vaginosis in non-pregnant women  </TITLE>
<SUMMARY_BODY MODIFIED="2009-05-12 11:26:48 -0300" MODIFIED_BY="[Empty name]">
<P>Bacterial vaginosis (BV) is a very common cause of symptomatic and asymptomatic vaginal infection. It has been associated with a high incidence of obstetric and gynaecologic complications and an increased risk of transmission of HIV (human immunodeficiency virus). This review evaluated the effectiveness and adverse effects of antimicrobial agents used to treat BV in non-pregnant women. Twenty-four trials involving 4422 women were reviewed. With regard to less treatment failure, clindamycin was superior to placebo but comparable to metronidazole, irrespective of the dose regimen. Metronidazole tended to cause a higher rate of adverse events, such as metallic taste and nausea and vomiting, than did clindamycin. Oral lactobacillus combined with metronidazole was more effective than metronidazole alone. Administered in an intravaginal gelatin tablet, lactobacillus was also more effective than oral metronidazole. Triple sulfonamide cream was less effective compared with clindamycin. Hydrogen peroxide douche was not as effective as a single 2 g dose of metronidazole yet caused more harms. Only one trial involved asymptomatic women and the result was not conclusive. There was insufficient evidence to reach a conclusion on the effectiveness of other promising drugs. Drugs effective for bacterial vaginosis include clindamycin preparations, oral metronidazole, and oral and intravaginal tablets of lactobacillus. Adverse effects of metronidazole include metallic taste, and nausea and vomiting. Information on possible side effects of lactobacillus preparations is required.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-05-08 08:10:40 -0300" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-05-08 07:59:51 -0300" MODIFIED_BY="[Empty name]">
<P>Bacterial vaginosis (BV) is a very common cause of vaginitis that has been associated with a high incidence of obstetric and gynaecologic complications and increased risk of HIV-1 transmission. This has led to renewed research interest in its treatment.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-05-08 08:00:05 -0300" MODIFIED_BY="[Empty name]">
<P>To assess the effects of antimicrobial agents on BV in non-pregnant women.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-05-08 08:03:12 -0300" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>), MEDLINE, EMBASE, LILACS, and African Healthline (December 2007); and proceedings of relevant international conferences (from 1981 to date).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-09-11 11:46:24 -0300" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials comparing any two or more antimicrobial agents, or antimicrobial agents with placebo or no treatment, in women with clinical or Gram-stain criteria of BV.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-05-08 08:05:49 -0300" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed trial quality and extracted data from the original publications while the third author cross checked the data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-05-08 08:10:31 -0300" MODIFIED_BY="[Empty name]">
<P>Twenty-four trials involving 4422 participants were reviewed. Most examined symptomatic women only. Only seven trials analysed results by intention to treat; we re-analysed the remainder.</P>
<P>Compared with placebo, clindamycin showed a lower rate of treatment failure (relative risk (RR) 0.25, 95% confidence interval (CI) 0.16 to 0.37). Clindamycin and metronidazole showed identical rates of treatment failure, irrespective of regimen type, at two and four-week follow up (RR 1.01, 95% CI 0.69 to 1.46; RR 0.91, 95% CI 0.70 to 1.18, respectively). Clindamycin tended to cause a lower rate of adverse events (RR 0.75, 95% CI 0.56 to 1.02); metallic taste, and nausea and vomiting were more common in the metronidazole group (RR 0.08, 95% CI 0.1 to 0.59; RR 0.23, 95% CI 0.10 to 0.51, respectively). Given intravaginally as gelatin tablets, lactobacillus was more effective than oral metronidazole  (RR 0.20, 95% CI 0.05 to 0.08). Similarly, oral lactobacillus combined with metronidazole was more effective than metronidazole alone (RR 0.33, 95% CI 0.14 to 0.77). Clindamycin showed a lower rate of clinical failure than triple sulfonamide cream (RR 0.46, 95% CI 0.29 to 0.72). Hydrogen peroxide douche showed a higher rate of clinical failure (RR 1.75, 95% CI 1.02 to 3.00) and adverse events (RR 2.33, 95% CI 1.21 to 4.52) than a single 2 g dose of metronidazole.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-05-08 08:10:40 -0300" MODIFIED_BY="[Empty name]">
<P>Clindamycin preparations, oral metronidazole, and oral and intravaginal tablets of lactobacillus were effective for bacterial vaginosis. Hydrogen peroxide douche and triple sulphonamide cream were ineffective. Metronidazole caused metallic taste, nausea and vomiting. We need better-designed trials with larger sample sizes to test the effectiveness of promising drugs.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-05-09 04:56:50 -0300" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-05-08 08:40:28 -0300" MODIFIED_BY="[Empty name]">
<P>Bacterial vaginosis (BV) is the name given to a vaginal disease that manifests as abnormal vaginal flora, sometimes in combination with malodorous discharge. This syndrome has been strongly associated with absence of lactobacilli and the presence of <I>Gardnerella vaginalis</I> and some anaerobes. There is still disagreement on the specific roles played by each organism and the exact sequence of events in the vagina that leads to the clinical expression we recognize as BV (<LINK REF="REF-Joesoef-1999a" TYPE="REFERENCE">Joesoef 1999a</LINK>).</P>
<P>
<I>Lactobacillus</I> species are the most prevalent organisms in the healthy vagina and serve to protect it from being colonised by potentially pathogenic organisms (<LINK REF="REF-Eschenbach-1989" TYPE="REFERENCE">Eschenbach 1989</LINK>; <LINK REF="REF-Hill-1984" TYPE="REFERENCE">Hill 1984</LINK>). They are able to do this because they produce lactic acid, which maintains an acidic vaginal environment. They also produce hydrogen peroxide which is toxic to other organisms and prevents them from colonizing the vagina (<LINK REF="REF-Klebanoff-1991" TYPE="REFERENCE">Klebanoff 1991</LINK>). <I>Gardnerella vaginalis</I>, anaerobes, and sometimes <I>Mycoplasma hominis</I> and <I>Mobiluncus</I> species also colonise the vagina but in small numbers. In BV, there is overgrowth of these other organisms, suppression of lactobacilli, and a rise in pH. The overgrowth of the other bacteria is associated with biochemical changes including increased concentration of diamines, polyamines, organic acids, and enzymes such as mucinases, sialidases, and collagenases in vaginal fluid. These biochemical end products cause a further increase in pH and are responsible for the unpleasant fishy smell of the vaginal discharge present in women with BV. The discharge is more noticeable after unprotected intercourse and is typically thin, greyish, and homogenous. However, the disease is not associated with an obvious inflammatory response so most women tend to be asymptomatic (<LINK REF="REF-Hay-1994" TYPE="REFERENCE">Hay 1994</LINK>).</P>
<P>In clinical practice BV is diagnosed using the Amsel criteria. These include a thin greyish homogenous discharge, pH of vaginal fluid &gt; 4.5, release of a fishy odour on adding alkali, and clue cells (bacteria adherent to epithelial cells seen on microscopy). At least three of the four criteria have to be present for the diagnosis to be confirmed (<LINK REF="REF-Amsel-1983" TYPE="REFERENCE">Amsel 1983</LINK>). An alternative diagnostic method which is more relevant for asymptomatic women is the use of a Gram-stained vaginal smear with the Nugent or Spiegel score. The vaginal flora are examined and graded as normal (lactobacillus predominant), intermediate, or BV (lactobacillus-deficient mixed flora) (<LINK REF="REF-Spiegel-1983" TYPE="REFERENCE">Spiegel 1983</LINK>; <LINK REF="REF-Nugent-1991" TYPE="REFERENCE">Nugent 1991</LINK>).</P>
<P>BV is a very common cause of vaginitis in women of childbearing age. It occurs more commonly in sexually active women although infection in those who are not sexually active has been documented (<LINK REF="REF-Priestley-1997" TYPE="REFERENCE">Priestley 1997</LINK>). Although not regarded as a sexually transmitted infection (STI), BV is associated with sexual intercourse and is commonly studied along with STIs. Prevalence ranges from 17.7% in pregnant women to 40% in commercial sex workers (<LINK REF="REF-Dan-2003" TYPE="REFERENCE">Dan 2003</LINK>; <LINK REF="REF-Riedner-2003" TYPE="REFERENCE">Riedner 2003</LINK>; <LINK REF="REF-Tosun-2003" TYPE="REFERENCE">Tosun 2003</LINK>). In 2002 in Ibadan, Nigeria, BV was found to be the third most common ailment in commercial sex workers (<LINK REF="REF-Bakare-2002" TYPE="REFERENCE">Bakare 2002</LINK>). Other studies have shown that 20% to 51% of women in sub-Saharan Africa are infected (<LINK REF="REF-Begum-2003" TYPE="REFERENCE">Begum 2003</LINK>; <LINK REF="REF-Laurent-2003" TYPE="REFERENCE">Laurent 2003</LINK>).</P>
<P>BV is a mild disease but even when asymptomatic it has been associated with a high incidence of endometritis and pelvic inflammatory disease (PID) following abortion and gynaecologic procedures (<LINK REF="REF-Larsson-1992" TYPE="REFERENCE">Larsson 1992</LINK>; <LINK REF="REF-Soper-1993" TYPE="REFERENCE">Soper 1993</LINK>). Many studies have shown a strong association between BV and obstetric complications such as late miscarriages, premature rupture of the membranes, and preterm birth (<LINK REF="REF-Guaschino-2003" TYPE="REFERENCE">Guaschino 2003</LINK>; <LINK REF="REF-Leitich-2003" TYPE="REFERENCE">Leitich 2003</LINK>).</P>
<P>The emergence of the HIV pandemic and the recognition that ulcerative and non-ulcerative genital diseases interact and reinforce each other has made the control of such diseases more important than ever. Both symptomatic and asymptomatic BV have been strongly associated with an increased risk of HIV-1 transmission (<LINK REF="REF-Martin-1999" TYPE="REFERENCE">Martin 1999</LINK>). Since treatment could help to restore normal vaginal flora, identification and treatment of every case could reduce susceptibility of women to HIV-1 infection.</P>
<P>Antibiotic therapy is the mainstay of management of BV. Antimicrobials are directed at altering the abnormal flora by killing some of the organisms vital to the maintenance of BV. Treatment is then generally followed by a reversion to more typical, normal flora. This change is accompanied by the disappearance of signs and symptoms characteristic of BV.</P>
<P>Antibiotics traditionally used to treat BV include the 5-nitro-imidazoles like metronidazole, tinidazole, and more recently secnidazole, which are available as tablets or gel in single or multiple doses. They inhibit anaerobes that support <I>Gardnerella vaginalis</I> but do not affect lactobacilli, thereby reducing the risk of late-stage relapse (<LINK REF="REF-Hillier-1993" TYPE="REFERENCE">Hillier 1993</LINK>; <LINK REF="REF-Joesoef-1995" TYPE="REFERENCE">Joesoef 1995</LINK>; <LINK REF="REF-Joesoef-1999b" TYPE="REFERENCE">Joesoef 1999b</LINK>; <LINK REF="REF-Baylson-2004" TYPE="REFERENCE">Baylson 2004</LINK>). They are associated with mild gastro-intestinal side effects such as nausea and vomiting. Other side effects include metallic taste and, less commonly, hypersensitivity reactions (<LINK REF="REF-Bhaduri-1997" TYPE="REFERENCE">Bhaduri 1997</LINK>).</P>
<P>Clindamycin, which is a lincosamide, is considered to be an effective alternative drug to the 5-nitro-imidazoles. It is available as tablets, cream or gel and side effects include diarrhea and pseudomembranous colitis (<LINK REF="REF-Trexler-1997" TYPE="REFERENCE">Trexler 1997</LINK>).</P>
<P>All these antibiotics have been shown to achieve cure rates of 70% to 80% after four weeks of treatment in controlled trials (<LINK REF="REF-Lugo_x002d_Miro-1992" TYPE="REFERENCE">Lugo-Miro 1992</LINK>; <LINK REF="REF-Hillier-1999" TYPE="REFERENCE">Hillier 1999</LINK>). Recently, there has been renewed research interest in BV and efforts to identify more effective treatment have resulted in clinical trials of other antimicrobial agents that were not previously used, such as ciprofloxaxin, erythromycin, ornidazole (a nitro-imidazole), lactic acid, and hydrogen peroxide administered alone and in combinations. It has thus become necessary to investigate their effectiveness and safety in a systematic review (<LINK REF="REF-Covino-1993" TYPE="REFERENCE">Covino 1993</LINK>; <LINK REF="REF-Saracoglu-1998" TYPE="REFERENCE">Saracoglu 1998</LINK>; <LINK REF="REF-Andreeva-2002" TYPE="REFERENCE">Andreeva 2002</LINK>; <LINK REF="STD-Chaithong-2003" TYPE="STUDY">Chaithong 2003</LINK>; <LINK REF="STD-Milani-2003" TYPE="STUDY">Milani 2003</LINK>; <LINK REF="REF-Wilson-2005" TYPE="REFERENCE">Wilson 2005</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of antimicrobial agents on bacterial vaginosis in non-pregnant women. </P>
</OBJECTIVES>
<METHODS MODIFIED="2009-05-09 03:16:50 -0300" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-05-08 08:48:16 -0300" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-09-11 11:55:28 -0300" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-05-08 08:41:39 -0300" MODIFIED_BY="[Empty name]">
<P>Women with clinical (<LINK REF="REF-Amsel-1983" TYPE="REFERENCE">Amsel 1983</LINK>) or Gram-stain criteria of BV (<LINK REF="REF-Spiegel-1983" TYPE="REFERENCE">Spiegel 1983</LINK>; <LINK REF="REF-Nugent-1991" TYPE="REFERENCE">Nugent 1991</LINK>) in whom other causes of vaginal discharge have been excluded.</P>
<P>Excluded: pregnant women; a Cochrane review of antibiotics in pregnant women has been published (<LINK REF="REF-McDonald-2005" TYPE="REFERENCE">McDonald 2005</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-05-08 08:43:45 -0300" MODIFIED_BY="[Empty name]">
<P>Any antimicrobial agent (antibiotics, vaginal acidifying preparations or devices, pre- and probiotics in any dosage or regimen using any route of administration) compared with placebo or no treatment.<BR/>Comparison of any two or more antimicrobial regimens.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-05-08 08:48:16 -0300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Primary</HEADING>
<P>
<I>Treatment failure<BR/>
</I>Defined as at least three Amsel criteria, at: seven days after treatment, one to two-month follow up (relapse), or any other follow-up period in symptomatic women.<BR/>Abnormal vaginal flora consistent with BV as defined by Gram-stain scores (for example Nugent score 7 to 10) in asymptomatic women seven days after treatment or at one to two-month follow up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary</HEADING>
<P>
<I>Adverse events</I>
<BR/>Known adverse effects such as metallic taste, nausea, vomiting, diarrhea, hypersensitivity, and pseudomembranous colitis.<BR/>Any unknown adverse events that the participant or clinician considered to be serious.<BR/>Any event leading to discontinuation of therapy.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-05-09 02:54:01 -0300" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress). Specialised guidance on comprehensive searches was provided by the South African Cochrane Centre in Capetown.</P>
<SUBSECTION>
<HEADING LEVEL="5">Databases</HEADING>
<P>Using search terms for "Bacterial vaginosis" and "antimicrobial agents" the following databases were searched (1981 to December 2007).</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2007, Issue 4)</LI>
<LI>MEDLINE</LI>
<LI>EMBASE</LI>
<LI>LILACS</LI>
<LI>Africa Healthline</LI>
</UL>
<P>
<BR/>The full search strategy is listed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Conference proceedings</HEADING>
<P>We searched all the available proceedings of the following international conferences (from 1981 to date):</P>
<UL>
<LI>International conference of AIDS and STDs in Africa;</LI>
<LI>Biennial meeting of the International Society of Sexually Transmitted Diseases and Research;</LI>
<LI>Microbicides conferences (2004 and 2006).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Researchers, organizations and pharmaceutical companies</HEADING>
<P>We contacted organizations and individual researchers working in the field for unpublished and ongoing trials but none were reported. We contacted pharmaceutical companies producing the various antimicrobial agents for on-going trials. Only Pfizer answered and indicated they were not conducting any trials. Such companies (and the antimicrobial agent) included:</P>
<UL>
<LI>Aventis (metronidazole);</LI>
<LI>Trichem (clindamycin);</LI>
<LI>Pharmacia Canada (clindamycin)</LI>
<LI>Pfizer (tinidazole);</LI>
<LI>Mission Pharmacal (tinidazole).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Reference lists</HEADING>
<P>We also reviewed the reference lists of all studies identified by the above methods.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-05-09 03:16:50 -0300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Study selection</HEADING>
<P>The abstracts obtained were evaluated using the selection criteria described above to identify all potentially relevant studies. This was done independently by the three authors (OO, RA, FT). Using a form based on the inclusion criteria, full articles of the studies found relevant were assessed for eligibility. Disagreements were handled by discussion to reach consensus and, when necessary, consulting the review mentor. Translations were obtained as applicable and multiple publications from the same data set were only used once.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Assessment of methodological quality</HEADING>
<P>Methodological quality of the included trials was assessed according to generation of allocation sequence, allocation concealment, blinding, and loss to follow up. We used the following criteria and assessments.</P>
<P>1. Generation of allocation sequence: adequate (if the method used was described and the resulting sequences were unpredictable), unclear (if the method was not described), inadequate (sequences could be related to prognosis such as alternative allocation), or not done.</P>
<P>2. Allocation concealment: adequate (if participants and investigators enrolling participants could not foresee assignment), unclear (if method was not described), inadequate (if participants and investigators could foresee upcoming assignment), or not done.</P>
<P>3. Blinding of participant, caregivers, and outcome assessors: yes, no, or not stated.</P>
<P>4. Intention-to-treat analysis: yes (if all participants randomised were included in the final analysis), or no (if some were not).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Data extraction</HEADING>
<P>We extracted data on a self-developed standardised form, which was piloted by OO. The information that was extracted included general information on the trials; details on inclusion and exclusion criteria; methods of randomisation, allocation concealment; and blinding; length of follow up; loss to follow up; treatment benefits and harms. Where possible, data were extracted to allow an intention-to-treat analysis (we sought data on every participant with each outcome by allocated treatment group irrespective of adherence to treatment or length of follow up). We had only categorical outcomes and so recorded the total number of particpants and those experiencing the event in each group. Authors were contacted for missing data, incomplete data, or unclear information. OO and RA independently extracted data from the original publications while FO cross checked the data. Differences of opinion were resolved by consensus. OO entered the extracted data into RevMan4. She used double data entry.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Data analysis</HEADING>
<P>Studies were stratified in subcategories according to type of antibiotic and comparison groups (other antibiotic, placebo, or no treatment). We looked at the relative effects of treatment by calculating the risk ratios (RR) with 95% confidence intervals (CI). For statistically significant results, we determined the absolute effect of treatment by calculating absolute risk reduction (RD) and number needed to treat (NNT).</P>
<P>We performed meta-analyses for studies that could be combined, using Review Manager 4.2.8 software. Data were pooled using the random-effects model. Heterogeneity was assessed by Cochrane Q test (with 90% CI) and the I<SUP>2 </SUP>statistic. Significant heterogeneity was indicated by P &lt; 0.1 and I<SUP>2</SUP> &gt; 70%. We had intended to explore significant heterogeneity in subgroup analyses but could not because of insufficient data. Subgroups planned were clinical versus bacteriological failures, low-income versus high-income countries, oral versus topical (gel, cream, solution) regimens, and poor versus good-quality studies. We were to perform sensitivity analyses to explore the robustness of findings and quality issues, but most comparisons included only one trial.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-05-09 04:21:03 -0300" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-05-09 03:36:21 -0300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Trial selection</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Results of the search</HEADING>
<P>The search identified 701 references out of which 53 were considered eligible after initial screening (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). One ongoing study (<LINK REF="STD-Wilson-2005" TYPE="STUDY">Wilson 2005</LINK>) was identified from a conference proceeding. An attempt was made to contact the author but there was no response.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Included studies</HEADING>
<P>Out of the 53 studies retrieved, 24 trials involving 4422 participants were included in the review (see table 'Characteristics of included studies'). Nine of them, especially the large ones, were funded by pharmaceutical companies. One was funded by a university research fund and one by a national government fund. Sources of funding were not reported in the remaining trials. The trials were of varying size, ranging from a clinic-based study involving 22 women to large multicentre trials involving 23 countries. The trials were carried out in many parts of the world including the United States of America, Germany, Sweden, Italy, Venezuela, Thailand, Belgium, United Kingdom, Nigeria, and Austria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Excluded studies</HEADING>
<P>A total of 29 studies were excluded (see table 'Characteristics of excluded studies') for various reasons including:</P>
<UL>
<LI>not a randomised controlled trial (10 trials);</LI>
<LI>BV not diagnosed by Amsel's or Gram-stain criteria (14 trials);</LI>
<LI>particpants with STDs not excluded before randomisation (two trials);</LI>
<LI>randomisation not to drug but to sexual partner (two trials);</LI>
<LI>duplicate publications (one trial).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Interventions</HEADING>
<P>Various preparations (gel, ovule, cream, tablet, douche) of antimicrobials, acid buffer, and probiotics were studied. Six studies compared clindamycin (topical in four, oral in two) preparations with oral metronidazole (<LINK REF="STD-Greaves-1988" TYPE="STUDY">Greaves 1988</LINK>; <LINK REF="STD-Andres-1992" TYPE="STUDY">Andres 1992</LINK>; <LINK REF="STD-Schmitt-1992" TYPE="STUDY">Schmitt 1992</LINK>; <LINK REF="STD-Fischbach-1993" TYPE="STUDY">Fischbach 1993</LINK>; <LINK REF="STD-Paavonen--2000" TYPE="STUDY">Paavonen 2000</LINK>; <LINK REF="STD-Beigi-2004" TYPE="STUDY">Beigi 2004</LINK>). Different concentrations and preparations of clindamycin were compared in two studies (<LINK REF="STD-Livengood-1990" TYPE="STUDY">Livengood 1990</LINK>; <LINK REF="STD-Sobel-2001" TYPE="STUDY">Sobel 2001</LINK>). Clindamycin cream was also compared with: triple sulfonamide (<LINK REF="STD-McCormack-2001" TYPE="STUDY">McCormack 2001</LINK>), tinidazole and metronidazole in combination with acid buffering gel (<LINK REF="STD-Milani-2003" TYPE="STUDY">Milani 2003</LINK>), and lactobacillus (<LINK REF="STD-Eriksson-2005" TYPE="STUDY">Eriksson 2005</LINK>; <LINK REF="STD-Anukam-2006a" TYPE="STUDY">Anukam 2006a</LINK>; <LINK REF="STD-Anukam-2006b" TYPE="STUDY">Anukam 2006b</LINK>). Various preparations and regimens of metronidazole, alone and in combination (<LINK REF="STD-Voorspoels-2002" TYPE="STUDY">Voorspoels 2002</LINK>; <LINK REF="STD-Schwebke-2006" TYPE="STUDY">Schwebke 2006</LINK>); and secnidazole (<LINK REF="STD-Nunez-2005" TYPE="STUDY">Nunez 2005</LINK>) were studied. Three studies looked at single-dose regimens (<LINK REF="STD-Voorspoels-2002" TYPE="STUDY">Voorspoels 2002</LINK>; <LINK REF="STD-Chaithong-2003" TYPE="STUDY">Chaithong 2003</LINK>; <LINK REF="STD-Nunez-2005" TYPE="STUDY">Nunez 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Participants and outcomes</HEADING>
<P>Inclusion of participants was based on the study inclusion and exclusion criteria. Twenty-three of the 24 included trials looked at symptomatic women only. The women studied were between 15 and 75 years of age.</P>
<P>The trials measured a wide variety of well-defined outcomes. All except one (<LINK REF="STD-Schwebke-2000" TYPE="STUDY">Schwebke 2000</LINK>) measured treatment failure and side effects. These were measured at one follow-up visit only in eight trials (<LINK REF="STD-Greaves-1988" TYPE="STUDY">Greaves 1988</LINK>; <LINK REF="STD-Burana-1990" TYPE="STUDY">Burana 1990</LINK>; <LINK REF="STD-Livengood-1990" TYPE="STUDY">Livengood 1990</LINK>; <LINK REF="STD-Voorspoels-2002" TYPE="STUDY">Voorspoels 2002</LINK>; <LINK REF="STD-Chaithong-2003" TYPE="STUDY">Chaithong 2003</LINK>; <LINK REF="STD-Gerli-2003" TYPE="STUDY">Gerli 2003</LINK>; <LINK REF="STD-Eriksson-2005" TYPE="STUDY">Eriksson 2005</LINK>; <LINK REF="STD-Nunez-2005" TYPE="STUDY">Nunez 2005</LINK>) and at two follow-up visits in 16 trials. Both Amsel and Gram-stain criteria were possible for BV diagnosis. Thirteen trials used Amsel criteria both at baseline and follow up (<LINK REF="STD-Piot-1983" TYPE="STUDY">Piot 1983</LINK>; <LINK REF="STD-Greaves-1988" TYPE="STUDY">Greaves 1988</LINK>; <LINK REF="STD-Wathne-1989" TYPE="STUDY">Wathne 1989</LINK>; <LINK REF="STD-Burana-1990" TYPE="STUDY">Burana 1990</LINK>; <LINK REF="STD-Schinder-1991" TYPE="STUDY">Schinder 1991</LINK>; <LINK REF="STD-Paavonen--2000" TYPE="STUDY">Paavonen 2000</LINK>; <LINK REF="STD-Sobel-2001" TYPE="STUDY">Sobel 2001</LINK>; <LINK REF="STD-Voorspoels-2002" TYPE="STUDY">Voorspoels 2002</LINK>; <LINK REF="STD-Chaithong-2003" TYPE="STUDY">Chaithong 2003</LINK>; <LINK REF="STD-Gerli-2003" TYPE="STUDY">Gerli 2003</LINK>; <LINK REF="STD-Milani-2003" TYPE="STUDY">Milani 2003</LINK>; <LINK REF="STD-Eriksson-2005" TYPE="STUDY">Eriksson 2005</LINK>; <LINK REF="STD-Nunez-2005" TYPE="STUDY">Nunez 2005</LINK>); in 11 trials both methods were used for diagnosis at baseline; in the remainder only Amsel criteria were used to define outcomes at follow up. Only one trial (<LINK REF="STD-Eriksson-2005" TYPE="STUDY">Eriksson 2005</LINK>) used both Amsel and Gram-stain criteria to define treatment failure.</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-05-09 03:46:28 -0300" MODIFIED_BY="[Empty name]">
<P>The description of the interventions used in the studies was good and the outcomes were well described.</P>
<P>
<B>Randomisation</B>
<BR/>Nine trials reported adequate methods of randomisation: seven used computer-generated random numbers (<LINK REF="STD-Andres-1992" TYPE="STUDY">Andres 1992</LINK>; <LINK REF="STD-Fischbach-1993" TYPE="STUDY">Fischbach 1993</LINK>; <LINK REF="STD-Schwebke-2000" TYPE="STUDY">Schwebke 2000</LINK>; <LINK REF="STD-Chaithong-2003" TYPE="STUDY">Chaithong 2003</LINK>; <LINK REF="STD-Milani-2003" TYPE="STUDY">Milani 2003</LINK>; <LINK REF="STD-Beigi-2004" TYPE="STUDY">Beigi 2004</LINK>; <LINK REF="STD-Anukam-2006a" TYPE="STUDY">Anukam 2006a</LINK>), one used a table of random numbers (<LINK REF="STD-Nunez-2005" TYPE="STUDY">Nunez 2005</LINK>), and one used block randomisation (<LINK REF="STD-Schwebke-2006" TYPE="STUDY">Schwebke 2006</LINK>). An inadequate method, a random list, was used in one trial (<LINK REF="STD-Sobel-2001" TYPE="STUDY">Sobel 2001</LINK>). The method was unclear in the remaining trials.</P>
<P>
<B>Allocation concealment</B>
<BR/>Out of the nine trials which used adequate randomisation methods, allocation concealment was adequate in only six. Two such studies gave sequentially numbered medication tubes and drug packets to participants (<LINK REF="STD-Fischbach-1993" TYPE="STUDY">Fischbach 1993</LINK>; <LINK REF="STD-Nunez-2005" TYPE="STUDY">Nunez 2005</LINK>; <LINK REF="STD-Anukam-2006a" TYPE="STUDY">Anukam 2006a</LINK>). Two trials concealed allocation by a centralised phone-call procedure (<LINK REF="STD-Milani-2003" TYPE="STUDY">Milani 2003</LINK>; <LINK REF="STD-Schwebke-2006" TYPE="STUDY">Schwebke 2006</LINK>). The name of the drug was written on a paper and presented to investigators in a sealed envelope at enrollment in another study (<LINK REF="STD-Beigi-2004" TYPE="STUDY">Beigi 2004</LINK>). Although the randomisation method was unclear in one study, allocation was concealed by use of numbered tubes containing 50 g of vaginal cream supplied in sequence to participants as they entered the study (<LINK REF="STD-Livengood-1990" TYPE="STUDY">Livengood 1990</LINK>).<BR/>
<BR/>
<B>Blinding </B>
<BR/>Most of the trials were blinded. The participants, investigators, and outcome assessors were blinded in two trials (<LINK REF="STD-Livengood-1990" TYPE="STUDY">Livengood 1990</LINK>; <LINK REF="STD-Chaithong-2003" TYPE="STUDY">Chaithong 2003</LINK>). Investigators and participants were blinded in 12 trials (<LINK REF="STD-Piot-1983" TYPE="STUDY">Piot 1983</LINK>; <LINK REF="STD-Greaves-1988" TYPE="STUDY">Greaves 1988</LINK>; <LINK REF="STD-Andres-1992" TYPE="STUDY">Andres 1992</LINK>; <LINK REF="STD-Schmitt-1992" TYPE="STUDY">Schmitt 1992</LINK>; <LINK REF="STD-Fischbach-1993" TYPE="STUDY">Fischbach 1993</LINK>; <LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>; <LINK REF="STD-Schwebke-2000" TYPE="STUDY">Schwebke 2000</LINK>; <LINK REF="STD-McCormack-2001" TYPE="STUDY">McCormack 2001</LINK>; <LINK REF="STD-Paavonen--2000" TYPE="STUDY">Paavonen 2000</LINK>; <LINK REF="STD-Voorspoels-2002" TYPE="STUDY">Voorspoels 2002</LINK>; <LINK REF="STD-Eriksson-2005" TYPE="STUDY">Eriksson 2005</LINK>; <LINK REF="STD-Nunez-2005" TYPE="STUDY">Nunez 2005</LINK>), while investigators only were blinded in four trials (<LINK REF="STD-Wathne-1989" TYPE="STUDY">Wathne 1989</LINK>; <LINK REF="STD-Sobel-2001" TYPE="STUDY">Sobel 2001</LINK>; <LINK REF="STD-Milani-2003" TYPE="STUDY">Milani 2003</LINK>; Wilson 2005a). Only outcome assessors were blinded in one trial (<LINK REF="STD-Gerli-2003" TYPE="STUDY">Gerli 2003</LINK>). Four studies were not blinded (<LINK REF="STD-Burana-1990" TYPE="STUDY">Burana 1990</LINK>; <LINK REF="STD-Schinder-1991" TYPE="STUDY">Schinder 1991</LINK>; <LINK REF="STD-Beigi-2004" TYPE="STUDY">Beigi 2004</LINK>; <LINK REF="STD-Anukam-2006b" TYPE="STUDY">Anukam 2006b</LINK>).</P>
<P>
<B>Exclusions</B>
<BR/>Only seven of the trials analysed results by intention to treat (<LINK REF="STD-Wathne-1989" TYPE="STUDY">Wathne 1989</LINK>; <LINK REF="STD-Fischbach-1993" TYPE="STUDY">Fischbach 1993</LINK>; <LINK REF="STD-Paavonen--2000" TYPE="STUDY">Paavonen 2000</LINK>; <LINK REF="STD-Sobel-2001" TYPE="STUDY">Sobel 2001</LINK>; <LINK REF="STD-Chaithong-2003" TYPE="STUDY">Chaithong 2003</LINK>; <LINK REF="STD-Gerli-2003" TYPE="STUDY">Gerli 2003</LINK>; <LINK REF="STD-Milani-2003" TYPE="STUDY">Milani 2003</LINK>). Three of the remaining trials had less than 10% exclusions from analysis, leaving 13 trials with exclusion rates between 20% and 42%. Two studies applied exclusion criteria after participants had been randomised (<LINK REF="STD-Andres-1992" TYPE="STUDY">Andres 1992</LINK>; Sanchez 2004). In four studies rates of exclusion of randomised participants from analysis, including loss to follow up, were similar in the two study arms (<LINK REF="STD-Greaves-1988" TYPE="STUDY">Greaves 1988</LINK>; <LINK REF="STD-Fischbach-1993" TYPE="STUDY">Fischbach 1993</LINK>; <LINK REF="STD-McCormack-2001" TYPE="STUDY">McCormack 2001</LINK>; <LINK REF="STD-Eriksson-2005" TYPE="STUDY">Eriksson 2005</LINK>). In the other studies the details were not available for comparison.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-05-09 04:21:03 -0300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Metronidazole versus placebo</HEADING>
<P>There were two trials that compared topical metronidazole with placebo gel (<LINK REF="STD-Schwebke-2000" TYPE="STUDY">Schwebke 2000</LINK>; <LINK REF="STD-Voorspoels-2002" TYPE="STUDY">Voorspoels 2002</LINK>). The Schwebke trial compared 0.75% metronidazole gel applied intravaginally at bedtime for five days with placebo. The Voorspoel study had four intervention arms with various concentrations of single-dose bioadhesive tape metronidazole (100 mg, 250 mg, and 500 mg) and a placebo. In order to include the three treatment arms in the meta-analysis, the number of participants in the placebo group was divided into three (Ramsay 2003). Metronidazole showed a lower failure rate compared with placebo. The combined RR was 0.58 (95% CI 0.44 to 0.78) with no heterogeneity (Comparison 01-01). Only the Schwebke trial had results for the second follow-up visit and metronidazole showed no effect at four weeks (Comparison 01-02: RR 0.68, 95% CI 0.44 to 1.07). In terms of adverse effects, Comparison 01 03 showed a higher rate of candida infection in the metronidazole group although this was not significant (RR 13.34, 95% CI 0.78 to 228.71).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Clindamycin versus placebo</HEADING>
<P>Clindamycin cream was compared with placebo in two trials (<LINK REF="STD-Livengood-1990" TYPE="STUDY">Livengood 1990</LINK>; <LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>). The Livengood trial had four intervention arms. In the three treatment arms 0.1%, 1%, or 2% clindamycin was applied intravaginally twice daily for five days. The participants in the placebo arm were divided into three for analysis (<LINK REF="REF-Ramsay-2003" TYPE="REFERENCE">Ramsay 2003</LINK>). The clindamycin regimen used in the Stein trial was 2% cream applied intravaginally at bedtime for seven days. Clindamycin cream showed a benefit with lower treatment failure compared to placebo. The combined RR was 0.25 (95% CI 0.16 to 0.37) with no heterogeneity (Comparison 02-01) while the combined RD was -0.46 (95% CI -0.65 to -0.28). In the Stein trial, clindamycin use was associated with a lower clinical failure rate (Comparison 02-02: RR 0.39, 95% CI 0.22 to 0.68) and a lower bacteriologic failure rate (RR 0.48, 95%CI 0.33 to 0.72) at the second follow-up visit; an NNT of 6 and 7, respectively, were calculated from the RD of -0.18 (95% CI -0.29 to -0.08) for clinical failure at first follow up, and RD of -0.14 (95% CI -0.2 to -0.03) for bacteriologic failure at the second follow-up visit.</P>
<P>
<B>Clindamycin versus metronidazole</B>
<BR/>Six trials (<LINK REF="STD-Greaves-1988" TYPE="STUDY">Greaves 1988</LINK>; <LINK REF="STD-Andres-1992" TYPE="STUDY">Andres 1992</LINK>; <LINK REF="STD-Schmitt-1992" TYPE="STUDY">Schmitt 1992</LINK>; <LINK REF="STD-Fischbach-1993" TYPE="STUDY">Fischbach 1993</LINK>; <LINK REF="STD-Paavonen--2000" TYPE="STUDY">Paavonen 2000</LINK>; <LINK REF="STD-Beigi-2004" TYPE="STUDY">Beigi 2004</LINK>) compared clindamycin with metronidazole. In three trials, 2% clindamycin cream 5 g at bedtime for seven days was compared with oral metronidazole 500 mg twice daily for seven days (Andres 1992; Schmitt 1992; Fischbach 1993). The Paavonen trial compared clindamycin ovule 100 mg daily for three days with oral metronidazole 500 mg twice daily for seven days. The Beigi trial compared clindamycin ovule 100 mg daily for three days with 0.75% metronidazole gel 5 g daily for five days, while the Greaves trial compared oral clindamycin 500 mg twice daily for seven days with oral metronidazole 500 mg twice daily for seven days.</P>
<P>Comparisons 03-01 and 03-02 for clinical failure at the first (RR 1.01, 95% CI 0.69 to 1.46) and second (RR 0.91, 95% CI 0.70 to 1.18) follow-up visit showed identical effects of clindamycin and metronidazole irrespective of regimen type, with no heterogeneity. Bacteriologic failure was an outcome measure only in the Fischbach trial. A lower rate favoured clindamycin but this effect was significant only at the second follow up (Comparison 03-03: RR 0.60, 95% CI 0.24 to1.53; Comparison 03-04: RR 0.45, 95% CI 0.23 to 0.89). Relapse rates in the Schmitt trial were comparable (Comparison 3-12: RR 1, 95% CI 0.44 to 2.27).</P>
<P>In four of the trials in which topical clindamycin was compared to oral metronidazole, clindamycin tended to cause a lower rate of adverse events (Comparison 03-06: RR 0.75, 95% CI 0.56 to 1.02). Analysed further the adverse effects metallic taste, and nausea and vomiting were more common in the metronidazole groups (Comparison 03-07: RR 0.08, 95% CI 0.1 to 0.59; Comparison 03-08: RR 0.23, 95% CI 0.10 to 0.51). In Comparisons 03-05, 03-06, and 03-09, rates of other reported side effects were identical (RR 1.62, CI 0.35 to 7.43; RR 1.12, 95% CI 0.79 to 1.58; RR 1.70, 95% CI 0.50 to 5.73, respectively).</P>
<P>
<B>Tinidazole versus metronidazole</B>
<BR/>A singe oral dose of 2 g tinidazole was compared with 500 mg metronidazole administered twice daily for seven days (Burana 1990) and one vaginal tablet of 400 mg metronidazole twice daily on five consecutive days (<LINK REF="STD-Schinder-1991" TYPE="STUDY">Schinder 1991</LINK>). While tinidazole appeared to be more effective in the Schinder trial (RR 0.17, 95% CI 0.02 to 1.35) it appeared less effective in the Burana trial (Comparison 04-01: RR 1.75, 95% CI 0.55 to 5.61), although neither finding was significant. Findings were similar for overall adverse events (Comparison 04-02: RR 0.36, 95% CI 0.12 to 1.07; RR 2.05, 95% CI 0.19 to 21.70) and for nausea and vomiting, respectively (Comparison 04-03: RR 0.38, 95% CI 0.11 to1.33; RR 1.03, 95% CI 0.07 to 5.82).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Clindamycin ovule versus clindamycin cream</HEADING>
<P>Clindamycin vaginal ovules 100 mg daily for three days were compared with 2% clindamycin vaginal cream 5 g at bedtime for seven days (<LINK REF="STD-Sobel-2001" TYPE="STUDY">Sobel 2001</LINK>). As shown in Comparisons 05-01 and 05-02, at both follow-up visits the rates of clinical failure were identical in both groups. The rates of adverse effects in general, discontinuation, and candida infection were also identical (Comparisons 05-03, 05-04, 05-05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Vaginal lactobacilli tampons versus placebo</HEADING>
<P>Lactobacilli tampons were compared with placebo adjunctive therapy after an open treatment with clindamycin ovule 100 mg daily for three days (<LINK REF="STD-Eriksson-2005" TYPE="STUDY">Eriksson 2005</LINK>). There was no difference in the rates of cure at first (Comparison 06-01: RR 0.90, 95% CI 0.71 to 1.14) or second (Comparison 06-02: RR 0.85, 95% CI 0.67 to 1.08) follow up; nor in adverse effects like candidiasis (Comparison 06-03: RR 1.70, 95% CI 0.58 to1.98), and itching or burning (Comparison 06-04: RR 0.50, 95% CI 0.16 to1.63).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lactobacilli versus metronidazole</HEADING>
<P>One<B> </B>trial compared two gelatin capsules of lactobacillus species (spp) (containing 10<SUP>9</SUP> organisms) inserted vaginally for five nights with metronidazole 500 mg given orally twice daily for five days (<LINK REF="STD-Anukam-2006b" TYPE="STUDY">Anukam 2006b</LINK>). Clinical failure rates were identical at two weeks (Comparison 14-01) but lower in the lactobacillus group at four-weeks follow up (Comparison 14-02: RR 0.27, 95% CI 0.09 to 0.83; RD -0.40, 95% CI -0.67 to -0.13, NNT 3). There was a similar trend for bacteriologic failure (Comparison 14-03: RR 0.20, 95% CI 0.05 to 0.08; RD -0.40, 95% CI -0.66 to -0.14, NNT 3).</P>
<P>In another trial, oral metronidazole 500 mg twice daily for seven days was compared with the same regimen of metronidazole combined with oral lactobacillus (containing 10<SUP>9</SUP> organisms) given twice daily for 30 days (<LINK REF="STD-Anukam-2006a" TYPE="STUDY">Anukam 2006a</LINK>). Comparison 14-03 showed a lower rate of bacteriological failure in the lactobacillus plus metronidazole group (Comparison 14-03: RR 0.33, 95% CI 0.14 to 0.77). Meta-analysis of this trial with <LINK REF="STD-Anukam-2006b" TYPE="STUDY">Anukam 2006b</LINK>, which compared lactobacillus intravaginal gelatin capsule with oral metronidazole, showed a lower combined bacteriological failure rate for lactobacillus therapy (Comparison 14-03: RR 0.28, 95% CI 0.14 to 0.59; RD -0.27, 95% CI -0.46 to -0.07, NNT 4). There was no difference in the rates of adverse effects like headache and overeating (Comparison 14-06: RR 6.4, 95% CI 0.34 to 122.71) although the discontinuation rate from the study was higher in the oral lactobacillus group (Comparison 14-05: RR 4.92, 95% CI 1.51 to 16.06).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oral tinidazole combined with an acid gel versus clindamycin</HEADING>
<P>In the Milani trial (<LINK REF="STD-Milani-2003" TYPE="STUDY">Milani 2003</LINK>), the effects of oral 2g single dose of tinidazole in addition to an acid buffering gel were compared with 2% clindamycin cream for seven days. One week after therapy, the women in the tinidazole group were treated with the acid gel 2 g every three days for an additional three weeks. Tinidazole was found to be comparable with clindamycin after one week of treatment (Comparison 08-01: RR 1.0, 95% CI 0.32 to 3.12). At the second follow-up visit, there appeared to be a lower failure rate in the clindamycin group although this effect was not significant (Comparison 08-02: RR 0.29, 95% CI 0.06 to 1.27). Relapse rates were also comparable (Comparison 08-05: RR 0.33, 95% CI 0.04 to 3.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Clindamycin cream versus triple sulfonamide cream</HEADING>
<P>A 2% clindamycin cream at bedtime for seven days was compared with triple sulfonamide cream at bedtime for seven days (<LINK REF="STD-McCormack-2001" TYPE="STUDY">McCormack 2001</LINK>). The comparison showed a lower clinical failure rate in the clindamycin group at first follow up, though this effect was not significant (Comparison 09-01: RR 0.61, 95% CI 0.34 to 1.09). However, a lower clinical failure rate at second follow up (Comparison 09-02: RR 0.36, 95% CI 0.23 to 0.59; RD -0.55, 95% CI -0.50 to -0.21, NNT 2) and lower bacteriologic failure rates at first (Comparison 09-03: RR 0.37, 95% CI 0.18 to 0.75; RD -0.19, 95% CI -0.32 to -0.07, NNT 5) and second (Comparison 09-04: RR 0.46, 95% CI 0.29 to 0.72; RD -0.28, 95% CI -0.42 to -0.13, NNT 4) follow ups were seen with clindamycin cream. The rate of discontinuation from the trial was comparable in both groups (Comparison 09-13: RR 3.11, 95% CI 0.13 to 75.68).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Polyhexamethylene biguanide (PHMB) douche compared with clindamycin cream</HEADING>
<P>A single dose of polyhexamethylene biguanide douche was compared with 2% clindamycin cream for seven days (<LINK REF="STD-Gerli-2003" TYPE="STUDY">Gerli 2003</LINK>). The rates of clinical failure were identical (Comparison 10-01: RR 1.03, 95% CI 0.37 to 2.86). The PMHB group had a higher rate of adverse effects (Comparison 01-02: RR 0.13, 95% CI 0.02 to 0.96) though the higher rates of individual adverse event like candidiasis (Comparison 10-03: RR 0.15, 95% CI 0.02 to 1.18) and discontinuation of treatment (Comparison 10-04: RR 0.15, 95% CI 0.02 to 1.18) were not significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Single hydrogen peroxide douche versus single-dose oral metronidazole</HEADING>
<P>A 20 ml douche of 3% hydrogen peroxide as a single dose was compared with a 2 g single dose of oral metronidazole (<LINK REF="STD-Chaithong-2003" TYPE="STUDY">Chaithong 2003</LINK>). The rate of clinical failure was higher in the hydrogen peroxide group than the metronidazole group (Comparison 11-01: RR 1.75, 95% CI 1.02 to 3.00). The rate of reduced eating and vomiting was lower (Comparison 11-02: RR 0.29, 95% CI 0.15 to 0.8) but the rate of vaginal irritation was higher (Comparison 11-03: RR 2.33, 95% CI 1.21 to 4.52) in the hydrogen peroxide group. An NNH of 5 was calculated from an RD of 0.19 (95% CI 0.05 to 0.33).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cefadroxil versus metronidazole</HEADING>
<P>Oral cefadroxil 500 mg twice a day for seven days was compared to oral metronidazole 400 mg twice a day for seven days (<LINK REF="STD-Wathne-1989" TYPE="STUDY">Wathne 1989</LINK>). Cefadroxil was comparable to metronidazole in clinical failure rates at both follow-up visits (Comparisons 12-01, 12-02). Candida infection rates were also comparable (Comparison 12-03: RR 1.00, 95% CI 0.17 to 5.89).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secnidazole 1 g versus 2 g</HEADING>
<P>A 1 g dose of secnidazole was compared with 2 g, both in a single-dose oral regimen (<LINK REF="STD-Nunez-2005" TYPE="STUDY">Nunez 2005</LINK>). Both were comparable in clinical failure rate (Comparison 13 01: RR 5.13, 95% CI 0.27 to 96.0) and rate of adverse events (Comparison 13-02: RR 1.00, 95% CI 0.17 to 5.89).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Seven-day versus 14-day regimen of metronidazole with or without azithromycin</HEADING>
<P>In the Schwebke trial, which had four arms, 750 mg oral metronidazole for seven days was compared with the same dose for 14 days, with or without 1g oral azithromycin on days one and three (<LINK REF="STD-Schwebke-2006" TYPE="STUDY">Schwebke 2006</LINK>). In order to compare the three arms with the recommended seven-day regimen (control group) in a meta-analysis, the number of participants in the control group was divided into three. The 14-day regimen of metronidazole combined with azithromycin showed a lower failure rate than the seven-day regimen without azithromycin at two weeks (Comparison 15-01: RR 0.49, CI 0.6 to 0.93), which was not sustained at four-weeks follow up. The 14-day regimen without azithromycin and the seven-day regimen with azithromycin had equivalent clinical failure and adverse effect rates with the seven-day regimen without azithromycin, at both follow-up visits (Comparisons 15-01,15-02, 15-03, 15-04, 15-05).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-05-09 04:49:27 -0300" MODIFIED_BY="[Empty name]">
<P>This review shows that clindamycin cream was more effective than placebo for eradicating symptoms of bacterial vaginosis. Meta-analysis of six trials also showed that clindamycin and metronidazole have equivalent effectiveness for eradication of symptoms of BV, achieving clinical cure in 91% and 91.9 % of cases after two to three weeks and 84.8% and 84.3% of cases after four weeks of treatment, respectively. The six trials compared various regimens of both topical and oral preparations of the antibiotics and individually showed a tendency for equivalent effectiveness, which meta-analysis confirmed. Clindamycin tablets, ovules, cream, and oral metronidazole were effective (<LINK REF="STD-Greaves-1988" TYPE="STUDY">Greaves 1988</LINK>; <LINK REF="STD-Livengood-1990" TYPE="STUDY">Livengood 1990</LINK>; <LINK REF="STD-Andres-1992" TYPE="STUDY">Andres 1992</LINK>; <LINK REF="STD-Schmitt-1992" TYPE="STUDY">Schmitt 1992</LINK>; <LINK REF="STD-Fischbach-1993" TYPE="STUDY">Fischbach 1993</LINK>; <LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>; <LINK REF="STD-Paavonen--2000" TYPE="STUDY">Paavonen 2000</LINK>; <LINK REF="STD-Beigi-2004" TYPE="STUDY">Beigi 2004</LINK>). Evidence for the effectiveness of metronidazole gel must be sought in future studies. The administration of metronidazole bioadhesive tape was studied in only one trial which investigated asymptomatic women and was reported to be ineffective (<LINK REF="STD-Voorspoels-2002" TYPE="STUDY">Voorspoels 2002</LINK>).</P>
<P>Topical preparations are available for both clindamycin and metronidazole and would be especially useful in pregnancy and other situations in which such preparations are preferred. They are, however, more expensive than oral preparations and are not likely to be available in developing countries.</P>
<P>The disadvantage of oral regimens is the long duration of treatment, five to seven days, which may not be complied with especially by women who are asymptomatic. A systematic review compared single with multiple-dose regimens of metronidazole and found them to have equivalent effectiveness (<LINK REF="REF-Lugo_x002d_Miro-1992" TYPE="REFERENCE">Lugo-Miro 1992</LINK>). None of the nine trials in the Lugo-Miro review were eligible for this review because the standardised methods of BV diagnosis, a criterion for eligibility in this review, were not used. Such trials which examine the clinical effectiveness of single-dose metronidazole are urgently needed, especially from developing countries where costs as well as compliance to long-duration regimens are a problem.</P>
<P>While both clindamycin and metronidazole were equivalent in resolving signs and symptoms of BV, clindamycin was shown in one trial to be more effective than metronidazole for bacteriological cure, although the evidence was not very strong (<LINK REF="STD-Fischbach-1993" TYPE="STUDY">Fischbach 1993</LINK>). A higher bacteriologic failure rate of metronidazole would be of concern because it is the more affordable option for developing countries.</P>
<P>Unfortunately only the Fischbach trial reported bacteriologic failure as an outcome. Though the trial was characterized by a large sample size, there was a high rate of exclusions from analysis. Intention-to-treat analysis in this review served to eliminate attrition bias; nevertheless we need to have good quality trials reporting bacteriologic failure so that the implication of this finding can be more meaningful. Furthermore, the higher bacteriologic failure was evident only at four weeks and not at two-weeks follow up, so it is not quite clear whether this outcome would actually mean failed therapy or relapse, especially since relapse was not reported as defined by this review. The only trial that reported relapse found high but equivalent rates with both antibiotics (<LINK REF="STD-Schmitt-1992" TYPE="STUDY">Schmitt 1992</LINK>).</P>
<P>Metronidazole is the cheaper, more available, and widely used option in developing countries but causes more adverse effects than clindamycin, in particular a metallic taste and gastro-intestinal symptoms (<LINK REF="STD-Greaves-1988" TYPE="STUDY">Greaves 1988</LINK>; <LINK REF="STD-Schmitt-1992" TYPE="STUDY">Schmitt 1992</LINK>; <LINK REF="STD-Fischbach-1993" TYPE="STUDY">Fischbach 1993</LINK>). One trial showed that metronidazole did not cause more candidiasis than placebo (<LINK REF="STD-Schwebke-2000" TYPE="STUDY">Schwebke 2000</LINK>). Also, the occurrence of post-antibiotic candidiasis was found to be equivalent for both drugs (<LINK REF="STD-Schmitt-1992" TYPE="STUDY">Schmitt 1992</LINK>; <LINK REF="STD-Fischbach-1993" TYPE="STUDY">Fischbach 1993</LINK>; <LINK REF="STD-Paavonen--2000" TYPE="STUDY">Paavonen 2000</LINK>; <LINK REF="STD-Beigi-2004" TYPE="STUDY">Beigi 2004</LINK>).</P>
<P>Oral metronidazole and topical clindamycin are not 100% effective and have high relapse rates, so it is clear that we need other agents that can increase their effectiveness or provide good alternatives. Lactobacillus probiotic given orally for 30 days to augment oral metronidazole proved to be more effective for clinical and bacteriologic eradication of BV compared with metronidazole alone (<LINK REF="STD-Anukam-2006a" TYPE="STUDY">Anukam 2006a</LINK>). When given intravaginally for five days as a gelatin tablet it was as effective as oral metronidazole administered for five days; but at four weeks lactobacillus gelatin tablets were more effective than oral metronidazole (<LINK REF="STD-Anukam-2006b" TYPE="STUDY">Anukam 2006b</LINK>). Adding lactobacillus to clindamycin ovules did not improve effectiveness but this was investigated in only one trial (<LINK REF="STD-Eriksson-2005" TYPE="STUDY">Eriksson 2005</LINK>).</P>
<P>The use of lactobacillus probiotic was not associated with adverse effects in any of the trials. In one of the two relevant trials some women reported headache and increased rate of eating, but there is no evidence that these were associated with the probiotic. However, the significantly higher rate of discontinuation from the lactobacillus group probably implies unreported but significantly higher rates of adverse effects attributable to the probiotic (<LINK REF="STD-Anukam-2006a" TYPE="STUDY">Anukam 2006a</LINK>). Emphasis should, therefore, be laid on identifying side effects in future studies.</P>
<P>Oral tinidazole appears to be an effective drug for BV and is equivalent in effectiveness to clindamycin (<LINK REF="STD-Milani-2003" TYPE="STUDY">Milani 2003</LINK>). Unfortunately only one trial with a small sample size of 32 participants provided this evidence. Moreover, the two trials that compared it with metronidazole gave opposite but insignificant results. The trials could not be combined because of significant heterogeneity (<LINK REF="STD-Burana-1990" TYPE="STUDY">Burana 1990</LINK>; <LINK REF="STD-Schinder-1991" TYPE="STUDY">Schinder 1991</LINK>). More trials should investigate the effectiveness and adverse effects of tinidazole as the single-dose regimen makes it attractive for use.</P>
<P>While there is good clinical and bacteriologic evidence that triple sulphonamide cream (<LINK REF="STD-McCormack-2001" TYPE="STUDY">McCormack 2001</LINK>) and hydrogen peroxide douche (<LINK REF="STD-Chaithong-2003" TYPE="STUDY">Chaithong 2003</LINK>) are not as effective as clindamycin, polyhexamethylene biguanide douche shows promise as there is good evidence of equivalent effectiveness with clindamycin, but in only one small trial which also found reduced side effects compared with clindamycin (<LINK REF="STD-Gerli-2003" TYPE="STUDY">Gerli 2003</LINK>). In case of cefadroxil versus metronidazole, the small sample size did not permit a clear effect to be found (<LINK REF="STD-Wathne-1989" TYPE="STUDY">Wathne 1989</LINK>).</P>
<P>A 1 g dose of secnidazole compared with 2 g secnidazole showed equivalent effectiveness in one trial but there is a need to compare this drug with either metronidazole or clindamycin, which are the current gold standards in a large population.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-05-09 04:56:50 -0300" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-05-09 04:53:53 -0300" MODIFIED_BY="[Empty name]">
<P>This review found clindamycin in cream, ovules, and tablets and oral metronidazole to be effective for eradicating symptoms of bacterial vaginosis. It also found that lactobacillus probiotic given orally for 30 days augments the therapeutic effects of metronidazole, and when given intravaginally as gelatin tablet twice daily for five days is more effective than metronidazole gel.</P>
<P>Metronidazole causes adverse effects like nausea and metallic taste. There is no evidence that either of the two antibiotics cause vaginal candidiasis if given for seven days, or that clindamycin causes diarrhoea if given for five days.</P>
<P>There is no advantage in increasing the duration of metronidazole therapy beyond seven days. With the two antibiotics, attention must be paid to the possibility of relapse or clinical failure, apparent at four-weeks follow up</P>
<P>Hydrogen peroxide douche and triple sulphonamide therapy are not effective for treatment of bacterial vaginosis.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-05-09 04:56:50 -0300" MODIFIED_BY="[Empty name]">
<P>There is a need for trials in asymptomatic women as the only trial in this review revealed lack of effectiveness of metronidazole gel, suggesting either the need to determine the effectiveness of metronidazole gel for BV or possible challenges of treatment in asymptomatic BV.</P>
<P>Larger, better-designed trials should investigate the effectiveness of topical metronidazole therapy and other promising drugs. There is an urgent need to study single-dose regimens of metronidazole, tinidazole and secnidazole, as well as relapse rates. Studies of adverse events associated with lactobacillus probiotic therapy are also needed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-05-09 04:57:23 -0300" MODIFIED_BY="[Empty name]">
<P>Dr Oyin Oduyebo was awarded a Reviews for Africa Programme Fellowship (www.mrc.ac.za/cochrane/rap.htm) funded by a grant from the Nuffield Commonwealth Programme, through The Nuffield Foundation. This review was partly developed at the South African Cochrane Centre. Drs George Schmid and Taryn Young provided guidance in the preparation of the review. We thank Dr Harriet MacLehose for her help during the various stages of protocol development.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-05-09 04:59:06 -0300" MODIFIED_BY="[Empty name]">
<P>OO Oduyebo: wrote the body of the review, contacted experts for trials and clarification of methods, contacted drug manufacturing companies, screened trials for inclusion, assessed methodical quality, and prepared submission for Cochrane HIV/AIDS Review Group.</P>
<P>R Anorlu: screened trials for inclusion, edited final versions of the protocol, and contributed to the body of the review.</P>
<P>FT Ogunsola: screened trials for inclusion, contacted drug manufacturing companies, edited the final versions of the protocol and review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-05-12 11:27:30 -0300" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-05-12 11:27:30 -0300" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-05-08 09:25:34 -0300" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Andres-1992" NAME="Andres 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andres FJ, Parker R, Hosein I, Benrubi GI</AU>
<TI>Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: A prospective double -blind clinical trial</TI>
<SO>Southern Medical Journal</SO>
<YR>1992</YR>
<VL>85</VL>
<NO>11</NO>
<PG>1077-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anukam-2006a" NAME="Anukam 2006a" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anukam K, Osazuwa E, Ahonkhai I, Ngwu M, Osemene G, Bruce A, Reid G</AU>
<TI>Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC -14: randomised, double blind, placebo controlled trial</TI>
<SO>Microbes and Infection</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>6</NO>
<PG>1450-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anukam-2006b" NAME="Anukam 2006b" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anukam K, Osazuwa E, Osemene G, Ahonkhai I, Ehigiagbe F, Bruce A, Reid G</AU>
<TI>Clinical study comparing probiotic Lactobacillus GR-1 and RC -14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis</TI>
<SO>Microbes and Infection</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>12-13</NO>
<PG>2772-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beigi-2004" MODIFIED="2009-05-08 09:04:37 -0300" MODIFIED_BY="[Empty name]" NAME="Beigi 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-08 09:04:37 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beigi RH, Austin MN, Meyn LA, Krohn MA, Hillier SL</AU>
<TI>Antimicrobial resistance associated with the treatment of bacterial vaginosis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>191</VL>
<PG>1124-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burana-1990" MODIFIED="2009-05-08 09:05:17 -0300" MODIFIED_BY="[Empty name]" NAME="Burana 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-05-08 09:05:17 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buranawarodomkul P, Chandeying V, Sutthijumroon S</AU>
<TI>Seven day metronidazole versus single dose tinidazole as therapy for non-specific vaginitis</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>1990</YR>
<VL>73</VL>
<PG>283-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaithong-2003" MODIFIED="2009-05-08 09:04:05 -0300" MODIFIED_BY="[Empty name]" NAME="Chaithong 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-08 09:04:05 -0300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chaithongwongwatthana S, Limpongsanurak S, Sitthi-Amorn C</AU>
<TI>Single hydrogen peroxide vaginal douching versus single dose oral metronidazole for the treatment of bacterial vaginosis: a randomised controlled study</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2003</YR>
<VL>86 Suppl 2</VL>
<PG>379-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eriksson-2005" MODIFIED="2009-05-08 09:07:18 -0300" MODIFIED_BY="[Empty name]" NAME="Eriksson 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-08 09:07:18 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eriksson K, Carlsson B, Forsum U, Larsson PG</AU>
<TI>A double blind treatment study of bacterial vaginosis with normal vaginal lactobacilli after an open treatment with vaginal clindamycin ovule</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>2005</YR>
<VL>85</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischbach-1993" MODIFIED="2009-05-08 09:07:43 -0300" MODIFIED_BY="[Empty name]" NAME="Fischbach 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-05-08 09:07:43 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fischbaach F, Peterson EE, Weissenbacher ER, Martius J, Hossmann J, Mayer H</AU>
<TI>Efficacy of clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>82</VL>
<PG>405-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerli-2003" MODIFIED="2009-05-08 09:08:25 -0300" MODIFIED_BY="[Empty name]" NAME="Gerli 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-08 09:08:25 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerli S, Rossetti D, Di Renzo GC</AU>
<TI>A new approach for the treatment of bacterial vaginosis: use of polyhexamethylene biguanide. A prospective randomised study</TI>
<SO>European Review for Medical and Pharmacological Sciences</SO>
<YR>2003</YR>
<VL>7</VL>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greaves-1988" NAME="Greaves 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greaves WL, Chungafung J, Morris B, Haile A, Townsend JL</AU>
<TI>Clindamycin versus metronidazole in the treatment of bacterial vaginosis</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1988</YR>
<VL>72</VL>
<PG>799-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Livengood-1990" NAME="Livengood 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Livengood CH, Thomason JL, Hill GB</AU>
<TI>Bacctterial vaginosis: Treatment with topical intravaginal clindamycin phosphate</TI>
<SO>Obstetrics and Gynaecology</SO>
<YR>1990</YR>
<VL>76</VL>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Livengood-1990a" NAME="Livengood 1990a" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Livengood-1990b" NAME="Livengood 1990b" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCormack-2001" MODIFIED="2009-05-08 09:09:08 -0300" MODIFIED_BY="[Empty name]" NAME="McCormack 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-08 09:09:08 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCormack WM, Covino JM, Thomason JL, Eschenbach DA, Mou S, Kaperick P et al</AU>
<TI>Comparison of clindamycin phosphate vaginal cream with triple sulphonamide vaginal cream in the treatment of bacterial vaginosis</TI>
<SO>Sexually Transmitted Diseases</SO>
<YR>2001</YR>
<VL>28</VL>
<PG>569-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milani-2003" MODIFIED="2009-05-08 09:10:28 -0300" MODIFIED_BY="[Empty name]" NAME="Milani 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-08 09:10:28 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milani M, Barcellona E, Agnello A</AU>
<TI>Efficacy of the combination of 2g oral tinidazole and acidic buffering vaginal gel in comparison with vaginal clindamycin alone in bacterial vaginosis: A randomised, investigator blinded, controlled trial</TI>
<SO>European Journal of Obstetrics, Gynaecology, and Reproductive Biology</SO>
<YR>2003</YR>
<VL>109</VL>
<PG>62-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nunez-2005" MODIFIED="2009-05-08 09:17:11 -0300" MODIFIED_BY="[Empty name]" NAME="Nunez 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-08 09:17:11 -0300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nunez JT, Gomez G</AU>
<TI>Low-dose secnidazole in the treatment of bacterial vaginosis</TI>
<SO>International Journal of Gynaecology and Obstetrics</SO>
<YR>2005</YR>
<VL>88</VL>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paavonen--2000" MODIFIED="2009-05-08 09:18:27 -0300" MODIFIED_BY="[Empty name]" NAME="Paavonen  2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-08 09:18:27 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paavonen J, Mangioni C, Martin MA, Wajszczuk CP</AU>
<TI>Vaginal clindamycin and oral metronidazole for bacterial vaginosis: A randomised trial</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>96</VL>
<PG>256-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piot-1983" MODIFIED="2009-05-08 09:19:02 -0300" MODIFIED_BY="[Empty name]" NAME="Piot 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-05-08 09:19:02 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piot P, Van Dyck E, Godts P, Vanderheyden</AU>
<TI>A placebo-controlled, double blind comparison of tinidazole and triple sulphonamide cream for the treatment of non-specific vaginitis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1983</YR>
<VL>147</VL>
<PG>85-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schinder-1991" MODIFIED="2009-05-08 09:21:59 -0300" MODIFIED_BY="[Empty name]" NAME="Schinder 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-05-08 09:21:59 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schinder EM, Thamm H, Ansmann EB, Sarnow E, Schinder AE</AU>
<TI>Treatment of bacterial vaginosis</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1991</YR>
<VL>109</VL>
<PG>138-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmitt-1992" MODIFIED="2009-05-08 09:20:21 -0300" MODIFIED_BY="[Empty name]" NAME="Schmitt 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-05-08 09:20:21 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scmitt C, Sobel JD, Meriwhether C</AU>
<TI>Bacterial vaginosis: Treatment with clindamycin cream versus oral metronidazole</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>79</VL>
<PG>1020-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwebke-2000" MODIFIED="2009-05-08 09:22:28 -0300" MODIFIED_BY="[Empty name]" NAME="Schwebke 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-08 09:22:28 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwebke JR</AU>
<TI>Asymptomatic bacterial vaginosis: Response to therapy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>183</VL>
<PG>1434-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwebke-2006" NAME="Schwebke 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schwebke JR, Desmond RA</AU>
<TI>A randomised trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2007</YR>
<VL>44</VL>
<PG>213-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwebke-2006a" NAME="Schwebke 2006a" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwebke-2006b" NAME="Schwebke 2006b" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sobel-2001" MODIFIED="2009-05-08 09:23:05 -0300" MODIFIED_BY="[Empty name]" NAME="Sobel 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-08 09:23:05 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sobel J, Peipert JF, McGregor JA, Livengood C, Matin M, Robbins J et al</AU>
<TI>Efficacy of clindamycin vaginal ovule (3 day) treatment versus clindamycin vaginal cream 7 day treatment in bacterial vaginosis</TI>
<SO>Infectious diseases Obstetrics and Gynecology</SO>
<YR>2001</YR>
<VL>9</VL>
<PG>9-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1993" MODIFIED="2009-05-08 09:23:26 -0300" MODIFIED_BY="[Empty name]" NAME="Stein 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-05-08 09:23:26 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein GE, Christensen SL, Mummaw NL, Soper DE</AU>
<TI>Placebo-controlled trrial of intravaginal clindamycin 2% cream for the treatment of bacterial vaginosis</TI>
<SO>The Annals of Pharmacotherapy</SO>
<YR>1993</YR>
<VL>27</VL>
<PG>1343-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Voorspoels-2002" MODIFIED="2009-05-08 09:25:05 -0300" MODIFIED_BY="[Empty name]" NAME="Voorspoels 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-08 09:25:05 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Voorspoels J, Casteels M, Renion JP, Temmerman M</AU>
<TI>Local treatment of bacterial vaginosis with a bioadhesive metronidazole tablet</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>2002</YR>
<VL>105</VL>
<PG>64-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Voorspoels-2002a" NAME="Voorspoels 2002a" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Voorspoels-2002b" NAME="Voorspoels 2002b" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wathne-1989" MODIFIED="2009-05-08 09:25:34 -0300" MODIFIED_BY="[Empty name]" NAME="Wathne 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-05-08 09:25:34 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wathne B, Hovelius B, Holst E</AU>
<TI>Cefadroxil as alternative to metronidazole in the treatment of bacterial vaginosis</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1989</YR>
<VL>21</VL>
<PG>585-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-05-12 11:27:30 -0300" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Andreeva-2002" MODIFIED="2009-05-08 09:26:03 -0300" MODIFIED_BY="[Empty name]" NAME="Andreeva 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-05-08 09:26:03 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andreeva P, Slavchev B, Kovachev S, Nacheva A, Vatcheva R</AU>
<TI>Treatment of Bacterial vaginosis with high dosage metronidazole and lactic acid</TI>
<SO>Akusherstvo i Ginekologiia</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>5</NO>
<PG>36-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-09-18 15:03:42 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blackwell-1983" MODIFIED="2008-09-18 15:15:35 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Blackwell 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blackwell AI, Fox AR, Phillips I, Barlow D</AU>
<TI>Anaerobic vaginosis (non-specific vaginitis): clinical, microbiological and therapeutic findings</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>2</VL>
<PG>1379-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eschenback--1983" MODIFIED="2009-05-08 09:26:30 -0300" MODIFIED_BY="[Empty name]" NAME="Eschenback  1983" YEAR="1983">
<REFERENCE MODIFIED="2009-05-08 09:26:30 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eschenbach DA, Crithlow CW, Watkins A</AU>
<TI>A dose duration study of metronidazole for the treatment of non-specific vaginosis</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1983</YR>
<VL>40 Suppl</VL>
<PG>73-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Facchin-1995" MODIFIED="2008-09-18 15:16:34 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Facchin 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Facchin S, Grasso A, Guanni E, Mega M</AU>
<TI>Bacterial vaginosis: New clinical approach</TI>
<TO>La vaginosi</TO>
<SO>Giornale Italiano di Ostetrica e Ginecologica</SO>
<YR>1995</YR>
<VL>17</VL>
<NO>4</NO>
<PG>241-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferris-1995" MODIFIED="2008-09-18 15:16:51 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Ferris 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferris DG, Litaker MS, Woodward L, Mathis D, Hendrick J</AU>
<TI>Treatmet of bacaterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel and clindamycin vaginal cream</TI>
<SO>Journal of Family Practice</SO>
<YR>1995</YR>
<VL>41</VL>
<NO>5</NO>
<PG>443-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fredricsson-1986" MODIFIED="2009-05-08 09:29:03 -0300" MODIFIED_BY="[Empty name]" NAME="Fredricsson 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-05-08 09:29:03 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fredricsson B, Hagstrom B, Moller AK, Nord CE</AU>
<TI>Bacterial vaginosis treated with metronidazole: effects on the vaginal microbial flora by a single dose versus a five day regimen</TI>
<SO>Zentralblatt fur Gynakologie</SO>
<YR>1986</YR>
<VL>108</VL>
<PG>799-804</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hagstrom-1983" MODIFIED="2009-05-08 09:27:28 -0300" MODIFIED_BY="[Empty name]" NAME="Hagstrom 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-05-08 09:27:28 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hagstrom B, Lindestedt J</AU>
<TI>Comparison of two different regimens of metronidazole in the treatment of non-specific vaginitis</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1983</YR>
<VL>40</VL>
<PG>95-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hovick-1983" MODIFIED="2009-05-08 09:29:35 -0300" MODIFIED_BY="[Empty name]" NAME="Hovick 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-05-08 09:29:35 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hovick P</AU>
<TI>Non-specific vaginitis in an outpatient clinic</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1983</YR>
<VL>40 Suppl</VL>
<PG>107-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Improda-1993" MODIFIED="2008-09-27 11:46:33 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Improda 1993" YEAR="1994">
<REFERENCE MODIFIED="2008-09-27 11:46:33 -0300" MODIFIED_BY="Oyinlola O Oduyebo" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Improda L, Nobler L, Chierego C, Iacono A, Sica C, Rullo F</AU>
<TI>Is it necesary to treat the partner of woman affected by bacterial vaginosis</TI>
<SO>Gior It Osst Gin</SO>
<YR>1994</YR>
<VL>78</VL>
<PG>371-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jerve-1984" MODIFIED="2008-09-18 16:41:07 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Jerve 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jerve F, Berdal TB, Boham P</AU>
<TI>Metronidazole in the treatment of non-specific vaginitis</TI>
<SO>British Journal of Venereal Disease</SO>
<YR>1984</YR>
<VL>60</VL>
<PG>171-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1985" MODIFIED="2009-05-08 09:35:10 -0300" MODIFIED_BY="[Empty name]" NAME="Jones 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-05-08 09:35:10 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones BM, Geary I, Alawattegama AB, Kinghorn GB, Duerden BI</AU>
<TI>In- vitro and in-vivo activity of metronidazole against Gardnerella vaginalis, Bacteroides spp. and Mobiluncus spp. in bacterial vaginosis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1985</YR>
<VL>16</VL>
<PG>189-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kira-1994" MODIFIED="2009-05-08 09:35:32 -0300" MODIFIED_BY="[Empty name]" NAME="Kira 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-05-08 09:35:32 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kira EF</AU>
<TI>Local application of clindamycin phosphate in therapy of bacterial vaginosis</TI>
<SO>Akusherstvo i Ginekologiia</SO>
<YR>1994</YR>
<VL>70</VL>
<NO>5</NO>
<PG>53-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lefevre-1985" MODIFIED="2008-09-18 16:41:44 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Lefevre 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lefevre JC</AU>
<TI>Bacterial vaginosis (non -specific vaginitis): clinical and bacteriological data</TI>
<TO>Vaginose bacterienne (vaginite non specique) donnees cliniques et bacteriologiques</TO>
<SO>Feuillets de Biologie</SO>
<YR>1985</YR>
<VL>XXVi</VL>
<NO>147</NO>
<PG>49-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linhares-1995" MODIFIED="2008-09-18 16:41:57 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Linhares 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linhares</AU>
<TI>Bacterial vaginosis: experience with thiamphenicol; clue cell</TI>
<TO>Vaginose bacteriana: experiencia com o tianfenicol</TO>
<SO>Journal Brasiliero et Ginecologia</SO>
<YR>1995</YR>
<VL>105</VL>
<NO>9</NO>
<PG>405-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malouf-1981" MODIFIED="2008-09-18 16:42:08 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Malouf 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malouf M, Fortier M, Morin G, Dube JL</AU>
<TI>Treatment of Haemophilus vaginalis vaginitis</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1981</YR>
<VL>57</VL>
<PG>711-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martins-1985" MODIFIED="2009-05-12 11:27:30 -0300" MODIFIED_BY="[Empty name]" NAME="Martins 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-05-12 11:27:30 -0300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martins NV</AU>
<TI>Ambulatory diagnosis of vaginitis: evaluation of 4903 patients treated with tinidazole with a single oral dose</TI>
<SO>Revista Brasileira de Clínica Terapêutica</SO>
<YR>1985</YR>
<VL>14</VL>
<PG>94-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milankovis-2002" MODIFIED="2008-09-18 16:42:34 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Milankovis 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milankovis M, Laszio B, Janos P</AU>
<TI>Comparative study of combined local treatment and the standard monotherapy of uncomplicated bacterial vaginsis</TI>
<TO>Szovodmenymentes bakterialis vaginosis kombinalt huvelyi kezelesenek (szulfadimidin, metronidazole es nystatin) es a standard monoterapiak osszehasonlito vizsgalata</TO>
<SO>Orvosi Hetilap</SO>
<YR>2002</YR>
<VL>143</VL>
<NO>51</NO>
<PG>2835-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohanty--1987" MODIFIED="2009-05-08 09:39:22 -0300" MODIFIED_BY="[Empty name]" NAME="Mohanty  1987" YEAR="1987">
<REFERENCE MODIFIED="2009-05-08 09:39:22 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohanty KC, Dieghton R</AU>
<TI>Comparison of 2g single dose of metronidazole, nimorazole and tinidazole in the treatment of vaginitis associated with Gadnerella vaginalis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1987</YR>
<VL>19</VL>
<PG>393-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naud-2003" MODIFIED="2009-05-08 09:41:07 -0300" MODIFIED_BY="[Empty name]" NAME="Naud 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-08 09:41:07 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naud P, Matos J, Hammes L, Magno V, Browers C, Spilki M et al</AU>
<TI>Efficacy and tolerability of fenticonazole for bacterial vaginosis</TI>
<TO>Estudo da eficacia e tolerabilidade do ffenticonazole no tratamento da vaginose bacteriana - Estudo duplo-cego, randomizado, prospectivo, controlado e comparado com grupo placebo</TO>
<SO>Revista Brasileira de Medicina</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>42</NO>
<PG>67-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Purdon-1984" MODIFIED="2008-09-18 16:43:27 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Purdon 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Purdon A, Hanna JH, Morse PL, Paine DD, Engelkirk PG</AU>
<TI>An evaluation of single dose metronidazole treatment for Gardnerella vaginalis vaginitis</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1984</YR>
<VL>64</VL>
<PG>271-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez-2004" MODIFIED="2008-09-18 16:43:47 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Sanchez 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez S, Garcia PJ, Thomas KK, Catlin M, Holmes KK</AU>
<TI>Intravaginal metronidazole gel versus metronidazole plus nystatin ovule for bacterial vaginosis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>191</VL>
<PG>1898-906</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanz-1995" MODIFIED="2009-05-08 09:53:36 -0300" MODIFIED_BY="[Empty name]" NAME="Sanz 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-05-08 09:53:36 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanz F, Vidriales I, Callejo C, Rodriguez-Noriega A</AU>
<TI>2% Clindamycin intravaginal cream in bacterial vaginosis treatment</TI>
<TO>Clindamicina, crema intravaginal al 2% en el tratamiento de la vaginosis bacteriana</TO>
<SO>Progressos de Obstetricia y Ginecologia</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>5</NO>
<PG>333-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanz-Sanz-1985" NAME="Sanz Sanz 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanz Sanz F, Hernanz AD, Sanchez EA, Alvarez CG, Noriega AR</AU>
<TI>Double-blind randomised comparative trial: Ornidazole (Tiberial) versus Tinidazole (Fasigin) for the treatment of non-specific vaginitis</TI>
<SO>Chemoterapia</SO>
<YR>1985</YR>
<VL>iv</VL>
<NO>3</NO>
<PG>218-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanz-Sanz-2001" MODIFIED="2009-05-08 09:55:03 -0300" MODIFIED_BY="[Empty name]" NAME="Sanz Sanz 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-05-08 09:55:03 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanz Sanz F, Hernanz AD, Sanchez EA, Alvarez CG, Muelas M, Rodriguez-Noriega</AU>
<TI>Controlled comparative study of metronidazole (flagyl) versus tinidazole (Tricolan) in the treatment of non-specific vaginitis (vaginitis due to Gardnerella vaginalis)</TI>
<SO>Revista Espanola de Obstetricia y Ginecologia</SO>
<YR>2001</YR>
<VL>44</VL>
<PG>3-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sobel-1993" MODIFIED="2008-09-18 16:44:25 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Sobel 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sobel JD, Schmitt C, Meriwhether C</AU>
<TI>Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1993</YR>
<VL>167</VL>
<PG>783-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swedberg-1985" MODIFIED="2008-09-18 16:44:38 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Swedberg 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swedberg J, Steiner JF, Deiss F, Steiner S, Driggers DA</AU>
<TI>Comparison of single dose versus one course of metronidazole for symptomatic bacterial vaginosis</TI>
<SO>JAMA</SO>
<YR>1985</YR>
<VL>254</VL>
<PG>1046-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Der-Meijden-1983" MODIFIED="2009-05-08 09:51:16 -0300" MODIFIED_BY="[Empty name]" NAME="Van Der Meijden 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-05-08 09:51:16 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Der Meijden</AU>
<TI>Treatment of non-specific vaginitis with a single dose of tinidazole</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1983</YR>
<VL>40 Suppl</VL>
<PG>85-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vutyavanich-1993" MODIFIED="2008-09-18 16:45:02 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Vutyavanich 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vutyavanich T, Pongsuthirak P, Vannareumol P, Ruangsri R, Luangsook P</AU>
<TI>A randomised double blind trial of tinidazole treatment of the sexual partners of females with bacterial vaginosis</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>82</VL>
<NO>4</NO>
<PG>550-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2001" MODIFIED="2008-09-18 16:45:18 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Wei 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei H, Xiaotang Z, Xiuting H, Ying P, Yong S, Lin Q et al</AU>
<TI>Clindamycin soluble suppository production and its efficacy in treating bacterial vaginosis</TI>
<SO>J WCUMS</SO>
<YR>2001</YR>
<VL>32</VL>
<NO>3</NO>
<PG>452-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2008-09-27 12:16:04 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<STUDY DATA_SOURCE="MIX" ID="STD-Wilson-2005" MODIFIED="2008-09-27 12:16:04 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="Wilson 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-27 12:16:04 -0300" MODIFIED_BY="Oyinlola O Oduyebo" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wilson JD, Carson CF, Wellard SJ, Riley TV</AU>
<TI>A randomised single blind (investigator blinded) study of intravaginal tea tree oil gel versus intravaginal metronidazole gel in the treatment of bacterial vaginosis</TI>
<SO>Proceedings of the 16th Bienniel meeting of the International Society for Sexually Transmitted Diseases Research (ISSTDR)</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-05-08 09:59:32 -0300" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-05-08 09:59:32 -0300" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Amsel-1983" NAME="Amsel 1983" TYPE="JOURNAL_ARTICLE">
<AU>Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenback D, Holmes KK</AU>
<TI>Diagnostic criteria and microbial and epidemiologic associations</TI>
<SO>American Journal of Medicine</SO>
<YR>1983</YR>
<VL>74</VL>
<NO>1</NO>
<PG>14-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreeva-2002" MODIFIED="2009-05-08 09:55:44 -0300" MODIFIED_BY="[Empty name]" NAME="Andreeva 2002" TYPE="JOURNAL_ARTICLE">
<AU>Andreeva P, Slavchev B, Kovschev S, Nachevz A, Vacheva R</AU>
<TI>Treatment of bacterial vaginisos with high dosage metronidazole and lactic acid</TI>
<TO>Lechenie na bakteialnata vaginoza s visokodoziran vaginalen metronidazole i mlechna kiselina</TO>
<SO>Akusherstvo i Ginekologiia</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>5</NO>
<PG>36-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bakare-2002" NAME="Bakare 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bakare RA, Oni AA, Umar S, Adewole IF, Shokunbi WA, Fayemiwo SA</AU>
<TI>Pattern of STDs among commercial sex workers (CSWs) in Ibadan, Nigeria</TI>
<SO>African Journal of Medical Sciences</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>3</NO>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baylson-2004" NAME="Baylson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Baylson FA, Nyirjesy P, Weitz MV</AU>
<TI>Treatment of recurrent bacterial vaginosis with tinidazole</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>104</VL>
<PG>931-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begum-2003" NAME="Begum 2003" TYPE="JOURNAL_ARTICLE">
<AU>Begum A, Nihifar S, Akther K, Rhaman R, Khatoun F, Rahman M</AU>
<TI>Prevalence of selected reproductive tract infections among pregnant women attending an urban maternal and childcare unit in Dhaka Bangladesh</TI>
<SO>Journal of Health Population and Nutrition</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>2</NO>
<PG>112-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhaduri-1997" NAME="Bhaduri 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bhaduri S, Riley VC</AU>
<TI>Metronidazole hypersensitivity in a patient with bacterial vaginosis</TI>
<SO>International Journal of STD and AIDS</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>1</NO>
<PG>57-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Covino-1993" NAME="Covino 1993" TYPE="JOURNAL_ARTICLE">
<AU>Covino JM, Black JR, Cummings M, Zwickl B, McCormack WM</AU>
<TI>Comparative evaluation of ofloxacin and metronidazole in the treatment of bacterial vaginosis</TI>
<SO>Sexually Transmitted Diseases</SO>
<YR>1993</YR>
<VL>20</VL>
<NO>5</NO>
<PG>262-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dan-2003" NAME="Dan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Dan M, Kaneh N, Levin D, Poch F. Samra F</AU>
<TI>Vaginitis in a gynaecologic practice in Israel: causes and risk factors</TI>
<SO>Israel Medical Association Journal</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>9</NO>
<PG>629-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eschenbach-1989" NAME="Eschenbach 1989" TYPE="JOURNAL_ARTICLE">
<AU>Eschenbach DA, Davick PR, Williams BL, Klebanoff SJ, Young-Smith K, Critchlow CM, et al</AU>
<TI>Prevalence of hydrogen peroxide - producing Lactobacillus species in normal women and women with bacterial vaginosis</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>1989</YR>
<VL>27</VL>
<PG>251-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guaschino-2003" MODIFIED="2009-05-08 09:56:43 -0300" MODIFIED_BY="[Empty name]" NAME="Guaschino 2003" TYPE="JOURNAL_ARTICLE">
<AU>Guaschino S, Ricci E, Franch M, Frate GD, Tibaldi C, Santo DD et al</AU>
<TI>Treatment of asymptomatic bacterial vaginosis to prevent pre term delivery: a randomized trial</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>2003</YR>
<VL>110</VL>
<NO>2</NO>
<PG>149-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hay-1994" MODIFIED="2009-05-08 09:57:08 -0300" MODIFIED_BY="[Empty name]" NAME="Hay 1994" TYPE="JOURNAL_ARTICLE">
<AU>Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J</AU>
<TI>Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<NO>6924</NO>
<PG>295-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hill-1984" NAME="Hill 1984" TYPE="JOURNAL_ARTICLE">
<AU>Hill GB, Eschenbach DA, Holmes KK</AU>
<TI>Bacteriology of the vagina</TI>
<SO>Scandinavian Journal of Urolology and Nephrology</SO>
<YR>1984</YR>
<VL>86 Suppl</VL>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hillier-1993" MODIFIED="2009-05-08 09:57:32 -0300" MODIFIED_BY="[Empty name]" NAME="Hillier 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hillier SL, Lipinski C, Briselden AM, Eschenbach DA</AU>
<TI>Efficacy of intraviginal 0.75% metronidazole gel for the treatment of bacterial vaginosis</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>81</VL>
<NO>6</NO>
<PG>963-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hillier-1999" NAME="Hillier 1999" TYPE="BOOK">
<AU>Hillier S</AU>
<SO>Sexually Transmitted Diseases</SO>
<YR>1999</YR>
<EN>3rd</EN>
<ED>Holmes KK, Mardh PA, Sparhry PF</ED>
<PB>McGraw-Hill</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joesoef-1995" NAME="Joesoef 1995" TYPE="JOURNAL_ARTICLE">
<AU>Joesoef MR, Schmid GP</AU>
<TI>Bacterial vaginosis: review of treatment options and potential clinical indications for therapy</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1995</YR>
<VL>20 Suppl 1</VL>
<PG>72-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joesoef-1999a" NAME="Joesoef 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Joesoef MR, Schmid GP, Hillier SL</AU>
<TI>Bacterial Vaginosis: Review of treatment options and potential clinical indications for therapy</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1999</YR>
<VL>28 Suppl 1</VL>
<PG>57-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joesoef-1999b" NAME="Joesoef 1999b" TYPE="JOURNAL_ARTICLE">
<AU>Joesoef MR, Schmid GP</AU>
<TI>Bacterial vaginosis</TI>
<SO>Journal of Clinical Evidence</SO>
<YR>1999</YR>
<VL>1</VL>
<PG>372-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klebanoff-1991" NAME="Klebanoff 1991" TYPE="JOURNAL_ARTICLE">
<AU>Klebanoff SJ, Hillier SL, Eschenbach DA, Waltersdorph AM</AU>
<TI>Control of the microbial flora of the vagina by H202 generating Lactobacilli</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1991</YR>
<VL>164</VL>
<PG>94-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Larsson-1992" NAME="Larsson 1992" TYPE="JOURNAL_ARTICLE">
<AU>Larsson PG, Platz-Christensen JJ, Thejls H, Forsum U, Pahlson C</AU>
<TI>Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double blind randomized study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1992</YR>
<VL>166</VL>
<PG>100-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laurent-2003" NAME="Laurent 2003" TYPE="JOURNAL_ARTICLE">
<AU>Laurent C, Seck K, Coumba N, Kane T, Samb N, Wade A, et al</AU>
<TI>Prevalence of HIV and other sexually transmitted infections, and risk behaviours in unregistered sex workers in Dakar, Senegal</TI>
<SO>AIDS</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>12</NO>
<PG>1811-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leitich-2003" NAME="Leitich 2003" TYPE="JOURNAL_ARTICLE">
<AU>Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P</AU>
<TI>Bacterial vaginosis as a risk factor for pre-term delivery: a meta analysis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>189</VL>
<NO>1</NO>
<PG>139-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lugo_x002d_Miro-1992" NAME="Lugo-Miro 1992" TYPE="JOURNAL_ARTICLE">
<AU>Lugo-Miro VI, Green M, Mazur L</AU>
<TI>Comparison of different metronidazole therapeutic regimens for bacterial vaginosis. A meta-analysis</TI>
<SO>JAMA</SO>
<YR>1992</YR>
<VL>268</VL>
<NO>1</NO>
<PG>92-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martin-1999" NAME="Martin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, Chohan B</AU>
<TI>Vaginal Lactobacilli, microbial flora and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisiton</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1999</YR>
<VL>180</VL>
<PG>1863-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDonald-2005" MODIFIED="2008-09-27 12:02:02 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NAME="McDonald 2005" TYPE="COCHRANE_REVIEW">
<AU>McDonald H, Brocklehurst P, Parsons J</AU>
<TI>Antibiotics for treating bacterial vaginosis in pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-09-27 12:02:02 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<IDENTIFIER MODIFIED="2008-09-27 12:02:02 -0300" MODIFIED_BY="Oyinlola O Oduyebo" TYPE="DOI" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nugent-1991" NAME="Nugent 1991" TYPE="JOURNAL_ARTICLE">
<AU>Nugent RP, Krohn MA, Hillier SL</AU>
<TI>Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>1991</YR>
<VL>29</VL>
<NO>2</NO>
<PG>297-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Priestley-1997" NAME="Priestley 1997" TYPE="JOURNAL_ARTICLE">
<AU>Priestley CF, Jones BM, Dhar J, Goodwin L</AU>
<TI>What is normal vaginal flora?</TI>
<SO>Genitourinary Medicine</SO>
<YR>1997</YR>
<VL>73</VL>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ramsay-2003" NAME="Ramsay 2003" TYPE="OTHER">
<AU>Ramsay C</AU>
<TI>How do you include trials with more than two groups into a single meta-analysis?</TI>
<SO>http/www.epoc.uottawa.ca/FAQmultiplegroups2003.pdf</SO>
<YR>(Accessed: 17/02/2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riedner-2003" NAME="Riedner 2003" TYPE="JOURNAL_ARTICLE">
<AU>Riedner G, Rusizoka M, Hoffmann O, Nichombe F, Lyamuya E, Mmbando D, et al</AU>
<TI>Baseline survey of sexually transmitted infections in a cohort of female bar workers in Mbeya region Tanzania</TI>
<SO>Sexually Transmitted Infections</SO>
<YR>2003</YR>
<VL>79</VL>
<NO>5</NO>
<PG>382-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saracoglu-1998" MODIFIED="2009-05-08 09:59:32 -0300" MODIFIED_BY="[Empty name]" NAME="Saracoglu 1998" TYPE="JOURNAL_ARTICLE">
<AU>Saracoglu F, Gol K, Sahin I, Turkkani B, Atalay C, Oztopcu C</AU>
<TI>Treatment of bacterial vaginosis with oral or vaginal ornidazole, secnidazole and metronidazole</TI>
<SO>International Journal of Gynaecology and Obstetrics</SO>
<YR>1998</YR>
<VL>62</VL>
<NO>1</NO>
<PG>59-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soper-1993" NAME="Soper 1993" TYPE="JOURNAL_ARTICLE">
<AU>Soper DE</AU>
<TI>Bacterial vaginosis and postoperative infections</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>169</VL>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spiegel-1983" NAME="Spiegel 1983" TYPE="JOURNAL_ARTICLE">
<AU>Spiegel CA, Amsel R, Holmes KK</AU>
<TI>Diagnosis of bacterial vaginosis by a direct gram stain of vaginal fluid</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>1983</YR>
<VL>18</VL>
<PG>170-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tosun-2003" NAME="Tosun 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tosun I, Aydin F, Kaklikkaya N, Yazici Y</AU>
<TI>Frequency of bacterial vaginosis among women attending for intrauterine device insertion at an inner-city family planning clinic</TI>
<SO>European Journal of Contraceptives and Reproductive Health Care</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>3</NO>
<PG>135-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trexler-1997" NAME="Trexler 1997" TYPE="JOURNAL_ARTICLE">
<AU>Trexler MF, Fraser TG, Jones MP</AU>
<TI>Fulminant pseudomembranous colitis caused by clindamycin phosphate vaginal cream</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>11</NO>
<PG>2112-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-2005" NAME="Wilson 2005" TYPE="CONFERENCE_PROC">
<AU>Wilson JD, Carson CF, Wellard SJ, Riley TV</AU>
<TI>A randomised single blind (investigator-blinded) study of intravaginal tea tree oil gel versus intravaginal metronidazole gel in the treatment of bacterial vaginosis (BV)</TI>
<SO>Proceedings of the 16th biennial meeting of the International Society for Sexually Transmitted Diseases Research (ISSTDR)</SO>
<YR>2005</YR>
<PG>308</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-05-09 05:51:21 -0300" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-05-09 05:51:21 -0300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-05-09 05:19:26 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andres-1992">
<CHAR_METHODS MODIFIED="2009-05-09 05:02:06 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: computer-generated list</P>
<P>Allocation concealment: not mentioned</P>
<P>Some exclusion criteria were applied after randomisation</P>
<P>Blinding: investigators, participants</P>
<P>Loss to follow up: 2</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-08 10:36:30 -0300" MODIFIED_BY="[Empty name]">
<P>60 women aged 18 to 60 years were randomised, 14 were excluded from analysis<BR/>
<BR/>Inclusion criteria: Amsel criteria, Gram-stain criteria</P>
<P>Exclusion criteria: pregnancy, breastfeeding, allergy to clindamycin or metronidazole, antimicrobials within the previous 2 weeks, antibiotic asociated colitis, diarrhea, presence of STDs, menstrual bleeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:19:26 -0300" MODIFIED_BY="[Empty name]">
<P>1. 2% Clindamycin 5g intravaginally at bedtime for 7 days</P>
<P>2. Oral metronidazole 500mg twice daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:14:00 -0300" MODIFIED_BY="[Empty name]">
<P>Primary: cure, clinically improved, and clinical failure 5-8 days and 4 weeks after treatment completion defined as follows<BR/>- Clinical cure if no evidence of bacterial vaginosis on examination<BR/>- Cllinically improved if the vaginal secretions were not entirely normal as regards odour<BR/>- Clinical failure if bacterial vaginosis did not clear at first or second follow up</P>
<P>Secondary: side effects</P>
<P>Clinical cure and clinically improved are not assessed in the review</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-08 10:36:42 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: no statement</P>
<P>Study location: no report</P>
<P>Study setting</P>
<P>Study duration: no report</P>
<P>Funding</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:19:39 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anukam-2006a">
<CHAR_METHODS MODIFIED="2009-05-08 10:37:30 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: computer-generated list</P>
<P>Allocation concealment: identical looking probiotic and placebo capsules prepared and distributed in numbered containers by the pharmacy</P>
<P>Blinding: investigators, participants</P>
<P>Loss to follow up: 19</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:05:19 -0300" MODIFIED_BY="[Empty name]">
<P>125 women out of the 500 screened, aged 18 to 44 years, were randomised; 19 were excluded from analysis<BR/>
<BR/>Inclusion criteria: symptomatic women Nugent score 7-10, positive sialidase test</P>
<P>Exclusion criteria: pregnancy; breastfeeding; allergy to metronidazole, warfarin, lithium or disulfiram; antimicrobials within the previous 2 weeks; presence of STDs and HIV; menstrual bleeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:19:39 -0300" MODIFIED_BY="[Empty name]">
<P>1. Oral metronidazole 500mg twice daily for 7 days</P>
<P>2. Oral metronidazole 500mg twice daily for 7 days + oral lactobacillus GR -1 and RC -14 twice daily for 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:05:41 -0300" MODIFIED_BY="[Empty name]">
<P>Primary: cure defined as normal Nugent score, absence of clue cells, negative sialidase tests, and no symptoms and treatment failure defined as BV 7-10 or positive sialidase test</P>
<P>Secondary: side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-08 10:38:11 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: no statement</P>
<P>Ethical approval: obtained from the local university</P>
<P>Study location: Benin city, Nigeria</P>
<P>Study setting: community clinics</P>
<P>Study duration: 6 months</P>
<P>Funding: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:19:50 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anukam-2006b">
<CHAR_METHODS MODIFIED="2009-05-09 05:06:04 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: method unclear</P>
<P>Blinding: no</P>
<P>Loss to follow up: 5</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:06:19 -0300" MODIFIED_BY="[Empty name]">
<P>40 out of the 350 premenopausal women screened were randomised</P>
<P>Inclusion criteria: symptomatic women Nugent score 7-10, positive sialidase test</P>
<P>Exclusion criteria: pregnancy, presence of STDs and HIV, menstrual bleeding, younger than 18 and older than 50 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:19:50 -0300" MODIFIED_BY="[Empty name]">
<P>1. Gelatin capsules containing (10<SUP>9</SUP> organisms) lactobacillus rhamnosus GR -1 and L reuteri RC -14: 2 capsules inserted vaginally at night for 5 days</P>
<P>2. 0.75% Metronidazole vaginal gel twice daily for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Symptoms failure<BR/>Bacteriologic failure: Nugent score 7-10 or positive sialidase test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-09 05:07:16 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: no statement</P>
<P>Ethical approval: University of Benin</P>
<P>Study location: Benin city, Nigeria</P>
<P>Study setting: community clinics</P>
<P>Study duration: not stated</P>
<P>Funding: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:20:00 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beigi-2004">
<CHAR_METHODS MODIFIED="2009-05-09 05:07:48 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocattion: permuted block design with a block size of 8</P>
<P>Allocation concealment: name of drug printed on a piece of paper, sealed in an envelop and opened by the investigator at enrolment</P>
<P>Blinding: no</P>
<P>Loss to follow up: 4</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:08:06 -0300" MODIFIED_BY="[Empty name]">
<P>119 women were randomised, 4 were excluded from analysis</P>
<P>Inclusion criteria: 3 or 4 Amsel criteria and a Gram-stain score of 4 or more</P>
<P>Exclusion criteria: pregnancy, hypersensitivity tometronidazole or clindamycin, currently menstruating, on IUCD, antibiotics in the previous 7 days, pesence of STDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:20:00 -0300" MODIFIED_BY="[Empty name]">
<P>1. Clindamycin intravaginal ovules daily for 3 days</P>
<P>2. Metronidazole intravaginal (metrogel) daily for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:08:34 -0300" MODIFIED_BY="[Empty name]">
<P>- Clinical failure defined as persistence of 2 or more Amsel criteria for BV<BR/>- Clinical success defined as having less than 2 of Amsel criteria<BR/>- Antimicrobial resistance (not assessed in this review)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-08 10:39:36 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: USA</P>
<P>Study setting:</P>
<P>Study duration: 14 months</P>
<P>Funding: 3M Pharmaceuticals, NIH/NIAD</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:20:09 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burana-1990">
<CHAR_METHODS MODIFIED="2009-05-09 05:08:57 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: method unclear</P>
<P>Blinding: no</P>
<P>Loss to follow up: 71</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:09:23 -0300" MODIFIED_BY="[Empty name]">
<P>171 women aged 15 to 45 years old enrolled, 71 were excluded from analysis; sexual partners also treated</P>
<P>Inclusion criteria: at least 3 Amsel criteria.</P>
<P>Exclusion criteria: pregnancy, lactation, prostitutes, antibiotic or vaginal suppositories in the previous 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:20:09 -0300" MODIFIED_BY="[Empty name]">
<P>1. Oral tinidazole 2g single dose*</P>
<P>2. Oral metronidazole 500mg twice daily for 7 days*</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:09:36 -0300" MODIFIED_BY="[Empty name]">
<P>Cure: defined as absence of symptoms and presence of &lt; 3 Amsel criteria</P>
<P>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-08 10:40:08 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: unclear</P>
<P>Ethical approval: no statement</P>
<P>Study location: Thailand</P>
<P>Study setting</P>
<P>Study duration: 12 months</P>
<P>Funding: BJ Limited</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:11:03 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaithong-2003">
<CHAR_METHODS MODIFIED="2009-05-08 10:40:23 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: computer-generated random numbers</P>
<P>Allocation concealment: not mentioned</P>
<P>Blinding: investigators, participants, outcome assessors</P>
<P>Loss to follow up: none</P>
<P>Analysis: ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:10:15 -0300" MODIFIED_BY="[Empty name]">
<P>142 women enrolled</P>
<P>Inclusion criteria: BV diagnosed by Amsel criteria</P>
<P>Age 15-45 years</P>
<P>Exclusion criteria: hydrogen peroxide or metronidazole allergy, pregnancy, vaginal or cervical ulceration or co-infection, current use of IUCD, immunosuppression, diabetes mellitus, antibiotic use within 2 weeks, menopause</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:10:43 -0300" MODIFIED_BY="[Empty name]">
<P>1. Hydrogen peroxide douching (single dose)</P>
<P>2. 2g Single dose oral metronidazole</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-08 10:40:42 -0300" MODIFIED_BY="[Empty name]">
<P>Primary: cure defined as absence of at least 3 of Amsel criteria</P>
<P>Secondary: adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-09 05:11:03 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: Bangkok, Thailand</P>
<P>Study setting:</P>
<P>Study duration: no report</P>
<P>Funding: university research fund</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:14:31 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eriksson-2005">
<CHAR_METHODS MODIFIED="2009-05-08 10:40:56 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: method unclear</P>
<P>Allocation concealment: not mentioned</P>
<P>Blinding: investigator, participants</P>
<P>Loss to follow up: 30</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:12:03 -0300" MODIFIED_BY="[Empty name]">
<P>255 women enrolled, 187 excluded from analysis</P>
<P>Inclusion criteria: BV by Amsel's criteria</P>
<P>Exclusion criteria: age &lt; 18 yrs, pregnancy, breastfeeding, antibiotic in the preceding week, ongoing STDs, unwilling to use tampons</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:12:45 -0300" MODIFIED_BY="[Empty name]">
<P>1. Clindamycin 100mg ovule daily for 3 days + tampons impregnated with lactobacillus during the next menstruation</P>
<P>2. Clindamycin 100mg ovule daily for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:14:31 -0300" MODIFIED_BY="[Empty name]">
<P>Primary: cure, improved, treatment failure<BR/>- Cure defined as no Amsel criteria fulfilled + Nugent score 0-3<BR/>- Improved defined as 1 or 2 Amsel criteria + Nugent score 4-6<BR/>- Treatment failure defined as 3 or 4 Amsel criteria + Nugent score 7-10</P>
<P>Secondary: adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-08 10:41:22 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: multicentre, 13 clinics in Swden</P>
<P>Study setting</P>
<P>Study duration: no report</P>
<P>Funding: Ellen Ab, Stockholm Sweden</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:20:57 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fischbach-1993">
<CHAR_METHODS MODIFIED="2009-05-09 05:15:16 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: computer random number-generation program to develop a drug randomisation code</P>
<P>Allocation concealment: sequentially-numbered medication tubes and bottles given to participants as they are enrolled</P>
<P>Blinding: investigators, participants</P>
<P>Loss to follow up: 64</P>
<P>Analysis: ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:16:13 -0300" MODIFIED_BY="[Empty name]">
<P>407 women enrolled, 173 were excluded from analysis</P>
<P>Inclusion criteria: BV by Amsel and Gram-stain (Spiegel) criteria</P>
<P>Exclusion criteria: pregnancy, breastfeeding, menstruation, allergy to clidamycin or metronidazole, antimicrobial therapy 2 weeks before the study, history of antibiotic associated colitis or frequent periodic diarrrhea, atrophic vaginitis, active CNS disease, blood dyscrasias</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:16:33 -0300" MODIFIED_BY="[Empty name]">
<P>1. 2% Clindamycin cream 5g intravaginally at bedtime for + placebo capsules twice daily for 7 days</P>
<P>2. Oral metronidazole 500mg twice daily for + placebo vaginal cream 5g intravaginally at bedtime for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:16:57 -0300" MODIFIED_BY="[Empty name]">
<P>Primary<BR/>- Cure<BR/>- Improvement<BR/>- Failure<BR/>- Side effect failure</P>
<P>Secondary<BR/>- Changes in Gram-stain<BR/>- Patients' evaluation of efficacy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-09 05:20:57 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: multicentre (7 sites) study - Germany, Austria, Switzerland</P>
<P>Study setting</P>
<P>Study duration: no report</P>
<P>Funding: Upjohn Company</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:18:04 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerli-2003">
<CHAR_METHODS MODIFIED="2009-05-08 10:42:32 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: randomisation table</P>
<P>Allocation concealment: not mentioned</P>
<P>Blinding: outcome assesors</P>
<P>Loss to follow up: 10</P>
<P>Analysis: ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-08 10:42:37 -0300" MODIFIED_BY="[Empty name]">
<P>110 symptomatic women 18-40 years old enrolled</P>
<P>Inclusion criteria: Amsel criteria</P>
<P>Exclusion criteria: not listed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:17:53 -0300" MODIFIED_BY="[Empty name]">
<P>1. Polyhexamethylene biguanide gel solution single dose</P>
<P>2. 2% Clindamycin cream 5g intravaginally for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:18:04 -0300" MODIFIED_BY="[Empty name]">
<P>- Achievement<BR/>- Improvement<BR/>- Failure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: Italy</P>
<P>Study setting</P>
<P>Study duration: no report</P>
<P>Funding: no infomation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:20:33 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greaves-1988">
<CHAR_METHODS MODIFIED="2009-05-09 05:18:38 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: method unclear (a pre-constructed random sequence)</P>
<P>Allocation concealment: not mentioned</P>
<P>Blinding: investigators, participants</P>
<P>Loss to follow up: 32</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:18:49 -0300" MODIFIED_BY="[Empty name]">
<P>143 symptomatic women enrolled, 44 excluded from analysis</P>
<P>Inclusion criteria: Amsel criteria</P>
<P>Exclusion criteria: menstruating, antibiotics or treatment for vaginitis in the preceding 2 weeks, allergy to metronidazole or clindamycin, &lt;18 years of age, STDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:20:33 -0300" MODIFIED_BY="[Empty name]">
<P>1. Oral clindamycin, 500mg twice daily for 7 days</P>
<P>2. Oral metronidazole, 500mg twice daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cure: defined as resolution of vaginal discharge, absence of complaints related to vaginitis after therapy and failure to satisfy pre-determined criteria</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-08 10:43:19 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: Washington</P>
<P>Study setting</P>
<P>Study duration: no report</P>
<P>Funding: no information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:21:51 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Livengood-1990">
<CHAR_METHODS MODIFIED="2009-05-08 10:43:50 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: unclear (method by Upjohn Company)</P>
<P>Allocation concealment: numbered tubes containing 50g of vaginal cream supplied in sequence to participants as they entered the study</P>
<P>Blinding: investigator, participants, outcome assessors</P>
<P>Loss to follow up: 5</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-08 10:43:56 -0300" MODIFIED_BY="[Empty name]">
<P>72 women aged 18 -45 years enrolled, 10 excluded from analysis</P>
<P>Inclusion criteria: Amsel criteria and Gram stain criteria (Spiegel)</P>
<P>Exclusion citeria: pregnancy, breastfeeding, allergy to clindamycin, antibiotic use in the previous 2 weeks, diarrhea, STDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:21:33 -0300" MODIFIED_BY="[Empty name]">
<P>1. Clindamycin 0.1%</P>
<P>2. Clindamycin 1%</P>
<P>3. Clindamycin 2%, all 5g intravaginal cream twice daily for 5 days</P>
<P>4. Placebo cream 5g twice daily for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:21:40 -0300" MODIFIED_BY="[Empty name]">
<P>- Cure: defined as absence of clue cells plus the presence of at least 2 other Amsel criteria<BR/>- Therapeutic failure: defined as criteria for cure not met (retreated with 1% clindamycin)<BR/>- Side effect failure: side effect severe enough to require discontinuation of treatment before completion of regimen</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-09 05:21:51 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: no statement</P>
<P>Study location: USA, 2 hospital clinics</P>
<P>Study setting</P>
<P>Study duration: no report</P>
<P>Funding: Upjohn Company</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Livengood-1990a">
<CHAR_METHODS>
<P>Same as for Livengood 1990</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Livengood-1990b">
<CHAR_METHODS>
<P>Same as for Livengood 1990</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:27:32 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCormack-2001">
<CHAR_METHODS MODIFIED="2009-05-09 05:22:04 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: method unclear</P>
<P>Blinding: investigators, participants</P>
<P>Loss to follow up: 23</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:22:36 -0300" MODIFIED_BY="[Empty name]">
<P>281 symptomatic women were enrolled, 122 excluded from analysis</P>
<P>Inclusion criteria: all 4 Amsel criteria, Nugent score for BV, and culture for Gardnerella vaginalis in women 16 years or older</P>
<P>Exclusion criteria: breastfeeding, allergy to clindamycin or sulphonamides, antimicrobial therapy in the previous 2 weeks, antibiotic associated diarrhoea, menstruation, presence of other vaginal or cervical infections</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:23:24 -0300" MODIFIED_BY="[Empty name]">
<P>1. 2% Clindamycin vaginal cream 5g at bedtime for 7 days</P>
<P>2. Triple sulfonamide vaginal cream 5g at bedtime for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:27:13 -0300" MODIFIED_BY="[Empty name]">
<P>Primary<BR/>- Treatment failure - defined as a return to normal of one or none of the diagnostic findings<BR/>- Improvement - defined as a return to normal for two of the 3 findings<BR/>- Cure defined as a return to normal for all 3 diagnostic findings<BR/>- Side effects</P>
<P>Secondary: Gram-stain, patients' evaluation of efficacy (not assessed in this review)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-09 05:27:32 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: multicentre, New York, USA</P>
<P>Study setting</P>
<P>Study duration: no report</P>
<P>Funding: no information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:46:18 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Milani-2003">
<CHAR_METHODS MODIFIED="2009-05-09 05:28:12 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: computer-generated list with blocks of 8</P>
<P>Allocation concealment: by a centralised phone-call procedure</P>
<P>Blinding: investigator only</P>
<P>Loss to follow up: 6</P>
<P>Analysis: intent to treat</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-08 10:45:34 -0300" MODIFIED_BY="[Empty name]">
<P>64 women were enrolled</P>
<P>Eligibility criteria: BV by Amsel criteria, age 20-75 years</P>
<P>Exclusion criteria: pregnancy, topical antibiotics in the previous 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:28:55 -0300" MODIFIED_BY="[Empty name]">
<P>1. 2g Tinidazole + acid buffering gel</P>
<P>2. Clindamycin cream alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:46:18 -0300" MODIFIED_BY="[Empty name]">
<P>Primary: laboratory cure rate<BR/>- Laboratory cure rate defined as clinical cure rate plus a negative result of the BV: clue and whiff tests</P>
<P>Secondary: clinical cure rate, vaginal normalisation<BR/>- Clinical cure defined as absence of at least 2 out of 4 sign and symptoms of BV<BR/>- Vaginal nomalisation defined as the percentage of women with a vaginal pH &lt; 4.5<BR/>- Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: no report</P>
<P>Study setting</P>
<P>Study duration: 6 months</P>
<P>Funding: Mipharm Spa</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:37:53 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nunez-2005">
<CHAR_METHODS MODIFIED="2009-05-09 05:30:17 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: table of random numbers</P>
<P>Allocation concealment: packets of drugs prepared and numbered independently</P>
<P>Blinding: participants, investigators</P>
<P>Loss to follow up: 4</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:36:08 -0300" MODIFIED_BY="[Empty name]">
<P>80 women 18 to 60 years old were enrolled, 4 excluded from analysis</P>
<P>Inclusion criteria: symptomatic women with at least 3 Amsel criteria</P>
<P>Exclusion criteria: pregnancy/breastfeeding, antibiotic therapy in the previous 4 weeks and allergy to metronidazole or its derivatives</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:36:42 -0300" MODIFIED_BY="[Empty name]">
<P>1. 1g oral secnidazole single dose</P>
<P>2. 2g oral secnidazole single dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:37:53 -0300" MODIFIED_BY="[Empty name]">
<P>Primary outcome: clinical curre, cytologic cure<BR/>- Clinical cure defined as absence of characteristic symptoms + at least 2 of (vaginal pH &lt; 5, no fishy odour, no clue cells)<BR/>- Cytologic cure defined as absence of Gardnerella vaginalis on a Pap smear (not assessed in this review)</P>
<P>Secondary outcome: adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: Venezuela</P>
<P>Study setting: clinic of an urban public hospital</P>
<P>Study duration: 3 years</P>
<P>Funding: no information</P>
<P>Socio-economic status: low and middle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:41:00 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paavonen--2000">
<CHAR_METHODS MODIFIED="2009-05-08 10:47:02 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: unclear (conducted and maintained by the sponsor)</P>
<P>Allocation concealment: not mentioned</P>
<P>Blinding: participants and investigators</P>
<P>Loss to follow up: 53</P>
<P>Analysis: ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:38:31 -0300" MODIFIED_BY="[Empty name]">
<P>399 women were enrolled, 166 were excluded from analysis</P>
<P>Inclusion criteria: women with BV but method of diagnosis not clear</P>
<P>Exclusion criteria: pregnancy, breastfeeding, menstruation, antibiotics in the previous 2 weeks, STDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:38:41 -0300" MODIFIED_BY="[Empty name]">
<P>1. Clindamycin ovule 100mg vaginally for 3 days</P>
<P>2. Metronidazole 500mg twice daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:41:00 -0300" MODIFIED_BY="[Empty name]">
<P>Primary: cure, failure, non-assessable efficacy<BR/>- Cure defined as resolution of amine odour and clue cells at both follow-up visits<BR/>- Clinical failure -defined as no resolution of amine odour or clue cells at either follow-up visit<BR/>- Non-assessable defined as inadequate data to categorise outcome as cure or failure<BR/>- Adverse effects failure: did not complete study therapy because of treatment-related adverse effects</P>
<P>Secondary: clinical status (cure, clinical failure, adverse effects, non-assessable status) at each follow-up visit<BR/>- Symptoms of vaginitis or cevicitis<BR/>- Patient evaluation efficacy (cure improvement, failure) at second follow-up visit<BR/>- Treatment safety: medical events reported spontaneously by participants</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-08 10:47:43 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: multicentre, multiracial (23 countries)</P>
<P>Study setting:</P>
<P>Study duration: no report</P>
<P>Funding: grant from Pharmacia and Upjohn which markets clindamycin, 2 of the 3 authors are employees of Pharmacia and Upjohn and one of them owns stock and stock options in the company</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:41:56 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Piot-1983">
<CHAR_METHODS MODIFIED="2009-05-08 10:47:51 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: method unclear</P>
<P>Allocation concealment: not mentioned</P>
<P>Blinding: Investigators, participants</P>
<P>Loss to follow up: 17</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-08 10:48:14 -0300" MODIFIED_BY="[Empty name]">
<P>85 women enrolled but 28 excluded from analysis</P>
<P>Inclusion criteria: nonspecific vaginitis (BV) by Amsel criteria</P>
<P>Exclusion criteria: antibiotics in the preceding 3 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:41:39 -0300" MODIFIED_BY="[Empty name]">
<P>1. Oral tinidazole 500mg twice daily for 5 days + triple sulfonamide cream intravaginally twice daily for7 days</P>
<P>2. Oral tinidazole 500mg twice daily for 5 days + placcebo cream intravaginally twice daily for7 days</P>
<P>3. Oral placebo twice daily for 5 days + triple sulfonamide cream intravaginally twice daily for7 days</P>
<P>4. Oral placebo twice daily for 5 days + placebo cream intravaginally twice daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cure: defined as absence of at least 3 of -abnormal vaginal discharge, clue cells, vaginal pH of 5 and positive amine test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-09 05:41:56 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: obtained</P>
<P>Ethical approval: no statement</P>
<P>Study location: Belgium</P>
<P>Study setting</P>
<P>Study duration: no report</P>
<P>Funding: National fonds voor Wettenschappeljik Onderzoek Belgium and Roerig NV, Belgium</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:42:27 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schinder-1991">
<CHAR_METHODS MODIFIED="2009-05-08 10:48:43 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: method unclear</P>
<P>Blinding: no</P>
<P>Some exclusion criteria applied after randomisation</P>
<P>Loss to follow up:</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 women aged 18 -55 years were enrolled, 25 were excluded from analysis</P>
<P>Inclusion criteria: 3 or more Amsel criteria</P>
<P>Exclusion criteria: STDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:42:12 -0300" MODIFIED_BY="[Empty name]">
<P>1. Oral tinidazole 2g single dose</P>
<P>2. Oral metronidazole 400mg twice daily fo 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-08 10:48:58 -0300" MODIFIED_BY="[Empty name]">
<P>Healing: defined as disappearanceof all symptoms of the infection</P>
<P>Improvement: defined as one or two inclusion criteria in the study still exist but clearly less pronounced</P>
<P>Failure: defined as all symptoms that existed before the treatment are still present</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-09 05:42:27 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: no statement</P>
<P>Study location: multicentre study</P>
<P>Study setting:</P>
<P>Study duration: no report</P>
<P>Funding: no information</P>
<P>
<BR/>Not clear if ethical approval or informed consent obtained</P>
<P>Multicentre study</P>
<P>Simultaneous treatment of partner if partner had complaints</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:44:19 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmitt-1992">
<CHAR_METHODS MODIFIED="2009-05-09 05:42:43 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: provided by Upjohn Pharmaceutical Company</P>
<P>Allocation concealment: not mentioned</P>
<P>Blinding: investigators, participants</P>
<P>Loss to follow up: 2</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:43:18 -0300" MODIFIED_BY="[Empty name]">
<P>61 women enrolled, 13 were excluded from analysis</P>
<P>Inclusion criteria: Amsel and Gram-stain criteria for BV</P>
<P>Exclusion criteria: age &lt;18 or &gt; 60 years, pregnancy, breastfeeding, allergy to clindamycin or metronidazole, antimicrobial therapy within the previous 2 weeks, presence of STDs, menses, diarrhea, antibiotic-associated colitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:43:38 -0300" MODIFIED_BY="[Empty name]">
<P>1. 2% Vaginal clindamycin cream 5g per day for 7 days</P>
<P>2. Oral metronidazole 500mg twice daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:43:51 -0300" MODIFIED_BY="[Empty name]">
<P>Primary outcome: cure, symptomatic failure, asymptomatic failure, non-evaluable</P>
<P>Secondary outcome: side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-09 05:44:19 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: Michigan State University Clinic</P>
<P>Study setting: clinic</P>
<P>Study duration: no report</P>
<P>Funding: Upjohn Company</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:46:52 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwebke-2000">
<CHAR_METHODS MODIFIED="2009-05-08 10:50:13 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: computer-generated randomisation scheme with a block of 6 patients in a 1:1 ratio</P>
<P>Blinding: investigators, participants</P>
<P>Loss to follow up: 4</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:44:37 -0300" MODIFIED_BY="[Empty name]">
<P>75 women enrolled but 17 excluded fom analysis</P>
<P>Inclusion criteria: women who denied symptoms of vaginal discharge and odour but met Amsel and Nugent criteria</P>
<P>Exclusion criteria: pregnancy, antibiotic therapy in the previous 2 weeks, current STD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:44:44 -0300" MODIFIED_BY="[Empty name]">
<P>1. Metronidazole gel 5g intravaginally daily at bedtime for 5 days<BR/>2. Placebo gel 5g intravaginally daily at bedtime for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Normalisation of clincal parameters: defined as vaginal pH 4.5 or more, negative whiff test, and an absence of clue cells</P>
<P>Improvement in Nugent score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-09 05:46:52 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: unclear</P>
<P>Ethical approval: yes</P>
<P>Study location: Birmingham, UK</P>
<P>Study setting</P>
<P>Study duration:</P>
<P>Funding: 3M Pharmaceuticals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:48:07 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwebke-2006">
<CHAR_METHODS MODIFIED="2009-05-08 10:50:59 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: block randomisation</P>
<P>Allocation concealment: randomisation scheme used to generate a list of randomisation numbers</P>
<P>Blinding: investigators, participants</P>
<P>Loss to follow up: 137</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-08 10:51:12 -0300" MODIFIED_BY="[Empty name]">
<P>567 women were randomised, 143 were excluded from analysis</P>
<P>Inclusion criteria: 3 or 4 Amsel criteria and a Gram-stain score of 7 or more</P>
<P>Exclusion criteria: pregnancy, breastfeeding, hypersensitivity to metronidazole or clindamycin, chronic disease, pesence of STDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Oral metronidazole 750mg daily for 7 days + azithromycin 1gm orally on days 1 and 3<BR/>2. Oral metronidazole 750mg daily for 14 days + azithromycin 1gm orally on days 1 and 3<BR/>3. Oral metronidazole 750mg daily for 14 days<BR/>4. Oral metronidazole 750mg daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:47:30 -0300" MODIFIED_BY="[Empty name]">
<P>Primary: not cured normalisation of 0 or 1 of the criteria, cured if vaginal pH and whiff tests results normalised and if clue cells were absent, improved if normalisation of or more of the criteria, and not cured normalisation of 0 or 1 of the criteria</P>
<P>Secondary: adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-09 05:48:07 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: no statement</P>
<P>Ethical approval: no statement</P>
<P>Study location: Birmingham UK</P>
<P>Study setting: an STD clinic</P>
<P>Study duration: 3 years</P>
<P>Funding: Pfizer, National institutes of Health</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schwebke-2006a">
<CHAR_METHODS>
<P>Same as for Schwbeke 2006</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schwebke-2006b">
<CHAR_METHODS>
<P>Same as for Schwbeke 2006</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:49:17 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sobel-2001">
<CHAR_METHODS MODIFIED="2009-05-09 05:48:18 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: using random list of patient numbers in a 1:1 ratio</P>
<P>Allocation concealment: not mentioned</P>
<P>Blinding: investigators only</P>
<P>Analysis was by intent to treat.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:48:40 -0300" MODIFIED_BY="[Empty name]">
<P>662 women were enrolled</P>
<P>Inclusion criteria: symptomatic women who fulfilled Amsel's criteria and were between 16 and 60 years of age</P>
<P>Exclusion criteria: allergy to clindamycin or lincomycin, pregnancy or breastfeeding, systemic or vaginal antimicrobial in the previous 2 weeks, STDs, anticipation of menses</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:49:02 -0300" MODIFIED_BY="[Empty name]">
<P>1. Vaginal clindamycin ovule 100mg at bedtime for 3 days<BR/>2. Vaginal clindamycin cream 5g intravaginally at bedtime for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:49:17 -0300" MODIFIED_BY="[Empty name]">
<P>Primary: cure defined as resolution of 2 or 3 diagnostic criteria at first follow-up visit and 3 or more criteria at second visit</P>
<P>Secondary: side effects, patient evaluation of efficacy and Gram-stain scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-08 10:52:15 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: multticentre, multiracial</P>
<P>Study setting</P>
<P>Study duration: no report</P>
<P>Funding: Phamacia and Upjohn</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:50:19 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stein-1993">
<CHAR_METHODS MODIFIED="2009-05-09 05:49:28 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: (unclear) randomisation schedule by the Upjohn Company</P>
<P>Allocation concealment: not mentioned</P>
<P>Blinding: investigators, paticipants</P>
<P>Loss to follow up: none</P>
<P>Analysis: No ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-08 10:52:46 -0300" MODIFIED_BY="[Empty name]">
<P>215 symptomatic women enrolled, 81 were excluded from analysis</P>
<P>Inclusion criteria: at least 3 Amsel and Gram-stain criteria</P>
<P>Exclusion criteria: allergy to clindamycin, nursing, menstruating, history of antibiotic asociated diarrhea, antibiotic therapy within the previous 2 weeks, concurrent genital infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:49:46 -0300" MODIFIED_BY="[Empty name]">
<P>Arm 1: 2% clindamycin cream, 5g intravaginally at bedtime for 7days<BR/>Arm 2: placebo cream 5g intravaginally at bedtime for 7days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-09 05:50:08 -0300" MODIFIED_BY="[Empty name]">
<P>First follow-up visit<BR/>- Clinical cure aand microbiologic cure (not assessed in this review)<BR/>- Clinical cure<BR/>- Improvement<BR/>- Failure</P>
<P>Final follow-up visit<BR/>- Cure<BR/>- Improvement<BR/>- Failure<BR/>- Recurrences</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-09 05:50:19 -0300" MODIFIED_BY="[Empty name]">
<P>Informed consent: written</P>
<P>Ethical approval: yes</P>
<P>Study location: Michigan</P>
<P>Study setting: ambulatory clinic the general community</P>
<P>Study duration: no report</P>
<P>Funding: Upjohn Company</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:50:34 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Voorspoels-2002">
<CHAR_METHODS MODIFIED="2009-05-08 10:53:14 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: unclear</P>
<P>Allocation concealment: not mentioned</P>
<P>Blinding: investigator, participants</P>
<P>Loss to follow up: 6</P>
<P>Analysis: no ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-09 05:50:34 -0300" MODIFIED_BY="[Empty name]">
<P>116 symptomatic women were enrolled, 16 were excluded from analysis</P>
<P>Inclusion criteria: at least 3 Amsel criteria for BV</P>
<P>Exclusion criteria: cervicitis, vulvovaginitis caused by other organisms, recent antimicrobial therapy, pregnancy, total hysterectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Arm 1: 100mg metronidazole single dose bioadhesive tablets<BR/>Arm 2: 250mg metronidazloe single dose bioadhesive tablets<BR/>Arm 3: 500mg metronidazole single dose bioadhesive tablets<BR/>Arm 4: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: cured, not cured</P>
<P>Secondary: side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Informed consent: unclear</P>
<P>Ethical approval: yes</P>
<P>Study location: Belgium</P>
<P>Study setting</P>
<P>Study duration: no report</P>
<P>Funding: no infomation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Voorspoels-2002a">
<CHAR_METHODS>
<P>Same as for Voorspoels 2002</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Voorspoels-2002b">
<CHAR_METHODS>
<P>Same as for Voorspoels 2002</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-09 05:51:21 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wathne-1989">
<CHAR_METHODS MODIFIED="2009-05-08 10:53:48 -0300" MODIFIED_BY="[Empty name]">
<P>Random allocation: unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: investigator</P>
<P>Loss to follow up: none</P>
<P>Analysis: ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>22 women enrolled</P>
<P>Inclusion criteria: 3 or 4 Amsel criteria + absence of lactobacillus</P>
<P>Exclusion criteria: STDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-09 05:51:21 -0300" MODIFIED_BY="[Empty name]">
<P>Arm 1: cefadroxil 500mg orally twice daily for 7 days<BR/>Arm 2: metronidazole 400mg orally twice daily for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Cure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Informed consent: unclear</P>
<P>Ethical approval: yes</P>
<P>Study location: Sweden</P>
<P>Study setting</P>
<P>Study duration: no report</P>
<P>Funding: no information</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>B = Allocation concealment unclear<BR/>ITT = intention-to-treat<BR/>IRB = Institutional review board<BR/>BV = bacterial vaginosis<BR/>STD = sexually transmittted diseases<BR/>* sexual partners also treated</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-05-08 09:02:09 -0300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Andreeva-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blackwell-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>BV not diagnosed by Amsel or Gram stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eschenback--1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>BV not diagnosed by Amsel or Gram stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Facchin-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ferris-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>STDs not excluded from participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fredricsson-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>BV not diagnosed by Amsel or Gram stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hagstrom-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>BV not diagnosed by Amsel or Gram stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hovick-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>BV not diagnosed by Amsel or Gram stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Improda-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomisation not to drug but tosexual partner</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jerve-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>BV not diagnosed by Amsel or Gram stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>BV not confimed by Amsel or Gram stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kira-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lefevre-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Linhares-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, BV not diagnosed by Amsel or Gram stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Malouf-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Diagnosis not by Amsel or Gram stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martins-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Milankovis-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mohanty--1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, trichomoniasis not excluded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Naud-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>BV not diagnosed by Amsel or Gram stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-08 09:01:44 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Purdon-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-08 09:01:44 -0300" MODIFIED_BY="[Empty name]">
<P>BV not diagnosed by Amsel or Gram-stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-22 11:08:30 -0300" MODIFIED_BY="Oyinlola O Oduyebo" STUDY_ID="STD-Sanchez-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-22 11:08:30 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<P>Candidiasis and trichomoniasis not excluded before randomisation, women without BV also randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sanz-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-08 09:02:09 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanz-Sanz-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-08 09:02:09 -0300" MODIFIED_BY="[Empty name]">
<P>Diagnosis of BV not by Amsel or Gram-stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-08 09:01:57 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanz-Sanz-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-08 09:01:57 -0300" MODIFIED_BY="[Empty name]">
<P>BV not diagnosed by Amsel or Gram-stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sobel-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-08 09:01:48 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swedberg-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-08 09:01:48 -0300" MODIFIED_BY="[Empty name]">
<P>BV not diagnosed by Amsel or Gram-stain criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-08 09:01:52 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Der-Meijden-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-08 09:01:52 -0300" MODIFIED_BY="[Empty name]">
<P>BV not confirmed by Amsel or Gram-stain criteria, STDs not excluded from participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vutyavanich-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomisation not to drug but to sexual partner</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wei-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>BV = bacterial vaginosis</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-09-27 12:16:04 -0300" MODIFIED_BY="Oyinlola O Oduyebo" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2008-09-27 12:16:04 -0300" MODIFIED_BY="Oyinlola O Oduyebo" STUDY_ID="STD-Wilson-2005">
<CHAR_STUDY_NAME/>
<CHAR_METHODS MODIFIED="2008-09-27 12:16:04 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<P>Random allocation: method unclear</P>
<P>Allocation concealment: unclear</P>
<P>Blinding: Investigator</P>
<P>Loss to follow-up: 13</P>
<P>Analysis:</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-27 12:16:04 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<P>51 symptomatic women were randomised</P>
<P>Inclusion criteria: Amsel criteria and Nugent score</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-27 12:16:04 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<P>1: 5 % tea tree oil gel 5 g daily fo 5 days</P>
<P>2: 0.75% metronidazole 5g daily for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-27 12:16:04 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<P>Pesistence<BR/>Recurrence<BR/>Adverse reactions</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2008-09-27 12:16:04 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<P>Incomplete information from conference proceedings. Author to be contacted</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-09-27 12:16:04 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-09-27 12:16:04 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Andres-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Anukam-2006a">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Anukam-2006b">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Beigi-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Burana-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chaithong-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eriksson-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Fischbach-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Gerli-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Greaves-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Livengood-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Livengood-1990a">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Livengood-1990b">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McCormack-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Milani-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Nunez-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Paavonen--2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Piot-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schinder-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schmitt-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schwebke-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schwebke-2006">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schwebke-2006a">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schwebke-2006b">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sobel-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stein-1993">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Voorspoels-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Voorspoels-2002a">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Voorspoels-2002b">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wathne-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2001-05-07 10:31:13 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2001-05-07 10:31:13 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1">
<TITLE>Search strategy</TITLE>
<TABLE COLS="2" ROWS="24">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>(BACTERIAL VAGINOSIS) OR (VAGINOSIS BACTERIAL) OR (BACTERIAL VAGINITIS)</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>(BACTERIAL INFECTION) OR (BACTERIAL INFECTIONS)</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>VAGINITIS OR VAGINOSIS</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>#2 AND #3</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>(NONSPECIFIC VAGINITIS) OR (NON-SPECIFIC VAGINITIS) OR (NONSPECIFIC VAGINOSIS) OR (NON-SPECIFIC VAGINOSIS)</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>#1 OR #4 OR #5</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>"ANTIMICROBIAL THERAPY" OR "ANTIMICROBIAL TREATMENT"</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>"ANTIMICROBIAL AGENTS" OR ANTIMICROBIAL* OR ANTIBIOTIC OR ANTIBIOTICS</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>TREATMENT OR THERAPY</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>#8 AND #9</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>#7 OR #10</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>RANDOMIZED CONTROLLED TRIAL[PT] OR CONTROLLED CLINICAL TRIAL[PT] OR RANDOMIZED CONTROLLED TRIALS[MH] OR CONTROLLED CLINICAL TRIALS[MH]</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>DOUBLE-BLIND METHOD[MH] OR SINGLE-BLIND METHOD[MH] OR CLINICAL TRIALS[MH] OR "CLINICAL TRIAL"</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>((SINGL* OR DOUBL* OR TRIPL* OR TREBL*) AND (MASK* OR BLIND*))</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>PLACEBO[TW] OR PLACEBOS[MH] OR RE DESIGN[MH:NOEXP]</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>CONTROL[TW] OR PROSPECTIVE*[TW] OR RANDOM*[TW] OR VOLUNTEER*[TW]</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>#12 OR #13 OR #14 OR #15 OR #16</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>(ANIMALS[TW] OR ANIMAL[MH]) NOT HUMAN[MH]</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>#17 NOT #18</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>#6 AND #11 AND #19</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>PREGNANCY[MH]</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>#20 NOT #21</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-05-08 10:00:46 -0300" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2001-05-13 18:36:26 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1">
<NAME>Topical metronidazole versus placebo</NAME>
<DICH_OUTCOME CHI2="0.5822323934551308" CI_END="0.78539939643709" CI_START="0.436320977143421" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5853940827351128" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.10490943681164336" LOG_CI_START="-0.3601939067962834" LOG_EFFECT_SIZE="-0.23255167180396338" METHOD="MH" MODIFIED="2001-05-13 18:35:37 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.9004875450272922" P_Q="0.0" P_Z="3.558073237808052E-4" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="68" WEIGHT="100.0" Z="3.5708627423185684">
<NAME>Clinical failure 1</NAME>
<GROUP_LABEL_1>Metronidazole</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour metronidazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favour placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.968686759662337" CI_START="0.43166883561525266" EFFECT_SIZE="0.6466466466466466" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" LOG_CI_END="-0.013816636306206052" LOG_CI_START="-0.36484930415559036" LOG_EFFECT_SIZE="-0.18933297023089823" ORDER="1" O_E="0.0" SE="0.2061983267344585" STUDY_ID="STD-Schwebke-2000" TOTAL_1="37" TOTAL_2="38" VAR="0.0425177499480905" WEIGHT="52.88758324301801"/>
<DICH_DATA CI_END="1.1214043802103641" CI_START="0.25591998834936863" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.049762248121915244" LOG_CI_START="-0.5918957926949913" LOG_EFFECT_SIZE="-0.27106677228653797" ORDER="2" O_E="0.0" SE="0.3769131094343789" STUDY_ID="STD-Voorspoels-2002" TOTAL_1="28" TOTAL_2="10" VAR="0.1420634920634921" WEIGHT="15.82856374303732"/>
<DICH_DATA CI_END="1.1364291167443012" CI_START="0.2715892885540059" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.05554235236468401" LOG_CI_START="-0.566087362571296" LOG_EFFECT_SIZE="-0.255272505103306" ORDER="3" O_E="0.0" SE="0.3651483716701107" STUDY_ID="STD-Voorspoels-2002a" TOTAL_1="30" TOTAL_2="10" VAR="0.13333333333333333" WEIGHT="16.864957797640958"/>
<DICH_DATA CI_END="1.0325879695223865" CI_START="0.21960101832233903" EFFECT_SIZE="0.47619047619047616" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.013927060861815495" LOG_CI_START="-0.6583656503296541" LOG_EFFECT_SIZE="-0.3222192947339193" ORDER="4" O_E="0.0" SE="0.39490806645646137" STUDY_ID="STD-Voorspoels-2002b" TOTAL_1="28" TOTAL_2="10" VAR="0.15595238095238093" WEIGHT="14.41889521630372"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:36:09 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="37" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure 2</NAME>
<GROUP_LABEL_1>Metronidazole</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursmetronidazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0650910342902398" CI_START="0.4401437082363224" EFFECT_SIZE="0.6846846846846847" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" LOG_CI_END="0.02738672890179076" LOG_CI_START="-0.3564055019135229" LOG_EFFECT_SIZE="-0.16450938650586605" ORDER="5" O_E="0.0" SE="0.22544145618309738" STUDY_ID="STD-Schwebke-2000" TOTAL_1="37" TOTAL_2="38" VAR="0.05082385016595542" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:36:26 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="37" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>Candida infection</NAME>
<GROUP_LABEL_1>Metronidazole</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursmetronidazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="228.71115516999734" CI_START="0.7783257127133671" EFFECT_SIZE="13.342105263157896" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.359287347425404" LOG_CI_START="-0.10883862199235218" LOG_EFFECT_SIZE="1.125224362716526" ORDER="6" O_E="0.0" SE="1.4497894118565786" STUDY_ID="STD-Schwebke-2000" TOTAL_1="37" TOTAL_2="38" VAR="2.101889338731444" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2001-05-13 18:38:00 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2">
<NAME>2% clindamycin cream versus placebo</NAME>
<DICH_OUTCOME CHI2="3.9356479884939946" CI_END="0.40897205938517067" CI_START="0.088310112427842" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19004307023448785" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="64" I2="23.773670593238887" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.38830636159984555" LOG_CI_START="-1.0539895623324085" LOG_EFFECT_SIZE="-0.7211479619661271" METHOD="MH" MODIFIED="2001-05-13 18:36:51 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.26849741919710524" P_Q="0.0" P_Z="2.171003442688507E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.17960007670328001" TOTALS="YES" TOTAL_1="156" TOTAL_2="129" WEIGHT="100.0" Z="4.246536585038174">
<NAME>Clinical failure 1</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6078012133891133" CI_START="0.011425519218235956" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="-0.2162384372477339" LOG_CI_START="-1.9421240548475156" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="7" O_E="0.0" SE="1.0137937550497031" STUDY_ID="STD-Livengood-1990" TOTAL_1="18" TOTAL_2="6" VAR="1.0277777777777777" WEIGHT="12.663891837437479"/>
<DICH_DATA CI_END="0.6791939310264701" CI_START="0.012940431441601718" EFFECT_SIZE="0.09375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="-0.16800620340823014" LOG_CI_START="-1.888051243792257" LOG_EFFECT_SIZE="-1.0280287236002434" ORDER="8" O_E="0.0" SE="1.0103629710818451" STUDY_ID="STD-Livengood-1990a" TOTAL_1="16" TOTAL_2="6" VAR="1.0208333333333333" WEIGHT="12.737151788868568"/>
<DICH_DATA CI_END="0.6078012133891133" CI_START="0.011425519218235956" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="-0.2162384372477339" LOG_CI_START="-1.9421240548475156" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="9" O_E="0.0" SE="1.0137937550497031" STUDY_ID="STD-Livengood-1990b" TOTAL_1="18" TOTAL_2="6" VAR="1.0277777777777777" WEIGHT="12.663891837437479"/>
<DICH_DATA CI_END="0.511863429110877" CI_START="0.18518295417929287" EFFECT_SIZE="0.30787721893491127" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="52" LOG_CI_END="-0.2908458981948362" LOG_CI_START="-0.7323989919876455" LOG_EFFECT_SIZE="-0.5116224450912408" ORDER="10" O_E="0.0" SE="0.25937047301696137" STUDY_ID="STD-Stein-1993" TOTAL_1="104" TOTAL_2="111" VAR="0.06727304227304227" WEIGHT="61.935064536256476"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:37:05 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="104" TOTAL_2="111" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure 2</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.710119452106204" CI_START="0.2121204217783443" EFFECT_SIZE="0.3881118881118881" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="33" LOG_CI_END="-0.1486685906794077" LOG_CI_START="-0.6734175180053634" LOG_EFFECT_SIZE="-0.4110430543423855" ORDER="11" O_E="0.0" SE="0.3082401174603494" STUDY_ID="STD-Stein-1993" TOTAL_1="104" TOTAL_2="111" VAR="0.09501197001197" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:38:00 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="104" TOTAL_2="111" WEIGHT="0.0" Z="0.0">
<NAME>Bacteriologic failure 2</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9264557827422253" CI_START="0.3592618696827748" EFFECT_SIZE="0.5769230769230769" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="37" LOG_CI_END="-0.0331753035650626" LOG_CI_START="-0.444588874265211" LOG_EFFECT_SIZE="-0.23888208891513676" ORDER="12" O_E="0.0" SE="0.2416663679592868" STUDY_ID="STD-Stein-1993" TOTAL_1="104" TOTAL_2="111" VAR="0.0584026334026334" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2001-05-13 18:49:13 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3">
<NAME>Metronidazole versus clindamycin</NAME>
<DICH_OUTCOME CHI2="7.316282311567269" CI_END="1.7457623250513021" CI_START="0.6389486418414292" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0561498314962063" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="48" I2="31.659280122435337" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.24198511683527932" LOG_CI_START="-0.19453404866672527" LOG_EFFECT_SIZE="0.023725534084277012" METHOD="MH" MODIFIED="2001-05-13 18:38:39 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.19816062449108418" P_Q="0.0" P_Z="0.8312844320819198" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11895013205334092" TOTALS="YES" TOTAL_1="596" TOTAL_2="593" WEIGHT="100.0" Z="0.2130545277006715">
<NAME>Clinical failure 1</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1080777784770572" CI_START="0.029647862445166522" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3238866303262053" LOG_CI_START="-1.52800661298213" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="13" O_E="0.0" SE="1.0878112581387145" STUDY_ID="STD-Andres-1992" TOTAL_1="30" TOTAL_2="30" VAR="1.1833333333333331" WEIGHT="5.048662159883351"/>
<DICH_DATA CI_END="1.346788761557534" CI_START="0.2967091820506432" EFFECT_SIZE="0.6321428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.1292994837080971" LOG_CI_START="-0.5276690136689223" LOG_EFFECT_SIZE="-0.1991847649804126" ORDER="14" O_E="0.0" SE="0.3859065474057715" STUDY_ID="STD-Beigi-2004" TOTAL_1="60" TOTAL_2="59" VAR="0.14892386333064297" WEIGHT="24.544335644506408"/>
<DICH_DATA CI_END="3.785108630605822" CI_START="0.8476145500414408" EFFECT_SIZE="1.7911764705882354" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.578078348035743" LOG_CI_START="-0.07180159685450245" LOG_EFFECT_SIZE="0.25313837559062025" ORDER="15" O_E="0.0" SE="0.3817426965861398" STUDY_ID="STD-Fischbach-1993" TOTAL_1="204" TOTAL_2="203" VAR="0.1457274863968576" WEIGHT="24.84074509827346"/>
<DICH_DATA CI_END="8.831803670425177" CI_START="0.2619880047209713" EFFECT_SIZE="1.5211267605633803" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.946049406195961" LOG_CI_START="-0.5817185926602122" LOG_EFFECT_SIZE="0.1821654067678744" ORDER="16" O_E="0.0" SE="0.8974184851016781" STUDY_ID="STD-Greaves-1988" TOTAL_1="71" TOTAL_2="72" VAR="0.8053599374021909" WEIGHT="7.113185791660112"/>
<DICH_DATA CI_END="1.7650600681088957" CI_START="0.42129941706431484" EFFECT_SIZE="0.8623333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.2467594897829514" LOG_CI_START="-0.37540914178918955" LOG_EFFECT_SIZE="-0.06432482600311905" ORDER="17" O_E="0.0" SE="0.36546493396987195" STUDY_ID="STD-Paavonen--2000" TOTAL_1="200" TOTAL_2="199" VAR="0.13356461796160288" WEIGHT="26.037248330049493"/>
<DICH_DATA CI_END="7.928103615791574" CI_START="0.643136821376161" EFFECT_SIZE="2.2580645161290325" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.89916931749544" LOG_CI_START="-0.1916966251354716" LOG_EFFECT_SIZE="0.3537363461799842" ORDER="18" O_E="0.0" SE="0.6407800545749016" STUDY_ID="STD-Schmitt-1992" TOTAL_1="31" TOTAL_2="30" VAR="0.41059907834101383" WEIGHT="12.415822975627178"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7012002130807823" CI_END="1.2688468486283195" CI_START="0.7486890518175172" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9746649393515606" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="77" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.1034092053811167" LOG_CI_START="-0.12569851757318123" LOG_EFFECT_SIZE="-0.01114465609603226" METHOD="MH" MODIFIED="2001-05-13 18:39:10 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.8729216307322072" P_Q="0.0" P_Z="0.8487763482183704" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="494" TOTAL_2="491" WEIGHT="100.00000000000001" Z="0.19067994990867437">
<NAME>Clinical failure 2</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="19" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Andres-1992" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="1.2635937268339823"/>
<DICH_DATA CI_END="1.4616365923972503" CI_START="0.7079598507342073" EFFECT_SIZE="1.0172413793103448" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="0.16483940713955214" LOG_CI_START="-0.14999137098113838" LOG_EFFECT_SIZE="0.0074240180792068755" ORDER="20" O_E="0.0" SE="0.18493315750557945" STUDY_ID="STD-Beigi-2004" TOTAL_1="60" TOTAL_2="59" VAR="0.034200272744983454" WEIGHT="52.95720949265539"/>
<DICH_DATA CI_END="1.7925452603452734" CI_START="0.5524101006298557" EFFECT_SIZE="0.9950980392156863" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.25347013006929153" LOG_CI_START="-0.25773838909466323" LOG_EFFECT_SIZE="-0.0021341295126858302" ORDER="21" O_E="0.0" SE="0.30028641467988865" STUDY_ID="STD-Fischbach-1993" TOTAL_1="204" TOTAL_2="203" VAR="0.09017193084130205" WEIGHT="20.085529849078792"/>
<DICH_DATA CI_END="1.4262019888487325" CI_START="0.5037247238715145" EFFECT_SIZE="0.8475925925925926" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="27" LOG_CI_END="0.1541810377389643" LOG_CI_START="-0.2978067325303023" LOG_EFFECT_SIZE="-0.07181284739566898" ORDER="22" O_E="0.0" SE="0.26549985363171397" STUDY_ID="STD-Paavonen--2000" TOTAL_1="200" TOTAL_2="199" VAR="0.07049017227846155" WEIGHT="25.693666931431842"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:40:06 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="204" TOTAL_2="203" WEIGHT="0.0" Z="0.0">
<NAME>Bacteriologic failure 1</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7941764632293973" CI_START="0.27043485559698016" EFFECT_SIZE="0.6965686274509804" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.25386515511716473" LOG_CI_START="-0.5679373341140228" LOG_EFFECT_SIZE="-0.157036089498429" ORDER="23" O_E="0.0" SE="0.482730850162329" STUDY_ID="STD-Fischbach-1993" TOTAL_1="204" TOTAL_2="203" VAR="0.2330290736984449" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:40:37 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="204" TOTAL_2="203" WEIGHT="0.0" Z="0.0">
<NAME>Bcteriologic failure 2</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.052945864389114" CI_START="0.25803135241669123" EFFECT_SIZE="0.5212418300653595" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" LOG_CI_END="0.022406043168907406" LOG_CI_START="-0.5883275213456676" LOG_EFFECT_SIZE="-0.28296073908838004" ORDER="24" O_E="0.0" SE="0.3587479189757629" STUDY_ID="STD-Fischbach-1993" TOTAL_1="204" TOTAL_2="203" VAR="0.12870006936944056" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.576419786344903" CI_END="1.4748735327056872" CI_START="0.16893366255995151" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4991550737924099" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.16875478207499225" LOG_CI_START="-0.7722838021319904" LOG_EFFECT_SIZE="-0.3017645100284991" METHOD="MH" MODIFIED="2001-05-13 18:42:00 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="5" P_CHI2="0.6647482596527451" P_Q="0.0" P_Z="0.20874994981347217" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="465" TOTAL_2="462" WEIGHT="99.99999999999999" Z="1.2570102467512525">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363438" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="25" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Andres-1992" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="11.742421021445567"/>
<DICH_DATA CI_END="2.2066299709146127" CI_START="0.028046730781296134" EFFECT_SIZE="0.24877450980392157" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.34372951256212" LOG_CI_START="-1.5521177542434166" LOG_EFFECT_SIZE="-0.6041941208406483" ORDER="26" O_E="0.0" SE="1.1136300691168957" STUDY_ID="STD-Fischbach-1993" TOTAL_1="204" TOTAL_2="203" VAR="1.240171930841302" WEIGHT="24.63815412541714"/>
<DICH_DATA CI_END="4.119044024195664" CI_START="0.009614604721780735" EFFECT_SIZE="0.19900497512437812" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6147964337051606" LOG_CI_START="-2.0170685658902134" LOG_EFFECT_SIZE="-0.7011360660925264" ORDER="27" O_E="0.0" SE="1.5459705287041827" STUDY_ID="STD-Paavonen--2000" TOTAL_1="200" TOTAL_2="199" VAR="2.3900248756218905" WEIGHT="12.784614706628748"/>
<DICH_DATA CI_END="4.4227050902110525" CI_START="0.21175376485466219" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6456879812045416" LOG_CI_START="-0.6741688594337621" LOG_EFFECT_SIZE="-0.014240439114610228" ORDER="28" O_E="0.0" SE="0.77529044158767" STUDY_ID="STD-Schmitt-1992" TOTAL_1="31" TOTAL_2="30" VAR="0.6010752688172043" WEIGHT="50.83481014650854"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5452578940389117" CI_END="1.0522806236598845" CI_START="0.5355646456882461" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.750709197609176" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="79" I2="15.379921865648262" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.022131573520061586" LOG_CI_START="-0.2711880998625754" LOG_EFFECT_SIZE="-0.12452826317125687" METHOD="MH" MODIFIED="2001-05-13 18:45:40 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="6" P_CHI2="0.31493973409877485" P_Q="0.0" P_Z="0.0960729984384927" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.01866990425006421" TOTALS="YES" TOTAL_1="465" TOTAL_2="462" WEIGHT="100.00000000000003" Z="1.664197345226124">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.627644034470314" CI_START="0.42665621581713864" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.21155943079342393" LOG_CI_START="-0.36992192288867354" LOG_EFFECT_SIZE="-0.07918124604762482" ORDER="29" O_E="0.0" SE="0.34156502553198664" STUDY_ID="STD-Andres-1992" TOTAL_1="30" TOTAL_2="30" VAR="0.1166666666666667" WEIGHT="21.93524154561461"/>
<DICH_DATA CI_END="1.7780841954704023" CI_START="0.6063819015849278" EFFECT_SIZE="1.0383631713554988" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.24995232174243973" LOG_CI_START="-0.21725376937978508" LOG_EFFECT_SIZE="0.01634927618132735" ORDER="30" O_E="0.0" SE="0.2744391706326448" STUDY_ID="STD-Fischbach-1993" TOTAL_1="204" TOTAL_2="203" VAR="0.07531685837753392" WEIGHT="31.585728564524324"/>
<DICH_DATA CI_END="1.0920228471928606" CI_START="0.3904388901501272" EFFECT_SIZE="0.65296875" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="32" LOG_CI_END="0.03823172472951309" LOG_CI_START="-0.40844693041003566" LOG_EFFECT_SIZE="-0.18510760284026126" ORDER="31" O_E="0.0" SE="0.262381253123974" STUDY_ID="STD-Paavonen--2000" TOTAL_1="200" TOTAL_2="199" VAR="0.06884392199090691" WEIGHT="33.921958398201916"/>
<DICH_DATA CI_END="1.0063360169131805" CI_START="0.16156735747894904" EFFECT_SIZE="0.4032258064516129" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.0027430164309928534" LOG_CI_START="-0.7916463780834255" LOG_EFFECT_SIZE="-0.3944516808262163" ORDER="32" O_E="0.0" SE="0.4666282626286914" STUDY_ID="STD-Schmitt-1992" TOTAL_1="31" TOTAL_2="30" VAR="0.217741935483871" WEIGHT="12.557071491659165"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.20745135909111284" CI_END="0.6785133720862491" CI_START="0.0116394491219146" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.08886800252586197" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-0.16844158887964128" LOG_CI_START="-1.9340675737217077" LOG_EFFECT_SIZE="-1.0512545813006744" METHOD="MH" MODIFIED="2001-05-13 18:46:15 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="7" P_CHI2="0.6487723910382523" P_Q="0.0" P_Z="0.01959954237784843" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="102" WEIGHT="100.0" Z="2.333927044142771">
<NAME>Metallic taste</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7542185495444222" CI_START="0.0076170402137120535" EFFECT_SIZE="0.14484126984126985" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.43999839891846426" LOG_CI_START="-2.118213751568603" LOG_EFFECT_SIZE="-0.8391076763250693" ORDER="33" O_E="0.0" SE="1.5027064805504802" STUDY_ID="STD-Greaves-1988" TOTAL_1="71" TOTAL_2="72" VAR="2.2581267666884104" WEIGHT="47.63479590907793"/>
<DICH_DATA CI_END="0.9456439284487493" CI_START="0.003433981489207789" EFFECT_SIZE="0.05698529411764706" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.02427236150536792" LOG_CI_START="-2.4642020502224464" LOG_EFFECT_SIZE="-1.2442372058639073" ORDER="34" O_E="0.0" SE="1.4332267769991602" STUDY_ID="STD-Schmitt-1992" TOTAL_1="31" TOTAL_2="30" VAR="2.0541389943074004" WEIGHT="52.36520409092208"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.746259433440653" CI_END="0.6881384181746414" CI_START="0.10785457074771498" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.27243141101429097" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="-0.16232419519023908" LOG_CI_START="-0.9671614452907068" LOG_EFFECT_SIZE="-0.564742820240473" METHOD="MH" MODIFIED="2001-05-13 18:46:56 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="8" P_CHI2="0.41764277088452706" P_Q="0.0" P_Z="0.005949393972351716" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="306" TOTAL_2="305" WEIGHT="100.0" Z="2.7505575520037966">
<NAME>Nausea/vomiting</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9855058219664803" CI_START="0.01569974406764247" EFFECT_SIZE="0.12438725490196079" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.006340805742277525" LOG_CI_START="-1.8041074272669815" LOG_EFFECT_SIZE="-0.9052241165046294" ORDER="35" O_E="0.0" SE="1.0560170125719102" STUDY_ID="STD-Fischbach-1993" TOTAL_1="204" TOTAL_2="203" VAR="1.115171930841302" WEIGHT="20.042390128902927"/>
<DICH_DATA CI_END="1.2335841514590629" CI_START="0.13338269772117867" EFFECT_SIZE="0.4056338028169014" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.09116878112023336" LOG_CI_START="-0.8749005030399222" LOG_EFFECT_SIZE="-0.39186586095984444" ORDER="36" O_E="0.0" SE="0.567473879635757" STUDY_ID="STD-Greaves-1988" TOTAL_1="71" TOTAL_2="72" VAR="0.3220266040688576" WEIGHT="69.40641119807657"/>
<DICH_DATA CI_END="1.5264870603213372" CI_START="0.005080950143873237" EFFECT_SIZE="0.08806818181818182" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.18369312723614872" LOG_CI_START="-2.2940550665238653" LOG_EFFECT_SIZE="-1.0551809696438583" ORDER="37" O_E="0.0" SE="1.4554415540659997" STUDY_ID="STD-Schmitt-1992" TOTAL_1="31" TOTAL_2="30" VAR="2.1183101173020527" WEIGHT="10.551198673020505"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.029218958063654" CI_END="1.577325333268854" CI_START="0.7846932461635981" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1125270945099792" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.19792127853589062" LOG_CI_START="-0.10530008533712373" LOG_EFFECT_SIZE="0.046310596599383434" METHOD="MH" MODIFIED="2001-05-13 18:47:21 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="9" P_CHI2="0.5663644415511322" P_Q="0.0" P_Z="0.5493826995472272" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="495" TOTAL_2="491" WEIGHT="100.0" Z="0.5986853978756387">
<NAME>Candida</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.513749663881348" CI_START="0.5820237283365991" EFFECT_SIZE="0.9386363636363636" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.18005405971874394" LOG_CI_START="-0.2350593093783168" LOG_EFFECT_SIZE="-0.027502624829786423" ORDER="38" O_E="0.0" SE="0.24383964785193063" STUDY_ID="STD-Beigi-2004" TOTAL_1="60" TOTAL_2="59" VAR="0.05945777386455353" WEIGHT="53.35635492441961"/>
<DICH_DATA CI_END="4.303690949926118" CI_START="0.8088969692444973" EFFECT_SIZE="1.8658088235294117" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.6338410768867809" LOG_CI_START="-0.09210679178467723" LOG_EFFECT_SIZE="0.2708671425510518" ORDER="39" O_E="0.0" SE="0.42642537155751964" STUDY_ID="STD-Fischbach-1993" TOTAL_1="204" TOTAL_2="203" VAR="0.18183859750796869" WEIGHT="17.44651646465747"/>
<DICH_DATA CI_END="3.3931452627556498" CI_START="0.39713419951947915" EFFECT_SIZE="1.1608333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5306024524723478" LOG_CI_START="-0.40106271171967056" LOG_EFFECT_SIZE="0.06476987037633866" ORDER="40" O_E="0.0" SE="0.5472647292633327" STUDY_ID="STD-Paavonen--2000" TOTAL_1="200" TOTAL_2="199" VAR="0.2994986838956688" WEIGHT="10.592534311229661"/>
<DICH_DATA CI_END="2.4457244572340406" CI_START="0.4846370809273592" EFFECT_SIZE="1.0887096774193548" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.388407526517299" LOG_CI_START="-0.314583359851757" LOG_EFFECT_SIZE="0.03691208333277101" ORDER="41" O_E="0.0" SE="0.4129403265141935" STUDY_ID="STD-Schmitt-1992" TOTAL_1="31" TOTAL_2="30" VAR="0.17051971326164875" WEIGHT="18.604594299693254"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:47:39 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="204" TOTAL_2="203" WEIGHT="0.0" Z="0.0">
<NAME>Diarrhea</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.85386432581888" CI_START="0.12233269110245214" EFFECT_SIZE="2.9853658536585366" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.862452592631328" LOG_CI_START="-0.9124574704517143" LOG_EFFECT_SIZE="0.47499756108980684" ORDER="42" O_E="0.0" SE="1.629995907081323" STUDY_ID="STD-Fischbach-1993" TOTAL_1="204" TOTAL_2="203" VAR="2.656886657101865" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7692228698176111" CI_END="8.171306499030027" CI_START="0.3108818811684341" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5938353541135628" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.9122915008354883" LOG_CI_START="-0.5074045887894592" LOG_EFFECT_SIZE="0.20244345602301453" METHOD="MH" MODIFIED="2001-05-13 18:48:53 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="11" P_CHI2="0.38045761038462755" P_Q="0.0" P_Z="0.5761840036027083" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="235" TOTAL_2="233" WEIGHT="100.0" Z="0.5589673530984338">
<NAME>Vaginal irritation</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.996393888924287" CI_START="0.14153292730108882" EFFECT_SIZE="0.9950980392156863" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8448742517744582" LOG_CI_START="-0.8491425107998299" LOG_EFFECT_SIZE="-0.0021341295126858302" ORDER="43" O_E="0.0" SE="0.9950738318543514" STUDY_ID="STD-Fischbach-1993" TOTAL_1="204" TOTAL_2="203" VAR="0.9901719308413021" WEIGHT="70.23528764464251"/>
<DICH_DATA CI_END="96.89320240013292" CI_START="0.2421420025484452" EFFECT_SIZE="4.84375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9862933099334763" LOG_CI_START="-0.6159298702327053" LOG_EFFECT_SIZE="0.6851817198503856" ORDER="44" O_E="0.0" SE="1.5285587772421023" STUDY_ID="STD-Schmitt-1992" TOTAL_1="31" TOTAL_2="30" VAR="2.336491935483871" WEIGHT="29.764712355357496"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:49:13 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2681887985251117" CI_START="0.4408804067149302" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.3556792013430275" LOG_CI_START="-0.3556792013430275" LOG_EFFECT_SIZE="0.0" ORDER="45" O_E="0.0" SE="0.41785544701867244" STUDY_ID="STD-Schmitt-1992" TOTAL_1="18" TOTAL_2="18" VAR="0.1746031746031746" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2001-05-13 18:56:58 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="4">
<NAME>Tinidazole versus metronidazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:55:00 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="87" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure 1</NAME>
<GROUP_LABEL_1>Tinidazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Clindamycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tinidazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clindamycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.6061784025822465" CI_START="0.5462723053175387" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7486669139779994" LOG_CI_START="-0.26259081660541056" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="46" O_E="0.0" SE="0.594017796751194" STUDY_ID="STD-Burana-1990" TOTAL_1="50" TOTAL_2="50" VAR="0.3528571428571428" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3538445537663377" CI_START="0.021641753300702234" EFFECT_SIZE="0.17117117117117117" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.13156880222429088" LOG_CI_START="-1.6647075578919477" LOG_EFFECT_SIZE="-0.7665693778338285" ORDER="47" O_E="0.0" SE="1.0551416256436648" STUDY_ID="STD-Schinder-1991" TOTAL_1="37" TOTAL_2="38" VAR="1.1133238501659555" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.718102762039445" CI_END="2.9842330963497834" CI_START="0.12927237197003094" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6211110133274135" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" I2="41.79626375706614" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.4748327425622806" LOG_CI_START="-0.8884942824130972" LOG_EFFECT_SIZE="-0.20683076992540836" METHOD="MH" MODIFIED="2001-05-13 18:55:33 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.1899375404743412" P_Q="0.0" P_Z="0.5520483707015131" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.6274660842498202" TOTALS="YES" TOTAL_1="87" TOTAL_2="88" WEIGHT="100.0" Z="0.5946934998311383">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Tinidazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tinidazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0656030513655157" CI_START="0.1240906778459671" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.027595455434811046" LOG_CI_START="-0.9062608430953362" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="48" O_E="0.0" SE="0.5485518124198396" STUDY_ID="STD-Burana-1990" TOTAL_1="50" TOTAL_2="50" VAR="0.3009090909090909" WEIGHT="69.0799115199624"/>
<DICH_DATA CI_END="21.69761919734676" CI_START="0.19445165935494998" EFFECT_SIZE="2.054054054054054" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.33641208287251" LOG_CI_START="-0.7111883464449171" LOG_EFFECT_SIZE="0.31261186821379633" ORDER="49" O_E="0.0" SE="1.2027706279666497" STUDY_ID="STD-Schinder-1991" TOTAL_1="37" TOTAL_2="38" VAR="1.4466571834992887" WEIGHT="30.920088480037602"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4292344803858074" CI_END="1.4155140405040019" CI_START="0.14188659486590724" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.44815451263151945" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.1509141814956604" LOG_CI_START="-0.8480586337939093" LOG_EFFECT_SIZE="-0.3485722261491245" METHOD="MH" MODIFIED="2001-05-13 18:56:58 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.5123648363742592" P_Q="0.0" P_Z="0.17138001542374462" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="88" WEIGHT="100.0" Z="1.3677829842951243">
<NAME>Nausea/vomiting</NAME>
<GROUP_LABEL_1>Tinidazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tinidazole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3322241466663844" CI_START="0.10555656144792527" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1245773010134763" LOG_CI_START="-0.9765147655580385" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="50" O_E="0.0" SE="0.6467869303977418" STUDY_ID="STD-Burana-1990" TOTAL_1="50" TOTAL_2="50" VAR="0.4183333333333333" WEIGHT="82.31141603503774"/>
<DICH_DATA CI_END="15.81979613729765" CI_START="0.06667497514441123" EFFECT_SIZE="1.027027027027027" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.199200882637185" LOG_CI_START="-1.1760371375375547" LOG_EFFECT_SIZE="0.011581872549815138" ORDER="51" O_E="0.0" SE="1.3952265706684663" STUDY_ID="STD-Schinder-1991" TOTAL_1="37" TOTAL_2="38" VAR="1.9466571834992887" WEIGHT="17.688583964962262"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2001-05-13 18:59:59 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="5">
<NAME>Clindamycin ovule versus clindamycin cream</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="104" EVENTS_2="111" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:58:32 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="327" TOTAL_2="335" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure 1</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Clind ovule</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Clind gel</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1958681528131498" CI_START="0.7704270620720024" EFFECT_SIZE="0.9598589415103177" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="111" LOG_CI_END="0.07768330033622309" LOG_CI_START="-0.11326847055885889" LOG_EFFECT_SIZE="-0.017792585111317892" ORDER="52" O_E="0.0" SE="0.11216601545028149" STUDY_ID="STD-Sobel-2001" TOTAL_1="327" TOTAL_2="335" VAR="0.012581215021992784" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="76" EVENTS_2="86" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:59:01 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="327" TOTAL_2="335" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure 2</NAME>
<GROUP_LABEL_1>Clindamyycin ovule</GROUP_LABEL_1>
<GROUP_LABEL_2>Clindamycin gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favoursclin ovule</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clin gel</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1839812812470887" CI_START="0.6922764446440957" EFFECT_SIZE="0.9053410141526207" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="86" LOG_CI_END="0.07334483624217082" LOG_CI_START="-0.1597204454146053" LOG_EFFECT_SIZE="-0.04318780458621722" ORDER="53" O_E="0.0" SE="0.13690370013694098" STUDY_ID="STD-Sobel-2001" TOTAL_1="327" TOTAL_2="335" VAR="0.01874262311118545" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="186" EVENTS_2="171" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:59:22 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="327" TOTAL_2="335" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Clindamycin ovule</GROUP_LABEL_1>
<GROUP_LABEL_2>Clindamycin gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clin ovule</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clin gel</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2831675411870416" CI_START="0.9677081778460047" EFFECT_SIZE="1.114330167927464" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="171" LOG_CI_END="0.10828336523119703" LOG_CI_START="-0.014255588826553646" LOG_EFFECT_SIZE="0.04701388820232166" ORDER="54" O_E="0.0" SE="0.07197998819112807" STUDY_ID="STD-Sobel-2001" TOTAL_1="327" TOTAL_2="335" VAR="0.0051811186999949355" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:59:39 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="327" TOTAL_2="335" WEIGHT="0.0" Z="0.0">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>Clindamycin ovule</GROUP_LABEL_1>
<GROUP_LABEL_2>Clindamycin gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clin ovule</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clinddamycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4104713451609083" CI_START="0.020669374800064977" EFFECT_SIZE="0.1707441386340469" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14936426754568652" LOG_CI_START="-1.6846726595598553" LOG_EFFECT_SIZE="-0.7676541960070844" ORDER="55" O_E="0.0" SE="1.0773223696110028" STUDY_ID="STD-Sobel-2001" TOTAL_1="327" TOTAL_2="335" VAR="1.160623488064266" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 18:59:59 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="327" TOTAL_2="331" WEIGHT="0.0" Z="0.0">
<NAME>Candida infection</NAME>
<GROUP_LABEL_1>clindamycin ovule</GROUP_LABEL_1>
<GROUP_LABEL_2>clindamycin gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clin ovule</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clin gel</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.001735462620959" CI_START="0.4064922623164203" EFFECT_SIZE="1.6870540265035678" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8452056983607102" LOG_CI_START="-0.39094771689713204" LOG_EFFECT_SIZE="0.22712899073178905" ORDER="56" O_E="0.0" SE="0.7261226351805489" STUDY_ID="STD-Sobel-2001" TOTAL_1="327" TOTAL_2="331" VAR="0.5272540813215444" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2001-05-13 19:01:10 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="6">
<NAME>Clindamycin ovule + lactobacilli versus clindamycin ovule alone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="51" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:00:22 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="91" TOTAL_2="96" WEIGHT="0.0" Z="0.0">
<NAME>Clinical cure 1</NAME>
<GROUP_LABEL_1>lactobacilli</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lactobacilli</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1387868084533257" CI_START="0.706081942950006" EFFECT_SIZE="0.8967032967032967" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="60" LOG_CI_END="0.05644242769768677" LOG_CI_START="-0.15114489483215168" LOG_EFFECT_SIZE="-0.047351233567232434" ORDER="57" O_E="0.0" SE="0.12193782082784614" STUDY_ID="STD-Eriksson-2005" TOTAL_1="91" TOTAL_2="96" VAR="0.014868832148243907" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="50" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:00:37 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="91" TOTAL_2="96" WEIGHT="0.0" Z="0.0">
<NAME>Clinical cure 2</NAME>
<GROUP_LABEL_1>lactobacillus</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favourslactobacillus</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0791773135077967" CI_START="0.670692583733443" EFFECT_SIZE="0.8507621410847217" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="62" LOG_CI_END="0.03309280701045836" LOG_CI_START="-0.17347649589797887" LOG_EFFECT_SIZE="-0.07019184444376027" ORDER="58" O_E="0.0" SE="0.12133983106295666" STUDY_ID="STD-Eriksson-2005" TOTAL_1="91" TOTAL_2="96" VAR="0.014723354602386862" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:00:53 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="127" TOTAL_2="128" WEIGHT="0.0" Z="0.0">
<NAME>Candida infection</NAME>
<GROUP_LABEL_1>Lactobacillus</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favourslactobacillus</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.975322344666629" CI_START="0.5765297045531169" EFFECT_SIZE="1.0671607225567392" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.2956379764622096" LOG_CI_START="-0.23917831162832226" LOG_EFFECT_SIZE="0.02822983241694364" ORDER="59" O_E="0.0" SE="0.3141537350077009" STUDY_ID="STD-Eriksson-2005" TOTAL_1="127" TOTAL_2="128" VAR="0.09869256921928876" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:01:10 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="127" TOTAL_2="128" WEIGHT="0.0" Z="0.0">
<NAME>Itching/burning</NAME>
<GROUP_LABEL_1>lactobacillus</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6315860264366318" CI_START="0.1556476359751901" EFFECT_SIZE="0.5039370078740157" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.21260997718719327" LOG_CI_START="-0.8078574711313328" LOG_EFFECT_SIZE="-0.2976237469720697" ORDER="60" O_E="0.0" SE="0.5994276305376393" STUDY_ID="STD-Eriksson-2005" TOTAL_1="127" TOTAL_2="128" VAR="0.3593134842519685" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2001-05-13 19:02:43 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="7">
<NAME>Clindamycin cream versus oral metronidazole</NAME>
<DICH_OUTCOME CHI2="3.3247684498140244" CI_END="3.596247225725056" CI_START="0.570618488848464" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4325100898313814" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="17" I2="39.845434947150295" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.5558495398680692" LOG_CI_START="-0.24365416069370238" LOG_EFFECT_SIZE="0.15609768958718334" METHOD="MH" MODIFIED="2001-05-13 19:02:17 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.18968638796145199" P_Q="0.0" P_Z="0.4440694620886262" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.27344124486311316" TOTALS="YES" TOTAL_1="265" TOTAL_2="263" WEIGHT="100.0" Z="0.7653394210578875">
<NAME>Clinical failure 1</NAME>
<GROUP_LABEL_1>clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metronidzole</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1080777784770572" CI_START="0.029647862445166522" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3238866303262053" LOG_CI_START="-1.52800661298213" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="61" O_E="0.0" SE="1.0878112581387145" STUDY_ID="STD-Andres-1992" TOTAL_1="30" TOTAL_2="30" VAR="1.1833333333333331" WEIGHT="15.139927882177583"/>
<DICH_DATA CI_END="3.785108630605822" CI_START="0.8476145500414408" EFFECT_SIZE="1.7911764705882354" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.578078348035743" LOG_CI_START="-0.07180159685450245" LOG_EFFECT_SIZE="0.25313837559062025" ORDER="62" O_E="0.0" SE="0.3817426965861398" STUDY_ID="STD-Fischbach-1993" TOTAL_1="204" TOTAL_2="203" VAR="0.1457274863968576" WEIGHT="52.61714533950993"/>
<DICH_DATA CI_END="7.928103615791574" CI_START="0.643136821376161" EFFECT_SIZE="2.2580645161290325" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.89916931749544" LOG_CI_START="-0.1916966251354716" LOG_EFFECT_SIZE="0.3537363461799842" ORDER="63" O_E="0.0" SE="0.6407800545749016" STUDY_ID="STD-Schmitt-1992" TOTAL_1="31" TOTAL_2="30" VAR="0.41059907834101383" WEIGHT="32.24292677831247"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3202099059182484" CI_END="1.8354135759623476" CI_START="0.5859824926967426" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.037072910827324" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.26373393971643644" LOG_CI_START="-0.23211535913340797" LOG_EFFECT_SIZE="0.015809290291514264" METHOD="MH" MODIFIED="2001-05-13 19:02:43 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.5714816542182082" P_Q="0.0" P_Z="0.9005393299005393" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="233" WEIGHT="100.00000000000001" Z="0.12498006819563916">
<NAME>Clinical failure 2</NAME>
<GROUP_LABEL_1>clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="64" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Andres-1992" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="5.91871475351633"/>
<DICH_DATA CI_END="1.7925452603452734" CI_START="0.5524101006298557" EFFECT_SIZE="0.9950980392156863" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.25347013006929153" LOG_CI_START="-0.25773838909466323" LOG_EFFECT_SIZE="-0.0021341295126858302" ORDER="65" O_E="0.0" SE="0.30028641467988865" STUDY_ID="STD-Fischbach-1993" TOTAL_1="204" TOTAL_2="203" VAR="0.09017193084130205" WEIGHT="94.08128524648369"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2001-05-13 19:03:48 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="8">
<NAME>Clindamycin cream versus oral tinidazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:03:05 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure</NAME>
<GROUP_LABEL_1>Clindamycin cream</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral tinidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tinidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.122506924700671" CI_START="0.32025549474029164" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4945034101705784" LOG_CI_START="-0.4945034101705784" LOG_EFFECT_SIZE="0.0" ORDER="66" O_E="0.0" SE="0.5809475019311126" STUDY_ID="STD-Milani-2003" TOTAL_1="32" TOTAL_2="32" VAR="0.3375" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:03:28 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>clinical failure 2</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2717076772742901" CI_START="0.0641913660820162" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.10438729312306158" LOG_CI_START="-1.192523381823613" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="67" O_E="0.0" SE="0.761811750275055" STUDY_ID="STD-Milani-2003" TOTAL_1="32" TOTAL_2="32" VAR="0.5803571428571428" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:03:48 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="27" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Tinidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tinidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0065554000778807" CI_START="0.03695628263102449" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.47806921075143305" LOG_CI_START="-1.432311720190758" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="68" O_E="0.0" SE="1.1221672153735642" STUDY_ID="STD-Milani-2003" TOTAL_1="27" TOTAL_2="27" VAR="1.2592592592592593" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2001-05-13 20:46:43 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="9">
<NAME>2%Clindamycin cream versus triple sulfonamide cream</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:04:10 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="79" TOTAL_2="79" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure1</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Triple sulfonamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulfonamide</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0944070442945661" CI_START="0.33854898769794495" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="0.03917887977846532" LOG_CI_START="-0.470378480457175" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="69" O_E="0.0" SE="0.29931651575202817" STUDY_ID="STD-McCormack-2001" TOTAL_1="79" TOTAL_2="79" VAR="0.08959037660193411" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 20:43:23 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="79" TOTAL_2="79" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure 2</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulfonamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulfonamide</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.587507259551061" CI_START="0.22507195070188793" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="44" LOG_CI_END="-0.23098676265028895" LOG_CI_START="-0.6476786250102363" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="70" O_E="0.0" SE="0.24476686260821787" STUDY_ID="STD-McCormack-2001" TOTAL_1="79" TOTAL_2="79" VAR="0.05991081703107021" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 20:44:29 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="79" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Bacteriological failure 1</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulfonamide</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7450731237412593" CI_START="0.18399188146269918" EFFECT_SIZE="0.370253164556962" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" LOG_CI_END="-0.12780110217936064" LOG_CI_START="-0.7352013395651238" LOG_EFFECT_SIZE="-0.4315012208722422" ORDER="71" O_E="0.0" SE="0.3567899061200634" STUDY_ID="STD-McCormack-2001" TOTAL_1="79" TOTAL_2="78" VAR="0.12729903710916365" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 20:46:43 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="78" TOTAL_2="73" WEIGHT="0.0" Z="0.0">
<NAME>Bacteriological failure 2</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>sulfonamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulfonamide</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7241760395671455" CI_START="0.28625555648531276" EFFECT_SIZE="0.4553014553014553" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="37" LOG_CI_END="-0.14015584855507154" LOG_CI_START="-0.5432460745123553" LOG_EFFECT_SIZE="-0.34170096153371343" ORDER="72" O_E="0.0" SE="0.23677719405610723" STUDY_ID="STD-McCormack-2001" TOTAL_1="78" TOTAL_2="73" VAR="0.056063439625083464" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:05:20 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="136" TOTAL_2="141" WEIGHT="0.0" Z="0.0">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>Clindamycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulfonamide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clindamycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulfonamide</GRAPH_LABEL_2>
<DICH_DATA CI_END="75.67501501246814" CI_START="0.1277690154047007" EFFECT_SIZE="3.1094890510948905" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.878952515784295" LOG_CI_START="-0.893574451891671" LOG_EFFECT_SIZE="0.49268903194631214" ORDER="73" O_E="0.0" SE="1.628596065042694" STUDY_ID="STD-McCormack-2001" TOTAL_1="136" TOTAL_2="141" VAR="2.652325143072547" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2001-05-13 19:06:45 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="10">
<NAME>Polyhexamethylene biguanide douche versus clindamycin cream</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:05:53 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="53" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure</NAME>
<GROUP_LABEL_1>PHMB</GROUP_LABEL_1>
<GROUP_LABEL_2>Clindamycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PHMB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clindamycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8612603493667903" CI_START="0.37409351474896" EFFECT_SIZE="1.0345911949685536" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.45655737655713297" LOG_CI_START="-0.4270198206260496" LOG_EFFECT_SIZE="0.01476877796554166" ORDER="74" O_E="0.0" SE="0.5190176194030669" STUDY_ID="STD-Gerli-2003" TOTAL_1="53" TOTAL_2="47" VAR="0.2693792892508268" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:06:13 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="53" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Discontinuation</NAME>
<GROUP_LABEL_1>PHMB</GROUP_LABEL_1>
<GROUP_LABEL_2>Clindamycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PHMB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Clindamycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.396178870492147" CI_START="0.006729451087517938" EFFECT_SIZE="0.12698412698412698" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.37951923423823103" LOG_CI_START="-2.1720203591615075" LOG_EFFECT_SIZE="-0.8962505624616381" ORDER="75" O_E="0.0" SE="1.498786987487693" STUDY_ID="STD-Gerli-2003" TOTAL_1="53" TOTAL_2="47" VAR="2.2463624338624335" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:06:27 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="53" TOTAL_2="53" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>PHMB</GROUP_LABEL_1>
<GROUP_LABEL_2>Clindamycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PHMB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clindamycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.964882745588886" CI_START="0.016193677492350407" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.015525459752298052" LOG_CI_START="-1.7906545142315888" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="76" O_E="0.0" SE="1.0427195936316707" STUDY_ID="STD-Gerli-2003" TOTAL_1="53" TOTAL_2="53" VAR="1.0872641509433962" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:06:45 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="53" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Candida infection</NAME>
<GROUP_LABEL_1>PHMB</GROUP_LABEL_1>
<GROUP_LABEL_2>Clindamycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PHMB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours clindamycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.183359995221187" CI_START="0.018459698034324536" EFFECT_SIZE="0.14779874213836477" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07311688338923038" LOG_CI_START="-1.733775407486661" LOG_EFFECT_SIZE="-0.8303292620487153" ORDER="77" O_E="0.0" SE="1.0613774759215895" STUDY_ID="STD-Gerli-2003" TOTAL_1="53" TOTAL_2="47" VAR="1.126522146393684" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2001-05-13 20:34:03 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="11">
<NAME>Single hydrogen peroxide douche versus single dose metronidazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:07:14 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure 1</NAME>
<GROUP_LABEL_1>H2O2</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours H2O2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.998955408036828" CI_START="1.0211889085755927" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" LOG_CI_END="0.4769700082111708" LOG_CI_START="0.009106089161418023" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="78" O_E="0.0" SE="0.27482558201357554" STUDY_ID="STD-Chaithong-2003" TOTAL_1="72" TOTAL_2="70" VAR="0.07552910052910053" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:07:31 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Reduced eating/vomitting</NAME>
<GROUP_LABEL_1>H2O2</GROUP_LABEL_1>
<GROUP_LABEL_2>Metonidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours H2O2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5334824372640157" CI_START="0.15326857741859246" EFFECT_SIZE="0.28594771241830064" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="34" LOG_CI_END="-0.2728798733807939" LOG_CI_START="-0.8145468735377396" LOG_EFFECT_SIZE="-0.5437133734592667" ORDER="79" O_E="0.0" SE="0.3181778771870841" STUDY_ID="STD-Chaithong-2003" TOTAL_1="72" TOTAL_2="70" VAR="0.10123716153127918" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 20:34:03 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="72" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Vaginal irritation</NAME>
<GROUP_LABEL_1>H2O2</GROUP_LABEL_1>
<GROUP_LABEL_2>Metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours H2O2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.515798188168245" CI_START="1.2056438790177402" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="10" LOG_CI_END="0.6547345249882408" LOG_CI_START="0.08121904560094804" LOG_EFFECT_SIZE="0.36797678529459443" ORDER="80" O_E="0.0" SE="0.33688583153950463" STUDY_ID="STD-Chaithong-2003" TOTAL_1="72" TOTAL_2="70" VAR="0.11349206349206348" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2001-05-13 19:09:22 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="12">
<NAME>Cefadroxil versus metronidazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:08:46 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure</NAME>
<GROUP_LABEL_1>Oral cefadroxil</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cefadroxil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.745176453876752" CI_START="0.05268507977100682" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6762523667148672" LOG_CI_START="-1.2783123580428297" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="81" O_E="0.0" SE="1.148120994574099" STUDY_ID="STD-Wathne-1989" TOTAL_1="11" TOTAL_2="11" VAR="1.3181818181818183" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:09:03 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure 2</NAME>
<GROUP_LABEL_1>Oral cefadroxil</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cefadroxil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.335349823814161" CI_START="0.28767156521481163" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8017706006492201" LOG_CI_START="-0.5411030636592078" LOG_EFFECT_SIZE="0.13033376849500614" ORDER="82" O_E="0.0" SE="0.7888106377466155" STUDY_ID="STD-Wathne-1989" TOTAL_1="10" TOTAL_2="9" VAR="0.6222222222222222" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:09:22 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Candida infection</NAME>
<GROUP_LABEL_1>Oral cefadroxil</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cefadroxil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetronidazole</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.887633468579433" CI_START="0.16984752962912952" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7699407654041357" LOG_CI_START="-0.7699407654041358" LOG_EFFECT_SIZE="0.0" ORDER="83" O_E="0.0" SE="0.9045340337332909" STUDY_ID="STD-Wathne-1989" TOTAL_1="11" TOTAL_2="11" VAR="0.8181818181818181" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2001-05-13 19:10:07 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="13">
<NAME>1g versus 2g secnidazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:09:48 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="44" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure 1</NAME>
<GROUP_LABEL_1>Secnidazole 1g</GROUP_LABEL_1>
<GROUP_LABEL_2>Secniddazole 2g</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 1g</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2g</GRAPH_LABEL_2>
<DICH_DATA CI_END="96.03355315975404" CI_START="0.2743948364305071" EFFECT_SIZE="5.133333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9824229976873615" LOG_CI_START="-0.5616240654537603" LOG_EFFECT_SIZE="0.7103994661168007" ORDER="84" O_E="0.0" SE="1.4943858381251587" STUDY_ID="STD-Nunez-2005" TOTAL_1="44" TOTAL_2="32" VAR="2.233189033189033" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2001-05-13 19:10:07 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="44" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Secnidazole 1g</GROUP_LABEL_1>
<GROUP_LABEL_2>Secnidazole 2g</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 1 g</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 2g</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.962602622535399" CI_START="0.570186359898206" EFFECT_SIZE="1.0578512396694215" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.29283237483670604" LOG_CI_START="-0.24398317617386947" LOG_EFFECT_SIZE="0.024424599331418297" ORDER="85" O_E="0.0" SE="0.3153281119434456" STUDY_ID="STD-Nunez-2005" TOTAL_1="44" TOTAL_2="32" VAR="0.09943181818181818" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2009-05-08 10:00:46 -0300" MODIFIED_BY="[Empty name]" NO="14">
<NAME>lactobacillus versus metronidazole</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.034413360242787" CI_START="0.060420719996627494" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.014694121155253958" LOG_CI_START="-1.2188141038111788" LOG_EFFECT_SIZE="-0.6020599913279624" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.05571375373764976" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.913267987438698">
<NAME>clinical failure</NAME>
<GROUP_LABEL_1>lactobacillu</GROUP_LABEL_1>
<GROUP_LABEL_2>metro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lacto</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metro</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.034413360242787" CI_START="0.060420719996627494" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.014694121155253958" LOG_CI_START="-1.2188141038111788" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="86" O_E="0.0" SE="0.7245688373094719" STUDY_ID="STD-Anukam-2006b" TOTAL_1="20" TOTAL_2="20" VAR="0.5249999999999999" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8325727832412549" CI_START="0.08933773333268213" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="-0.07957779028005475" LOG_CI_START="-1.0489650705970706" LOG_EFFECT_SIZE="-0.5642714304385626" METHOD="MH" MODIFIED="2001-05-13 19:10:50 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.022503864450917534" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.2817540597454617">
<NAME>clinical failure 2</NAME>
<GROUP_LABEL_1>lactobbacillu</GROUP_LABEL_1>
<GROUP_LABEL_2>metro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lacto</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metro</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8325727832412549" CI_START="0.08933773333268213" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.07957779028005475" LOG_CI_START="-1.0489650705970706" LOG_EFFECT_SIZE="-0.5642714304385626" ORDER="87" O_E="0.0" SE="0.5694228870026425" STUDY_ID="STD-Anukam-2006b" TOTAL_1="20" TOTAL_2="20" VAR="0.3242424242424242" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.34477089517566295" CI_END="0.5911840652215664" CI_START="0.13675099239520547" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2843325651543999" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="-0.22827728043124365" LOG_CI_START="-0.8640695133294658" LOG_EFFECT_SIZE="-0.5461733968803547" METHOD="MH" MODIFIED="2001-05-13 21:31:35 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.5570884209304534" P_Q="0.0" P_Z="7.58833063464961E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="80" WEIGHT="100.0" Z="3.3673899485046386">
<NAME>bacteriologic failure 2</NAME>
<GROUP_LABEL_1>lactobacillus</GROUP_LABEL_1>
<GROUP_LABEL_2>metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lactob</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metronidazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7714593641686107" CI_START="0.1375838285810454" EFFECT_SIZE="0.3257918552036199" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.11268694501512293" LOG_CI_START="-0.8614326094925617" LOG_EFFECT_SIZE="-0.4870597772538422" ORDER="88" O_E="0.0" SE="0.4398169096648619" STUDY_ID="STD-Anukam-2006a" TOTAL_1="65" TOTAL_2="60" VAR="0.1934389140271493" WEIGHT="72.10440456769983"/>
<DICH_DATA CI_END="0.7996876315834762" CI_START="0.0500195306519813" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.09707962097234013" LOG_CI_START="-1.3008603876996974" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="89" O_E="0.0" SE="0.7071067811865475" STUDY_ID="STD-Anukam-2006b" TOTAL_1="20" TOTAL_2="20" VAR="0.49999999999999994" WEIGHT="27.895595432300166"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.034413360242787" CI_START="0.060420719996627494" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-014.04" LOG_CI_END="0.014694121155253958" LOG_CI_START="-1.2188141038111788" LOG_EFFECT_SIZE="-0.6020599913279624" METHOD="MH" MODIFIED="2001-05-13 19:11:52 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.05571375373764976" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.913267987438698">
<NAME>bacteriologic failure 1</NAME>
<GROUP_LABEL_1>lactobacillus</GROUP_LABEL_1>
<GROUP_LABEL_2>metronidazole gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lactobacilus</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetro gel</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.034413360242787" CI_START="0.060420719996627494" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.014694121155253958" LOG_CI_START="-1.2188141038111788" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="90" O_E="0.0" SE="0.7245688373094719" STUDY_ID="STD-Anukam-2006b" TOTAL_1="20" TOTAL_2="20" VAR="0.5249999999999999" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.055849117111045" CI_START="1.509523801186138" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.923076923076924" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-014.05" LOG_CI_END="1.2056332782690418" LOG_CI_START="0.17883996508505937" LOG_EFFECT_SIZE="0.6922366216770505" METHOD="MH" MODIFIED="2001-05-13 19:12:35 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.008224527061468851" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="60" WEIGHT="99.99999999999999" Z="2.6427107185954024">
<NAME>discontinuation</NAME>
<GROUP_LABEL_1>metro +lactobacillus</GROUP_LABEL_1>
<GROUP_LABEL_2>metro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lactobacillu</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metro</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.055849117111038" CI_START="1.5095238011861378" EFFECT_SIZE="4.923076923076923" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.2056332782690415" LOG_CI_START="0.1788399650850593" LOG_EFFECT_SIZE="0.6922366216770505" ORDER="91" O_E="0.0" SE="0.6031434748731443" STUDY_ID="STD-Anukam-2006a" TOTAL_1="65" TOTAL_2="60" VAR="0.36378205128205127" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="122.70681573934326" CI_START="0.34111372402181594" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.469696969696969" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-014.06" LOG_CI_END="2.0888686862459758" LOG_CI_START="-0.4671008072796654" LOG_EFFECT_SIZE="0.8108839394831552" METHOD="MH" MODIFIED="2001-05-13 19:13:06 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.2136464119959518" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="60" WEIGHT="100.0" Z="1.243601162732733">
<NAME>Headache</NAME>
<GROUP_LABEL_1>metro +lactobacillus</GROUP_LABEL_1>
<GROUP_LABEL_2>metro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metro +lacto</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metro</GRAPH_LABEL_2>
<DICH_DATA CI_END="122.70681573934326" CI_START="0.34111372402181594" EFFECT_SIZE="6.46969696969697" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0888686862459758" LOG_CI_START="-0.4671008072796654" LOG_EFFECT_SIZE="0.8108839394831552" ORDER="92" O_E="0.0" SE="1.5013891327500075" STUDY_ID="STD-Anukam-2006a" TOTAL_1="65" TOTAL_2="60" VAR="2.25416932793982" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2001-05-13 19:16:03 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="15">
<NAME>metronidazole vs metronidazole + azithromycin</NAME>
<DICH_OUTCOME CHI2="1.6589859287238007" CI_END="0.9191398038638205" CI_START="0.45799131456638936" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6488127981489611" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-0.03661842612332576" LOG_CI_START="-0.3391427579604466" LOG_EFFECT_SIZE="-0.18788059204188612" METHOD="MH" MODIFIED="2001-05-13 19:13:45 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1" P_CHI2="0.43627067846699563" P_Q="0.0" P_Z="0.014914708887398527" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="422" TOTAL_2="132" WEIGHT="100.0" Z="2.434443481355541">
<NAME>clinical failure 1</NAME>
<GROUP_LABEL_1>metro 7+azth</GROUP_LABEL_1>
<GROUP_LABEL_2>metro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metro 7+azth</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metro</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5031525194358333" CI_START="0.48304879465485884" EFFECT_SIZE="0.852112676056338" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="12" LOG_CI_END="0.17700304910904333" LOG_CI_START="-0.3160089972422562" LOG_EFFECT_SIZE="-0.06950297406660641" ORDER="93" O_E="0.0" SE="0.2895977164757418" STUDY_ID="STD-Schwebke-2006" TOTAL_1="142" TOTAL_2="44" VAR="0.08386683738796413" WEIGHT="37.653517984461295"/>
<DICH_DATA CI_END="0.9292297950483527" CI_START="0.25903010842893803" EFFECT_SIZE="0.49061032863849763" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="-0.03187687332549075" LOG_CI_START="-0.5866497526578391" LOG_EFFECT_SIZE="-0.30926331299166493" ORDER="94" O_E="0.0" SE="0.3258763354898638" STUDY_ID="STD-Schwebke-2006a" TOTAL_1="142" TOTAL_2="44" VAR="0.10619538603230225" WEIGHT="29.73652234690349"/>
<DICH_DATA CI_END="1.1246149420158487" CI_START="0.33207525186713543" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.051003849395616245" LOG_CI_START="-0.4787634892857782" LOG_EFFECT_SIZE="-0.21387981994508098" ORDER="95" O_E="0.0" SE="0.3111879571320709" STUDY_ID="STD-Schwebke-2006b" TOTAL_1="138" TOTAL_2="44" VAR="0.09683794466403162" WEIGHT="32.609959668635206"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3960078712416535" CI_END="1.8295071003787176" CI_START="0.8156582697540968" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2215779123730666" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="0.26233409933741864" LOG_CI_START="-0.08849175625250538" LOG_EFFECT_SIZE="0.08692117154245661" METHOD="MH" MODIFIED="2001-05-13 19:14:08 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="2" P_CHI2="0.8203666951331672" P_Q="0.0" P_Z="0.3314449306435874" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="422" TOTAL_2="132" WEIGHT="100.0" Z="0.9712075834933745">
<NAME>clinical failure 2</NAME>
<GROUP_LABEL_1>metronidazole + azth</GROUP_LABEL_1>
<GROUP_LABEL_2>metro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metro + azit</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metronidazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.133085181202492" CI_START="0.5127055514713821" EFFECT_SIZE="1.045774647887324" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="8" LOG_CI_END="0.3290081986222149" LOG_CI_START="-0.29013198008186547" LOG_EFFECT_SIZE="0.019438109270174697" ORDER="96" O_E="0.0" SE="0.36368600576408977" STUDY_ID="STD-Schwebke-2006" TOTAL_1="142" TOTAL_2="44" VAR="0.13226751078863755" WEIGHT="32.10740525613456"/>
<DICH_DATA CI_END="2.4174757266530507" CI_START="0.5963619906845602" EFFECT_SIZE="1.2007042253521127" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="8" LOG_CI_END="0.383362122120681" LOG_CI_START="-0.2244900442297609" LOG_EFFECT_SIZE="0.07943603894546006" ORDER="97" O_E="0.0" SE="0.35705537143100025" STUDY_ID="STD-Schwebke-2006a" TOTAL_1="142" TOTAL_2="44" VAR="0.12748853826772955" WEIGHT="33.31096762747884"/>
<DICH_DATA CI_END="2.85151877451164" CI_START="0.7219314677554818" EFFECT_SIZE="1.434782608695652" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="8" LOG_CI_END="0.4550762353424688" LOG_CI_START="-0.1415040276218796" LOG_EFFECT_SIZE="0.15678610386029457" ORDER="98" O_E="0.0" SE="0.35043419958518723" STUDY_ID="STD-Schwebke-2006b" TOTAL_1="138" TOTAL_2="44" VAR="0.12280412823891085" WEIGHT="34.58162711638659"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7056787471325188" CI_END="1.014080953011327" CI_START="0.4429168724285609" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.670189200224199" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="0.006072625650950856" LOG_CI_START="-0.3536777754319943" LOG_EFFECT_SIZE="-0.17380257489052164" METHOD="MH" MODIFIED="2001-05-13 19:14:37 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="3" P_CHI2="0.7026901541902115" P_Q="0.0" P_Z="0.05825220211977167" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="422" TOTAL_2="132" WEIGHT="100.00000000000001" Z="1.8937951767687258">
<NAME>bacteriologic failure 1</NAME>
<GROUP_LABEL_1>metronidazole+azth</GROUP_LABEL_1>
<GROUP_LABEL_2>metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metro + azth</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metro</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5826245777531067" CI_START="0.3962063315171268" EFFECT_SIZE="0.7918622848200313" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="9" LOG_CI_END="0.1993779059255921" LOG_CI_START="-0.4020785885627943" LOG_EFFECT_SIZE="-0.10135034131860106" ORDER="99" O_E="0.0" SE="0.3532985221201425" STUDY_ID="STD-Schwebke-2006" TOTAL_1="142" TOTAL_2="44" VAR="0.12481984573227684" WEIGHT="35.77619393895222"/>
<DICH_DATA CI_END="1.0977058588124053" CI_START="0.24296302228587818" EFFECT_SIZE="0.5164319248826291" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.0404859821830467" LOG_CI_START="-0.6144598187440721" LOG_EFFECT_SIZE="-0.2869869182805127" ORDER="100" O_E="0.0" SE="0.384718405498591" STUDY_ID="STD-Schwebke-2006a" TOTAL_1="142" TOTAL_2="44" VAR="0.14800825152937827" WEIGHT="30.171148988012046"/>
<DICH_DATA CI_END="1.4408072908596263" CI_START="0.34843057302639063" EFFECT_SIZE="0.7085346215780999" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.1586058974600698" LOG_CI_START="-0.45788374484085537" LOG_EFFECT_SIZE="-0.14963892369039275" ORDER="101" O_E="0.0" SE="0.3621290675605096" STUDY_ID="STD-Schwebke-2006b" TOTAL_1="138" TOTAL_2="44" VAR="0.13113746157224415" WEIGHT="34.052657073035746"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.521112210121715" CI_END="1.8068885915806974" CI_START="0.680764656771824" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1090833565933438" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-015.04" LOG_CI_END="0.2569313758297018" LOG_CI_START="-0.16700299958534992" LOG_EFFECT_SIZE="0.04496418812217599" METHOD="MH" MODIFIED="2001-05-13 19:14:54 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="4" P_CHI2="0.46740654627664013" P_Q="0.0" P_Z="0.6775831765864149" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="422" TOTAL_2="132" WEIGHT="100.0" Z="0.4157633559546424">
<NAME>bacteriologic failure 2</NAME>
<GROUP_LABEL_1>metronidazole + azth</GROUP_LABEL_1>
<GROUP_LABEL_2>metronidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metro +azth</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metro</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.768693511309042" CI_START="0.29554910752601204" EFFECT_SIZE="0.7230046948356808" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.2476525825540005" LOG_CI_START="-0.5293703477585497" LOG_EFFECT_SIZE="-0.14085888260227464" ORDER="102" O_E="0.0" SE="0.45642711559112986" STUDY_ID="STD-Schwebke-2006" TOTAL_1="142" TOTAL_2="44" VAR="0.2083257118468386" WEIGHT="29.766625017264516"/>
<DICH_DATA CI_END="2.6237438422092896" CI_START="0.49198299587694433" EFFECT_SIZE="1.136150234741784" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="6" LOG_CI_END="0.4189214323250297" LOG_CI_START="-0.3080499072416426" LOG_EFFECT_SIZE="0.05543576254169354" ORDER="103" O_E="0.0" SE="0.42702656342763107" STUDY_ID="STD-Schwebke-2006a" TOTAL_1="142" TOTAL_2="44" VAR="0.1823516858728126" WEIGHT="34.00655889918534"/>
<DICH_DATA CI_END="3.4672991132559887" CI_START="0.6849350119290681" EFFECT_SIZE="1.541062801932367" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="6" LOG_CI_END="0.5399913085249292" LOG_CI_START="-0.16435063332440245" LOG_EFFECT_SIZE="0.18782033760026334" ORDER="104" O_E="0.0" SE="0.4137339431911399" STUDY_ID="STD-Schwebke-2006b" TOTAL_1="138" TOTAL_2="44" VAR="0.17117577574848936" WEIGHT="36.22681608355013"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.20126634497859036" CI_END="4.416352045136287" CI_START="0.8191333159069873" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9019939786826592" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-015.05" LOG_CI_END="0.6450636854562242" LOG_CI_START="-0.0866454100210829" LOG_EFFECT_SIZE="0.2792091377175706" METHOD="MH" MODIFIED="2001-05-13 19:15:31 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="5" P_CHI2="0.9042647603101372" P_Q="0.0" P_Z="0.13470961351819935" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="422" TOTAL_2="132" WEIGHT="100.00000000000001" Z="1.4957852990031457">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>metronidazole+ azith</GROUP_LABEL_1>
<GROUP_LABEL_2>metroniidazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metro+azithr</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metro</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.015040882370439" CI_START="0.7821429963308748" DF="1.0" EFFECT_SIZE="2.1690140845070425" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="4" I2="0.0" ID="CMP-015.05.01" LOG_CI_END="0.7792385834510175" LOG_CI_START="-0.10671383921624181" LOG_EFFECT_SIZE="0.33626237211738785" NO="1" P_CHI2="1.0" P_Z="0.13680237635961476" STUDIES="2" TAU2="0.0" TOTAL_1="284" TOTAL_2="88" WEIGHT="68.21126550386568" Z="1.487804811734484">
<NAME>metro + azith vs metro</NAME>
<DICH_DATA CI_END="9.177519965892474" CI_START="0.5126245561191126" EFFECT_SIZE="2.1690140845070425" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="0.9627253379940571" LOG_CI_START="-0.29020059375928153" LOG_EFFECT_SIZE="0.33626237211738785" ORDER="105" O_E="0.0" SE="0.7359748943952993" STUDY_ID="STD-Schwebke-2006" TOTAL_1="142" TOTAL_2="44" VAR="0.5416590451801719" WEIGHT="34.10563275193284"/>
<DICH_DATA CI_END="9.177519965892474" CI_START="0.5126245561191126" EFFECT_SIZE="2.1690140845070425" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="0.9627253379940571" LOG_CI_START="-0.29020059375928153" LOG_EFFECT_SIZE="0.33626237211738785" ORDER="106" O_E="0.0" SE="0.7359748943952993" STUDY_ID="STD-Schwebke-2006a" TOTAL_1="142" TOTAL_2="44" VAR="0.5416590451801719" WEIGHT="34.10563275193284"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.392595650114407" CI_START="0.32202899211663083" DF="0.0" EFFECT_SIZE="1.434782608695652" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" ID="CMP-015.05.02" LOG_CI_END="0.8056772349394528" LOG_CI_START="-0.4921050272188636" LOG_EFFECT_SIZE="0.15678610386029457" NO="2" P_CHI2="1.0" P_Z="0.6358068558691141" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="44" WEIGHT="31.78873449613434" Z="0.4735696053226636">
<NAME>metro 7 days vs 14 days</NAME>
<DICH_DATA CI_END="6.392595650114407" CI_START="0.32202899211663083" EFFECT_SIZE="1.434782608695652" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.8056772349394528" LOG_CI_START="-0.4921050272188636" LOG_EFFECT_SIZE="0.15678610386029457" ORDER="107" O_E="0.0" SE="0.7623237249175997" STUDY_ID="STD-Schwebke-2006b" TOTAL_1="138" TOTAL_2="44" VAR="0.5811374615722442" WEIGHT="31.78873449613434"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0887473600451534" CI_END="1.182944693334882" CI_START="0.3387954390916685" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6330689273685373" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" I2="8.151327231826562" I2_Q="0.0" ID="CMP-015.06" LOG_CI_END="0.07296444036676544" LOG_CI_START="-0.4700624448308629" LOG_EFFECT_SIZE="-0.19854900223204883" METHOD="MH" MODIFIED="2001-05-13 19:16:03 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="6" P_CHI2="0.2967493815732263" P_Q="0.0" P_Z="0.15178403593093934" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.016809052273375587" TOTALS="YES" TOTAL_1="284" TOTAL_2="88" WEIGHT="100.0" Z="1.4332582940144931">
<NAME>Candida</NAME>
<GROUP_LABEL_1>metronidazole +azith</GROUP_LABEL_1>
<GROUP_LABEL_2>metro</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metro+azith</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favoursmetro</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0939386397227753" CI_START="0.17911816094518818" EFFECT_SIZE="0.4426559356136821" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.03899296260329558" LOG_CI_START="-0.7468603784255473" LOG_EFFECT_SIZE="-0.3539337079111259" ORDER="108" O_E="0.0" SE="0.46161414255711813" STUDY_ID="STD-Schwebke-2006" TOTAL_1="142" TOTAL_2="44" VAR="0.21308761660874337" WEIGHT="44.257327924035856"/>
<DICH_DATA CI_END="1.8678083690242275" CI_START="0.378710606990889" EFFECT_SIZE="0.8410462776659959" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.27133231699875243" LOG_CI_START="-0.42169253091534625" LOG_EFFECT_SIZE="-0.07518010695829694" ORDER="109" O_E="0.0" SE="0.4070862261930656" STUDY_ID="STD-Schwebke-2006a" TOTAL_1="142" TOTAL_2="44" VAR="0.16571919555611178" WEIGHT="55.742672075964144"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-09-27 12:05:22 -0300" MODIFIED_BY="Oyinlola O Oduyebo"/>
<FEEDBACK/>
<APPENDICES MODIFIED="2001-05-07 10:33:51 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<APPENDIX ID="APP-01" MODIFIED="2001-05-07 10:33:51 -0300" MODIFIED_BY="Oyinlola O Oduyebo" NO="1">
<TITLE MODIFIED="2008-12-23 19:05:31 -0200" MODIFIED_BY="[Empty name]">Detailed search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2001-05-07 10:33:51 -0300" MODIFIED_BY="Oyinlola O Oduyebo">
<TABLE COLS="2" ROWS="25">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>(BACTERIAL VAGINOSIS) OR (VAGINOSIS BACTERIAL) OR (BACTERIAL VAGINITIS)</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>(BACTERIAL INFECTION) OR (BACTERIAL INFECTIONS)</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>VAGINITIS OR VAGINOSIS</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>#2 AND #3</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>(NONSPECIFIC VAGINITIS) OR (NON-SPECIFIC VAGINITIS) OR (NONSPECIFIC VAGINOSIS) OR (NON-SPECIFIC VAGINOSIS)</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>#1 OR #4 OR #5</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>"ANTIMICROBIAL THERAPY" OR "ANTIMICROBIAL TREATMENT"</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>"ANTIMICROBIAL AGENTS" OR ANTIMICROBIAL* OR ANTIBIOTIC OR ANTIBIOTICS</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>TREATMENT OR THERAPY</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>#8 AND #9</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>#7 OR #10</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>RANDOMIZED CONTROLLED TRIAL[PT] OR CONTROLLED CLINICAL TRIAL[PT] OR RANDOMIZED CONTROLLED TRIALS[MH] OR CONTROLLED CLINICAL TRIALS[MH]</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>DOUBLE-BLIND METHOD[MH] OR SINGLE-BLIND METHOD[MH] OR CLINICAL TRIALS[MH] OR "CLINICAL TRIAL"</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>((SINGL* OR DOUBL* OR TRIPL* OR TREBL*) AND (MASK* OR BLIND*))</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>PLACEBO[TW] OR PLACEBOS[MH] OR RE DESIGN[MH:NOEXP]</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>CONTROL[TW] OR PROSPECTIVE*[TW] OR RANDOM*[TW] OR VOLUNTEER*[TW]</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>#12 OR #13 OR #14 OR #15 OR #16</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>(ANIMALS[TW] OR ANIMAL[MH]) NOT HUMAN[MH]</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>#17 NOT #18</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>#6 AND #11 AND #19</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>PREGNANCY[MH]</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>#20 NOT #21</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
<P>Search set numbers</P>
<P>CENTRAL 43</P>
<P>EMBASE 510</P>
<P>MEDLINE 148</P>
<P>Total 701</P>
<P>Number of records retrieved 53</P>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>